

Ernst WAGNER

Date of birth: May 10th, 1960
Place of birth: Dachau, Germany
Citizenship: Austrian

EDUCATION

Technical University of Vienna	Diploma (Dipl.Ing.)	1983	Chemistry/Biochemistry
Technical University of Vienna	Ph. D. (Dr. tech.)	1985	Organic Chemistry
University of Vienna, Medical Faculty	Habilitation (Doz.)	1994	Biochemistry

RESEARCH AND PROFESSIONAL EXPERIENCE

1985-1987 Postdoc and Scientist at the Federal School of Technology (ETH) Zurich, Switzerland; working on sugar phosphates and origin-of-life chemistry (prebiotic formation of nucleic acid precursors).

1988-1995 Group leader, Institute of Molecular Pathology, Vienna, Austria; working on receptor-mediated gene delivery, artificial virus-like gene transfer systems containing targeting and endosomal escape domains

1996 Professor Biopharmaceutical Sciences, Utrecht University, The Netherlands.

1992-2001 Director Cancer Vaccines & Gene Therapy, Boehringer Ingelheim Austria; research, development and production of gene-modified cancer vaccines; human clinical gene therapy trials in Austria and Germany started in 1994 (first-on-world polymer-based gene therapy) and 1998.

1995-2002 Group leader, Institute of Biochemistry, Vienna University Biocenter.

Since 2001 C4 Professor for Pharmaceutical Biology - Biotechnology, LMU Munich, Germany.

Since 2005 Member of Munich Center of Nanoscience (CeNS)

2006-2008 Director, Department of Pharmacy

2007-2010 Coordinator of Area "Programmed Drug Delivery" within the DFG Excellence Cluster "Nanosystems Initiative Munich (NIM)"

2010-2019 Area Coordinator of "Biomedical Nanotechnologies" and Executive Board Member of "Nanosystems Initiative Munich (NIM)"

2016-2018 Deputy Director, Department of Pharmacy

2018-2020 Director, Department of Pharmacy

≥ 513 publications, ≥ 20 patents, ≥ 315 international lectures, > 52 296 citations on GS, h-index 115

SUPPORT OF YOUNG RESEARCHERS

95 Doctoral students (from many nations, including 7 CSC student fellows) graduated successfully under his supervision, plus 15 currently active PhD students. 15 academics under his former supervision (doctoral students or postdocs) received a professorship/associate professorship.

MEMBERSHIPS & COMMITTEE MEMBERSHIPS

Member of GÖCH (Austrian Chemical Society), GDCH (German Chemical Society), ACS (American Chemical Society), ASCGT (American Society for Gene and Cell Therapy), DGGT (German Society for Gene Therapy), Controlled Release Society (CRS), EurASc (European Academy of Science).

1995-2003 Gene Analysis & Therapy Panel of the Austrian Gene Technology Commission
1996-2003 DECHEMA Arbeitsgruppe Medizinische Biotechnologie

Ernst Wagner

- 1997-2000 Gene Therapy Committee, American Society for Gene Therapy
- 1998-2001 European Gene Therapy Working Group EFPIA
- 2001-2002 European Society for Gene Therapy, Committee nonviral vectors
- Since 2005 Member of Center of Nanoscience (CeNS, Munich)
- Since 2004 Member of EUFEPS Committee for Academic Research
- 2007-2010 Nonviral Vector Committee, ASGT, American Society for Gene Therapy
- Since 2007 Deutsche Gesellschaft für Gentherapie (DG-GT), Beirat, physicochemical vectors
- 2010-2014 European Society for Gene and Cell Therapy, Committee nonviral vectors
- 2012-2016 Physical Gene & Cell Therapy and Vectorology Committee, ASGCT
- 2015-2016 Chair, Physical Gene & Cell Therapy and Vectorology Committee, ASGCT
(now: Physical Delivery Therapeutics & Vector Development Committee)
- 2014-2017 Chemical Gene & Cell Therapy Committee, ASGCT
(now: Nanoagents & Synthetic Formulations Committee)
- Since 2018 European Academy of Sciences (EurASc), Officer, Division Medicine and Life Sciences
- 2022-2025 Nonviral Therapeutic Delivery Committee, ASGCT

EDITORIAL ACTIVITIES

- 1995-1998 Editorial Board of "Cytokines and Molecular Therapy"
- 1999-2012 Editorial Board of "Gene Therapy and Regulation"
- 1999-2009 Editorial Board of "Gene Therapy"
- 1999-2001 Editorial Board of "Tumor Targeting"
- 1999-2004 Editorial Board of "AAPS PharmSci"
- 1998-2010 Editor of "Current Opinion in Molecular Therapeutics"
- 2002-2016 Associate Editor of "Journal of Gene Medicine"
- 2003-2016 Editorial Board of "European Journal of Pharmaceutical Sciences"
- Since 2005 Editorial Board of "Journal of Controlled Release"
- 2007-2010 Associate Editor of "Molecular Therapy"
- 2007-2012 Editorial Board of "Bioconjugate Chemistry"
- 2008-2020 Editor, "Pharmaceutical Research"
- Since 2009 Editorial Board of "Polymers"
- 2009-2014 Editorial Board of "Nanomedicine: NBM"
- Since 2012 Editorial Board of "Pharmaceutical Nanotechnology"
- Since 2015 Editorial Board of "European Journal of Pharmaceutics and Biopharmaceutics"
- Since 2015 Editorial Board of "OpenNano"
- 2016-2022 Editor-in-Chief of "Journal of Gene Medicine"

HONORS

- 1996 F.C. Donders Chair for Biopharmaceutical Sciences, Utrecht University, Netherlands
- 2007 Honorary Member of Balkan Union of Oncology (BUON)
- 2012/13 Fudan University Key Laboratory, Shanghai, Senior Visiting Scholarship (guest professor)
- 2012 Election into Board of Scientific Advisors of Controlled Release Society (CRS)
- 2012 Attocube Research Award
- 2014 Sichuan University, Chengdu, Guest Professorship 2014-2017
- 2014 Phoenix Pharma Science Award 2014
- 2017 Election into CRS College of Fellows
- 2017 Election as Academician into European Academy of Sciences (EurASc)
- 2018 Honorary Professorship Sichuan University
- 2021 Honorary Professorship Jinan University
- 2022 Huaxia Medical Science and Technology Award (International Cooperation Promotion Award, with Fudan U)

GRANTS

1995-2000	Austrian FWF Forschungsschwerpunkt	Projekt S07405-MOB
1997-2000	European Community (EC) FP4 Biotechnology Program Grant Bio4CT972191	Non-viral gene transfer vectors
2000-2003	Austrian FWF	Project P14289
2000-2004	EC FP5 Research Training Network	(‘MakeMAC’, Artificial Chromosomes)
2003-2009	DFG SFB486 network	(‘Nanoman’, Synthetic viruses)
2004-2006	Sanders Stiftung Project	(P450 Gene Therapy)
2004-2006	Dr. Mildred Scheel Stiftung Project	(Colon cancer)
2005-2009	EC FP6 Network	(‘GIANT’)
2006-2009	Participant in DFG research network SPP1230	(Gene therapy – vector safety)
2010-2012	Munich BMBF Spitzencluster m4, Project T12	(project leader Wagner), siRNA as new therapeutic platform suitable for personalized healthcare – Dynamic polymer systems to facilitate safe and efficient cytoplasmic delivery of siRNAs
2012-2016	SinoGermanCenter and DFG project	‘Programmed dual targeted lipopolymeric delivery systems for cancer gene therapy’ (with Sichuan U / Prof. Z. Gu, Prof. Y. Nie)
2012-2017	European Community, Innovative Medicines Initiative (IMI) project	‘Collaboration on the optimisation of macromolecular pharmaceutical access to cellular targets (COMPACT)’, WP2 (siRNA), WP5 (Delivery across BBB)
2014-2017	SinoGermanCenter project	‘Novel peptide-modified precise oligomers for cascade-targeting gene therapy of glioma’ (with Fudan U / Prof. R. Huang)
2010-2018	DFG Research Group FOR 1406	‘Exploiting the potential of natural compounds: Myxobacteria as source for therapeutic leads and chemical tools in cancer research.’
2006-2019	German Network of Excellence – Cluster Nanosystems Initiative Munich	(‘NIM’).
2013-2021	DFG SFB824	‘Polyplexes for systemic NIS gene transfer’, co-PI with Prof. Ch. Spitzweg
2017-2021	DFG SFB1066	‘Nanodimensional Polymer Therapeutics for Tumor Therapy’ (Mainz), Project B5
2019-2022	DFG-NSFC Joint Sino-German Research Project	(LRP1-targeted carbon nanodots for crossing BBB and delivering small molecule or protein drugs into brain) together with Prof. Rongqin Huang, Fudan University, and Prof. Yi Wang, Donghua University, Shanghai
2012-2024	DFG SFB1032 Nanoagents, projekt B4	(Molecular nanoagents utilizing the intracellular microRNA machinery for switching functions in cells)
2019-2024	European Community Horizon 2020, Unlocking Precision Gene Therapy	(UPGRADE)
Since 2023	CNATM Cluster for Nucleic Acid Therapeutics Munich	(BMBF Clusters4Future)

LIST OF PUBLICATIONS

Books/Volumes:

- L. Huang, M.C. Hung, E. Wagner (1999) *Nonviral Vectors for Gene Therapy*, Academic Press, San Diego.
- G. Storm, E. Wagner (1999) Volume **38** in *Adv. Drug Del. Rev.* Theme title: Membrane destabilization for improved cytosolic delivery.
- L. Huang, M.C. Hung, E. Wagner (2005) *Nonviral Vectors for Gene Therapy*, Second Edition, Elsevier, Academic Press
- L. Huang, Dexi Liu, E. Wagner (2014) *Nonviral Vectors for Gene Therapy*, Third Edition, Lipid- and Polymer-based Gene Transfer, *Advances in Genetics* **88**, Elsevier.
- L. Huang, Dexi Liu, E. Wagner (2015) *Nonviral Vectors for Gene Therapy*, Third Edition, Physical Methods and Medical Translation, *Advances in Genetics* **89**, Elsevier.

Papers:

- 1) Noe, C.R., Knollmüller, M., Wagner, E., und Völlenklee, H. (1985). Selektivitäten bei Acetalisierungsreaktionen enantiomerenreiner Lactole am Beispiel von Octahydro-8,9,9-trimethyl-5,8-methano-2H-1-benzopyran-2-ol. *Chem. Ber.* 118, 1733-1745.
- 2) Noe, C.R., Knollmüller, M., Wagner, E., und Völlenklee, H. (1985). Kohlenhydrat-Modelle, I. Kinetische und thermodynamische Effekte bei Acetalisierungsreaktionen enantiomerenreiner Thiolactole. *Chem. Ber.* 118, 3299-3310.
- 3) Noe, C.R., Knollmüller, M., und Wagner, E. (1986). Ein einfaches Verfahren zur Herstellung anellierter Thiophene. *Monatsh. Chemie* 117, 621-629.
- 4) Noe, C.R., Knollmüller, M., Oberhauser, B., Steinbauer, G., und Wagner, E. (1986). Chirale Lactole, VI. Eine Methode zur Bestimmung der Absolutkonfiguration chiraler alpha-hydroxysubstituierter Nitrile, Alkine und Aldehyde. *Chem. Ber.* 119, 729-743.
- 5) Wagner, E., Xiang, Y.-B., Baumann, K., Gück, J., und Eschenmoser, A. (1990). Chemie von alpha-Aminonitrilen. Aziridin-2-carbonitril, ein Vorläufer von rac-O3-Phosphoserinnitril und Glycolaldehydphosphat. *Helv. Chim. Acta* 73, 1391-1409.
- 6) Müller, D., Pitsch, S., Kittaka, A., Wagner, E., Wintner, C.E., und Eschenmoser, A. (1990) Chemie von alpha-Aminonitrilen. Aldomerisierung von Glycolaldehyd-phosphat zu racemischen Hexose-2,4,6-triphosphaten und (in Gegenwart von Formaldehyd) racemischen Pentose-2,4-diphosphaten: rac-Allose-2,4,6-triphosphat und rac-Ribose-2,4-diphosphat sind die Reaktionshauptprodukte. *Helv. Chim. Acta* 73, 1410-1468.
- 7) Wagner, E., Zenke, M., Cotten, M., Beug, H. and Birnstiel, M.L. (1990). Transferrin-polycation conjugates as carriers for DNA uptake into cells. *Proc. Natl. Acad. Sci. USA* 87, 3410-3414.
- 8) Zenke, M., Steinlein, P., Wagner, E., Cotten, M., Beug, H. and Birnstiel, M.L. (1990) Receptor-mediated endocytosis of transferrin polycation conjugates: An efficient way to introduce DNA into hematopoietic cells. *Proc. Natl. Acad. Sci. USA* 87, 3655-3659.
- 9) Cotten, M., Laengle-Rouault, F., Kirlappos, H., Wagner, E., Mechtler, K., Zenke, M., Beug, H. and Birnstiel, M.L. (1990) Transferrin-polycation-mediated introduction of DNA into human leukemic cells: stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels. *Proc. Natl. Acad. Sci. USA* 87, 4033-4037.
- 10) Wagner, E., Cotten, M., Foisner, R. and Birnstiel, M.L. (1991). Transferrin-polycation-DNA complexes: The effect of polycations on the structure of the complex and DNA delivery to cells. *Proc. Natl. Acad. Sci. USA* 88, 4255-4259.
- 11) Wagner, E., Cotten, M., Mechtler, K., Kirlappos, H. and Birnstiel, M.L. (1991). DNA-binding transferrin conjugates as functional gene-delivery agents: synthesis by linkage of polylysine or ethidium homodimer to the transferrin carbohydrate moiety. *Bioconjugate Chem.* 2, 226-231.
- 12) Curiel, D.T., Agarwal, S., Wagner, E., and Cotten, M. (1991). Adenovirus enhancement of transferrin-polylysine-mediated gene delivery. *Proc. Natl. Acad. Sci. USA* 88, 8850-8854.

- 13) Cotten, M., Oberhauser, B., Brunar, H., Holzner, A., Issakides, G., Noe, C.R., Schaffner, G., Wagner, E., and Birnstiel, M.L. (1991). 2'-O-methyl, 2'-O-ethyl oligoribonucleotides and phosphorothioate oligodeoxyribonucleotides as inhibitors of the in vitro U7 snRNP-dependent mRNA processing event. *Nucleic Acids Res.* 19, 2629-2635.
- 14) Wagner, E., Oberhauser, B., Holzner, A., Brunar, H., Issakides, G., Schaffner, G., Cotten, M., Knollmüller, M., and Noe, C.R. (1991). A simple procedure for the preparation of protected 2'-O-methyl or 2'-O-ethyl ribonucleoside-3'-O-phosphoramidites. *Nucleic Acids Res.* 19, 5965-5971.
- 15) Noe, C.R., Knollmüller, M., Steinbauer G., Wagner, E., Kurner, H., Ettmayer, P., and Vollenkle H. (1991) A simple method to direct the reduction of alpha-alkoxy-carbonyl compounds. *Monatshefte Chemie* 122, 299-317.
- 16) Oberhauser, B., and Wagner, E. (1992). Effective incorporation of 2'-O-methyl-oligoribonucleotides into liposomes and enhanced cell association through modification with thiocholesterol. *Nucleic Acids Res.* 20, 533-538.
- 17) Curiel, D.T., Wagner, E., Cotten, M., Birnstiel, M.L., Agarwal, S., Li, C.-M., Loechel, S., and Hu, P.-C. (1992) High-efficiency gene transfer by adenovirus coupled to DNA-polylysine complexes. *Human Gene Therapy* 3, 147-154.
- 18) Curiel, D.T., Agarwal, S., Romer, N., Wagner, E., Cotten, M., Birnstiel, M.L., and Boucher, R.C. (1992). Gene transfer to respiratory epithelial cells via the receptor-mediated endocytosis pathway. *Am. J. Resp. Cell Mol. Biol.* 6, 247-252.
- 19) Wagner, E., Cotten, M., Zatloukal, K. and Birnstiel, M. (1992) Transferrin receptor mediated gene transfer, *Quarterly News* 1, 13-25.
- 20) Wagner, E., Zatloukal, K., Cotten, M., Kirlappos, H., Mechtler, K., Curiel, D.T., and Birnstiel, M.L. (1992). Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. *Proc. Natl. Acad. Sci. USA* 89, 6099-6103.
- 21) Cotten, M., Wagner, E., Zatloukal, K., Phillips, S., Curiel, D.T., and Birnstiel, M.L. (1992). High-efficiency receptor-mediated delivery of small and large (48kb) gene constructs using the endosome disruption activity of defective or chemically inactivated adenovirus particles. *Proc. Natl. Acad. Sci. USA* 89, 6094-6098.
- 22) Wagner, E., Plank, C., Zatloukal, K., Cotten, M., and Birnstiel, M.L. (1992) Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine/DNA complexes: Towards a synthetic virus-like gene transfer vehicle. *Proc. Natl. Acad. Sci. USA* 89, 7934-7938.
- 23) Zatloukal, K., Wagner, E., Cotten, M., Phillips, S., Plank, C., Steinlein, P., Curiel, D., and Birnstiel, M.L. (1992). Transferrin infection: A highly efficient way to express gene constructs in eukariotic cells. *Ann. N. Y. Acad. Sci.* 660, 136-153.
- 24) Plank, C., Zatloukal, K., Cotten, M., Mechtler, K., and Wagner, E. (1992) Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand. *Bioconjugate Chem.* 3, 533-539.
- 25) Cotten, M., Wagner, E., and Birnstiel, M.L. (1993). Receptor mediated transport of DNA into eukariotic cells. *Methods Enzymol.* 217, 618-644.
- 26) Gao, L., Wagner, E., Cotten, M., Agarwal, S., Harris, C., Romer, M., Miller, L., Hu, P.-c., and Curiel, D. (1993) Direct in vivo gene transfer to the airway epithelium employing adenovirus-polylysine-DNA complexes. *Human Gene Therapy* 4, 17-24.
- 27) Michael, S.I., Huang, C.-h., Romer, M.U., Wagner, E., Hu, P.-c. and Curiel, D.T. (1993) Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway. *J. Biol. Chem.* 268, 6866-6869.
- 28) Cotten, M., Wagner, E., Zatloukal, K. and Birnstiel, M.L. (1993) Chicken adenovirus (CELO virus) particles augment receptor-mediated DNA delivery to mammalian cells and yield exceptional levels of stable transformants. *J. Virol.* 67, 3777-3785.
- 29) Wagner, E. (1993) Gentherapie: Neue Wege in der Krebsbehandlung. In "Genetische Kunst-Künstliches Leben", *Ars Electronica* 93, K. Gerbel, P. Weibel (Eds.) PVS Verleger, Wien, pp. 151-154.
- 30) Cotten, M. and Wagner, E. (1993) Non-viral approaches to gene therapy. *Current Op. Biotech.* 4, 705-710.

- 31) Zatloukal, K., Schmidt, W., Cotten, M., Wagner, E., Stingl, G., and Birnstiel, M.L. (1993) Somatic gene therapy for cancer: the utility of transferrin infection in generating 'tumor vaccines'. *Gene* 135, 199-207.
- 32) Harris, C.E., Agarwal S., Hu, P., Wagner E., and Curiel, D.T. (1993) Receptor-mediated gene transfer to airway epithelial cells in primary culture. *Am. J. Respir. Cell Mol. Biol.* 9, 441-7.
- 33) Noe, C.R., Knollmüller, M., Miculka, C., Dungler, K., Wagner, E., and Eitmayer, P. (1994) A method for the determination of the absolute-configuration of chiral alkanols. *Chemische Berichte* 127, 887-892.
- 34) Curiel, T.J., Cook, D.R., Bogedain, C., Jilg, W., Harrison, G.S., Cotten, M., Curiel, D.T., and Wagner, E. (1994) Foreign gene expression in Epstein-Barr virus transformed human B cells, *Virology* 198, 577-585.
- 35) Plank, C., Oberhauser, B., Mechtler, K., Koch, C., and Wagner, E. (1994) The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. *J. Biol. Chem.* 269, 12918-12924.
- 36) Wagner, E., Cotten, M., Plank, C., Mechtler, K., Zatloukal, K., and Birnstiel, M.L. (1994) Receptor-mediated gene delivery into mammalian cells. In: "Animal cell technology: Products of today, prospects for tomorrow" R.E. Spier, J.B. Griffiths, W. Berthold (Eds.) Butterworth-Heinemann Ltd, Oxford, pp 30-34.
- 37) Wagner, E., Curiel, D. and Cotten, M. (1994) Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. *Adv. Drug Del. Rev.* 14, 113-136.
- 38) Cheng, Q., Cant, C.A., Moll, T., Hofer-Warbinek, R., Wagner, E., Birnstiel, M.L., Bach, F.H., and de Martin, R. (1994) NF- κ B Subunit-specific regulation of the I κ B promoter. *J. Biol. Chem.* 269, 13551-13557.
- 39) Zatloukal, K., Cotten, M., Berger, M., Schmidt, W., Wagner, E. and Birnstiel, M.L. (1994) In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery. *Proc. Natl. Acad. Sci. USA* 91, 5148-5152.
- 40) Wagner, E., Buschle, M., Cotten, M., Plank, C., Zauner, W., and Birnstiel, M.L. (1994) Synthetic virus-like gene delivery systems. *Proc Int Symp. Control. Rel. Bioact. Mater.* 21, 3-4.
- 41) Thurnher, M., Wagner, E., Clausen, H., Mechtler, K., Rusconi, S., Dinter, A., Berger, E.G., Birnstiel, M.L., and Cotten, M. (1994) Carbohydrate receptor-mediated gene transfer to human T-leukemic cells, *Glycobiology* 4, 429-435.
- 42) Cotten, M., Baker, A., Saltik, M., Wagner, E., and Buschle, M. (1994) Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary cells in the presence of adenovirus. *Gene Therapy* 1, 239-246.
- 43) Zelphati, O., Wagner, E., and Leserman, L. (1994) Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes. *Antiviral Research* 25, 13-25.
- 44) Maass, G., Zatloukal, K., Schmidt, W., Berger, M., Cotten, M., Buschle, M., Wagner, E., Birnstiel, M.L. (1994) Generation of tumor vaccines by adenovirus-enhanced transfection of cytokine genes into tumor cells. *Nato ASI Series H88*, 467-479.
- 45) Batra, R.K., Wang-Johanning, F., Wagner, E., Garver, R.I., Curiel, D.T. (1994) Receptor-mediated gene delivery employing lectin-binding specificity. *Gene Therapy* 1, 255-260.
- 46) Cotten, M., Saltik, M., Kursal, M., Wagner, E., Maass, G., and Birnstiel, M.L. (1994) Psoralen treatment of adenovirus particles eliminates virus replication and transcription while maintaining the endosomolytic activity of the virus capsid. *Virology* 205, 254-261.
- 47) Frank, S., Krasznai, K., Durovic, S., Lobentanz, E.-M., Dieplinger, H., Wagner, E., Zatloukal, K., Cotten, M., Utermann, G., Kostner, G. M., and Zechner, R. (1994) High-Level Expression of Various Apolipoprotein(a) Isoforms by "Transferrin infection": The Role of Kringle IV Sequences in the Extracellular Association with Low-Density Lipoprotein. *Biochemistry* 33, 12329-12339.
- 48) Zatloukal, K., Schneeberger, A., Berger, M., Koszik, F., Schmidt, W., Wagner, E., Cotten, M., Buschle, M., Maass, G., Stingl, G., Birnstiel, M.L., (1994) Genetic modification of cells by receptor-mediated adenovirus-augmented gene delivery: a new approach for immunotherapy of cancer. *Verh. Dtsch. Ges. Pathol.* 78, 171-6.
- 49) Cook, D. R., Maxwell, I.H., Glode, L. M., Maxwell, F., Stevens, J. O., Purner, M. B., Wagner, E., Curiel, D. T., Curiel, T. J. (1994) Gene therapy for B-cell lymphoma in a SCID mouse model using an

- immunoglobulin-regulated diphtheria toxin gene delivered by a novel adenovirus-polylysine conjugate. *Cancer Biother* 9, 131-41.
- 50) Zauner, W., Blaas, D., Kuchler, E., and Wagner, E. (1995) Rhinovirus mediated endosomal release of transfection complexes. *J. Virol.*69, 1085-1092.
- 51) Moll, T., Czyz, M., Holzmueller, H., Hofer-Warbinek, R., Wagner, E., Winkler, H., Bach, F.H., and Hofer, E. (1995) Regulation of the tissue factor promoter in endothelial cells. *J. Biol. Chem.*270, 3849-3857.
- 52) von Rüden, T., Stingl, L., Cotten, M., Wagner, E., and Zatloukal, K. (1995) Generation of high-titer retroviral vectors following receptor-mediated, adenovirus-augmented transfection. *Biotechniques*18, 484-489.
- 53) Zatloukal, K., Schneeberger, A., Berger, M., Schmidt, W., Kosik, F., Kutil, R., Cotten, M., Wagner, E., Buschle, M., Maass, G., Payer, E., Stingl, G., Birnstiel, M.L. (1995) Elicitation of a systemic and protective anti-melanoma immune response by an IL-2 based vaccine: assessment of critical parameters. *J.Immunol.* 154, 3406-3419.
- 54) Buschle, M., Cotten, M., Kirlappos, H., Mechtler, K., Birnstiel, M.L., and Wagner, E. (1995) Receptor-mediated gene transfer into T-lymphocytes via binding of DNA/CD3 antibody particles to the CD3 T cell receptor complex. *Human Gene Therapy* 6, 753-761.
- 55) Oberhauser, B., Plank, C., and Wagner, E. (1995) Enhancing endosomal exit of nucleic acids using pH-sensitive viral fusion peptides. Chapter 16 in "Delivery strategies for antisense oligonucleotide therapeutics", S. Akhtar (Ed.), CRC Press, Inc, Florida, p. 247-268.
- 56) Prchla, E., Plank, C., Wagner, E., Blaas, D., and Fuchs, R. (1995) Virus-mediated release of endosomal content in vitro: Different Behaviour of adenovirus and Rhinovirus serotype 2. *J. Cell Biology* 131, 111-123.
- 57) Zauner, W., Kichler, A., Schmidt, W., Sinski, A., Wagner, E.(1996) Glycerol enhancement of ligand-polylysine/DNA transfection. *Biotechniques* 20, 905-913.
- 58) Wagner, E. (1996) Rezeptorvermittelter Gentransfer: Anwendung in der Tumorimmunotherapie? Chapter 37 in " Molekularbiologische Grundlagen in der Gastroenterologie", Beger et al. (Ed), Scientific publishing services (P) LTD, Bangalore.
- 59) Stingl, G., Wolff, K., Bröcker, E.-B., R. Mertelsmann, K. Wolff, S. Schreiber et al.(1996) Phase I Study to the Immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. *Human Gene Therapy* 7, 551-563.
- 60) Morrison, C., Wagner, E. (1996) Extrachromosomal recombination occurs efficiently in cells defective in various DNA repair systems. *Nucleic Acid Res.* 24, 2053-58.
- 61) Wagner, E., Cotten, M., and Zatloukal, K. (1996) Receptor-mediated gene delivery with synthetic virus-like particles. p 67-77, in: Targeting of Drugs 5: Strategies for Oligonucleotide and Gene Delivery in Therapy, Cape Sounion, Greece. Ed. Grigoriadis, G., Plenum Press, New York
- 62) Plank, C., Mechtler, K., Wagner, E., and Szoka, F. (1996) Complement activation by polylysine-DNA complexes. In: Targeting of Drugs 5: Strategies for Oligonucleotide and Gene Delivery in Therapy, Cape Sounion, Greece. Ed. Grigoriadis, G., Plenum Press, New York.
- 63) Kichler, A., Zauner, W., Morrison, C., and Wagner, E. (1996) Ligand-polylysine mediated gene transfer. ACS book. Chapter 12, 120-128, in "Artificial Self-Assembling Systems for Gene Delivery", Felgner, P.L., et al. (Ed.), American Chemical Society, WashingtonDC.
- 64) Wagner, E., Cotten, M., Berger, M., Schmidt, W., Zauner, W., Buschle, M., Schweighoffer, T., Maass, G., Zatloukal, K., Schreiber, S., Stingl, G., and Birnstiel, M.L. (1996) Adenovirus enhanced receptor mediated transferrinfection (AVET) applied to the generation of tumor vaccines. Chapter in OECD Biotechnology, Gene Delivery Systems, A state-of-the-Art Review, pp 153-162.
- 65) Plank, C., Mechtler, K., Szoka, F., and Wagner, E. (1996) Activation of the complement system by synthetic DNA complexes: A potential barrier for intravenous gene delivery. *Hum. Gene Ther.* 7, 1437-1446.
- 66) Cotten, M., Baker, A., Birnstiel, M.L., Zatloukal, K., Wagner, E. (1996) Adenovirus polylysine DNA conjugates. (1996) In *Current Protocols in Human Genetics*, John Wiley and Sons, Inc. New York. Pp. 12.3.1 – 12.3.33 .

- 67) Gagnoux-Palacios, L., Vailly, J., Durand-Clement, M., Wagner, E., Ortonne, J.P., and Meneguzzi, G. (1996) Functional re-expression of laminin-5 in laminin-gamma2-deficient human keratinocytes modifies cell morphology, motility, and adhesion. *J. Biol. Chem.* 271, 18437-44.
- 68) Bögre, L., Jonak, C., Mink, M., Meskiene, I., Traas, J., Ha, D.T.C., Swoboda, I., Plank, C., Wagner, E., Heberle-Bors, E., and Hirt, H. (1996). Developmental and cell cycle regulation of alfalfa nucMs1, a plant homolog of the yeast Nsr1 and mammalian nucleolin. *The Plant Cell* 8, 417-428
- 69) Bögre, L., Zwerger, K., Meskiene, I., Binarova, P., Csizmadia, V., Plank, C., Wagner, E., Hirt, H., and Heberle-Bors, E. (1997) The cdc2Ms kinase is differently regulated in the cytoplasm and in the nucleus. *Plant Physiology* 113, 841-852.
- 70) Zauner, W., Kichler, A., Mechtler, K., Schmidt, W., and Wagner, E. (1997) Glycerol and polylysine synergize in their ability to rupture vesicular membranes and increase transferrin-polylysine mediated gene transfer. *Exp. Cell Res.* 232, 137-145.
- 71) Ebert, O., Finke, S., Salahi, A., Herrmann, M., Trojaneck, B., Lefterova, P., Wagner, E., Kircheis, R., Huhn, D., Schriever, F., and Schmidt-Wolf, I.G.H. (1997) Lymphocyte apoptosis: induction by gene transfer techniques. *Gene Therapy* 4, 296-302.
- 72) Kichler, A., Mechtler, K., Behr, J.-P., and Wagner, E. (1997) The influence of membrane-active peptides and helper lipids on lipospermine/DNA complex mediated gene transfer. *Bioconjugate Chem.* 8, 213-221.
- 73) Mechtler, K., and Wagner, E. (1997) Gene transfer mediated by Influenza virus peptides: The role of peptide sequences. *New J. Chemistry* 21, 105-111.
- 74) Coll, J.-L., Wagner, E., Combaret, V., Mechtler, K., Amstutz, H., Iacono-DiCacito, I., Simon, N., and Favrot, M.C. (1997) In vitro targeting and specific transfection of human neuroblastoma cells by chCE7 antibody-mediated gene transfer. *Gene Therapy* 4, 156-161.
- 75) Stingl, G., Brocker, E.B., Mertelsmann, R., Wolff, K., Schreiber, S., Kampgen, E., Schneeberger, A., Trcka, J., Brennscheidt, U., Veelken, H., Birnstiel, M.L., Zatloukal, K., Maass, G., Wagner, E., Buschle, M., Kempe, R., Weber, H.A., and Voigt, T. (1997) Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. *J.Mol. Medicine* 75, 297-299.
- 76) Kircheis, R., Kichler, A., Wallner, G., Kursa, M., Ogris, M., Felzmann, T., Buchberger, M., and Wagner, E. (1997) Coupling of cell-binding ligands to polyethylenimine for targeted delivery. *Gene Therapy* 4, 409-418.
- 77) Felgner, P.L., Barenholz, Y., Behr, J.P., Cheng, S.H., Cullis, P., Huang, L., Jessee, J.A., Seymour, L., Szoka, F., Thierry, A.R., Wagner, E., and Wu, G. (1997) Nomenclature for synthetic gene delivery systems. *Human Gene Therapy* 8, 511-512.
- 78) Talsma, H., Cherng, J.-Y., Lehrmann, H., Kursa, M., Ogris, M., Hennink, W.E., Cotten, M., and Wagner, E. (1997) Stabilization of gene delivery systems by freeze-drying. *Int. J. Pharm.* 157, 233-238.
- 79) van Slooten, M.L., Koppenhagen, F.J., Bergers, J.J., Kircheis, R., Crommelin, D.J.A., Wagner, E., and Storm, G. (1998) Liposomal delivery of cytokines for anticancer vaccination. In "Future Strategies for Drug Delivery with Particulate Systems", JE Diederichs and RH Müller (Eds), CRC Press.
- 80) Wagner, E. (1998) Polylysine-conjugate based DNA delivery. pp. 309-322, In: Self-assembling complexes for gene delivery. From laboratory to clinical trials, Kabanov, Felgner, Seymour (Eds), Wiley, England.
- 81) Finke, S., Trojaneck, B., Lefterova, P., Csipai, M., Wagner, E., Kircheis, R., Neubauer, A., Huhn, D., Wittig, B., and Schmidt-Wolf, I.G.H. (1998) Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+CD56+ immunological effector cells by receptor-mediated transfection with the IL-7 gene. *Gene Therapy* 5, 31-39.
- 82) Zauner, W., Ogris, M., and Wagner, E. (1998) Polylysine-based transfection systems utilizing receptor-mediated delivery, *Adv. Drug Del. Rev.* 30, 97-113.
- 83) Wagner, E. (1998) Effects of membrane-active agents in gene delivery. *J. Controlled Release* 53, 155-158.
- 84) Harbottle, R.P., Cooper, R.G., Hart, S.L., Ladhoff, A., McKay, T., Knight, A.M., Wagner, E., Miller, A.D., and Coutelle, C. (1998) An RGD-oligolysine peptide: a prototype construct for integrin-mediated gene delivery. *Human Gene Therapy* 9, 1037-1047.

- 85) Kichler, A., Zauner, W., Ogris, M., and Wagner, E. (1998) Influence of the DNA complexation medium on the transfection efficiency of lipospermine/DNA particles. *Gene Therapy* 5, 855-860.
- 86) Diebold, S.S., Cotten, M., Wagner, E., and Zenke, M. (1998) Gene-modified dendritic cells by receptor-mediated transfection. *Adv. Exp. Med. Biol.* 451, 449-455.
- 87) Koppenhagen, F.J., Küpcü, Z., Wallner, G., Crommelin, D.J.A., Wagner, E., Storm, G., and Kircheis, R. (1998) Sustained cytokine delivery for anticancer vaccination: liposomes as alternative for gene-transfected tumor cells. *Clin. Cancer Res.* 4, 1881-1886.
- 88) Kircheis, R., Küpcü, Z., Wallner, G., Wagner, E. (1998) Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2+IFN-gamma. *Cytokines Cell. Mol. Therapy* 4, 95-103.
- 89) Wagner, E. (1998) Receptor-mediated delivery of plasmid DNA. *Biogenic Amines* 14, 519-536.
- 90) Plank, C., Zauner, W., and Wagner, E. (1998) Application of membrane-active peptides for drug and gene delivery across cellular membranes. *Adv. Drug Del. Rev.* 34, 21-35.
- 91) Ogris, M., Steinlein, P., Kursa, M., Mechtler, K., Kircheis, R., and Wagner, E. (1998) The size of DNA/transferrin-PEI complexes is an important factor for gene expression in cultured cells. *Gene Therapy* 5, 1425-1433.
- 92) Wagner, E. Receptor-mediated gene transfer (1999) In: *Gene Therapy, Principles and applications*. Blankenstein (Ed), Birkhäuser, Basel, Switzerland.
- 93) Cotten, M. and Wagner, E. (1999) Receptor-mediated gene delivery strategies. *The Development of Human Gene Therapy*, CSHL Press, p. 261-277.
- 94) Wagner, E. (1999) Gentherapie, In: *Pathophysiologie*, Wick, et al (Eds), Gustav-Fischer-Verlag, Stuttgart.
- 95) Ogris, M., Brunner, S., Schueller, S., Kircheis, R. and Wagner, E. (1999) PEGylated DNA/Transferrin-PEI complexes: Reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. *Gene Therapy* 6, 595-605.
- 96) Kircheis, R., Schueller, S., Brunner, S., Ogris, M., Heider, K.-H., Zauner, W., and Wagner, E. (1999) Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. *J. Gene Medicine* 1, 111-120.
- 97) Diebold, S.S., Lehrmann, H., Kursa, M., Wagner, E., Cotten, M., and Zenke, M. (1999) Efficient Gene Delivery into Human Dendritic Cells by Adenovirus Polyethylenimine and Mannose Polyethylenimine transfection. *Human Gene Therapy* 10, 775-786.
- 98) Schreiber, S., Kämpgen, E., Wagner, E., Pirkhammer, D., Trcka, J., Korschan, H., Lindemann, A., Dorffner, R., Kittler, H., Kasteliz, F., Küpcü, Z., Sinski, A., Zatloukal, K., Buschle, M., Schmidt, W., Birnstiel, M.L., Kempe, R.E., Voigt, T., Weber, H., Pehamberger, H., Mertelsmann, R., Bröcker, E.B., Wolff, K., and Stingl, G. (1999) Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a Phase I Study. *Human Gene Therapy* 10, 983-993.
- 99) Zauner, W., Brunner, S., Buschle, M., Ogris, M., Wagner, E. (1999) Differential behaviour of lipid based and polycation based gene transfer systems in transfecting primary human fibroblasts: a potential role of polylysine in nuclear transport. *Biophys. Biochim. Acta* 1428, 57-67.
- 100) Wagner, E. (1999) Ligand-polycation conjugates for receptor-targeted gene transfer. Chapter 10 (p. 208-227) in "Non-Viral Vectors for Gene Therapy", L. Huang, M.C. Hung, E. Wagner (Eds), Academic Press.
- 101) Diebold, S.S., Kursa, M., Wagner, E., Cotten, M., and Zenke, M. (1999) Mannose-polyethylenimine (ManPEI) conjugates for targetted DNA delivery into dendritic cells. *J. Biol. Chem.* 274, 19087-19094.
- 102) van Slooten, M.L., Kircheis, R., Koppenhagen, F.J., Wagner, E., Storm, G. (1999) Liposomes as cytokine-supplement in tumor cell-based vaccines. *Int. J. Pharm.* 183, 33-36.
- 103) Wagner, E. (1999) Application of membrane-active peptides for nonviral gene delivery. *Adv. Drug Del. Rev.* 38, 279-289.
- 104) Storm, G. and Wagner, E. (1999) Volume theme title: Membrane destabilization for improved cytosolic delivery. (Theme Eds. G. Storm, E. Wagner) Preface. *Adv. Drug Del. Rev.* 38, 195.

- 105) Kircheis, R., Ogris, M., Brunner, S., Schüller, S., Wightman, L., Kursa, M. and Wagner, E. (1999) Transferrin-polycation DNA complexes for tumor-targeted in vivo gene transfer. In: *Progress in Drug Delivery Systems VIII*, N. Oku, Ed., 83-94.
- 106) Culver, K.W. and Wagner, E. (1999) An introduction to *Current Opinion in Molecular Therapeutics*. *Curr. Opin. Mol. Ther.* 1, 1-2.
- 107) Wightman, L., Patzelt, E., Wagner, E., and Kircheis, R. (1999) Development of transferrin-polycation/DNA based vectors for gene delivery to melanoma cells. *J. Drug Targeting* 7, 293-303.
- 108) Schober, D., Bayer, N., Murphy, R.F., Wagner, E., and Fuchs, R. (1999) Establishment of an assay to determine adenovirus-induced endosome rupture required for receptor-mediated gene delivery. *Gene Ther Mol Biol.* 3, 25-33.
- 109) Wagner, E., Ameri, K. (2000) Receptor mediated gene transfer. Chapter 8 in “*Gene Therapy. Therapeutic Mechanisms and Strategies*”, N. Smyth-Templeton, D.Lasic (Eds), Marcel Dekker Inc, New York, p 141-164.
- 110) Kircheis, R., Kursa, M., Wightman, L., Brunner, S., Ogris, M., Schüller, S., and Wagner, E. (2000) Systemic in vivo gene delivery into tumors by the use of transferrin-polyethylenimine DNA complexes. *NATO Science Series, A: Life Sciences*, 323, 186-191.
- 111) Kircheis, R., and Wagner, E. (2000) Polycation/DNA complexes for in vivo gene delivery. *Gene Therapy and Regulation* 1, 95-114.
- 112) Kircheis, R., Wightman, L., Ogris, M., Brunner, S., Kursa, M., Schüller, S., and Wagner, E. (2000) Receptor -mediated gene transfer based on plasmid DNA complexes. Chapter in: *Gene Therapy*, Bertolotti, Ed.
- 113) Brunner, S., Sauer, T., Carotta, S., Cotten, M., Saltik, M., and Wagner, E. (2000) Cell cycle dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus. *Gene Therapy* 7, 401-407.
- 114) van Slooten, M.L., Storm, G., Zoepfel, A., Küpcü, Z., Boerman, O., Crommelin, D.J.A., Wagner, E., Kircheis, R. (2000) Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines. *Pharm. Res.* 17, 42-48.
- 115) Ogris, M., Wagner, E., and Steinlein, P. (2000) A versatile assay to study cellular uptake of gene transfer complexes by flow cytometry. *Biophys. Biochim. Acta* 1474, 237-43.
- 116) Huber, M., Limat, A., Wagner, E., and Hohl, D. (2000) Efficient in vitro transfection of human keratinocytes with an adenovirus-enhanced receptor-mediated system. *J. Invest. Dermatol.* 114, 661-666.
- 117) Kircheis, R., Küpcü, Z., Wallner, G., Rössler, V., Schweighoffer, T., and Wagner, E. (2000) IL-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumor challenge in mice. *Cancer Gene Therapy* 7, 870-878.
- 118) Felzmann, T., Buchberger, M., Jechlinger, M., Kircheis, R., Wagner, E., and Gadner, H. (2000) Xenogenization by tetanus toxoid loading into lymphoblastoid cell lines and primary human tumor cells mediated by polycations and liposomes. *Cancer Letters* 161, 241-250.
- 119) Kircheis, R., Wightman, L., Schreiber, A., Robitza, B., Rössler, V., Kursa, M., and Wagner, E. (2001) Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. *Gene Therapy* 8, 28-40.
- 120) Döchler, M., Pengg, M., Brunner, S., Müller, M., Brem, G., and Wagner, E. (2001) Transfection of epithelial cells is enhanced by combined treatment with mannitol and polyethyleneglycol. *J. Gene Medicine* 3, 115-124.
- 121) van Slooten, M.L., Hayon, I., Babai, I., Zakay-Rones, Z., Wagner, E., Storm, G., and Kedar, E. (2001) Immunoadjuvant activity of interferon-gamma-liposomes co-administered with influenza vaccines. *Biochim. Biophys. Acta* 1531, 99-110.
- 122) Kircheis, R., Blessing, T., Wightman, L., Brunner, S., and Wagner, E. (2001) Tumor targeting with surface-shielded ligand-polycation DNA complexes. *J. Controlled Rel.* 72, 165-170.
- 123) Kircheis, R., Wightman, L., and Wagner, E. (2001) Design and gene delivery activity of modified polyethylenimines. *Adv. Drug Del. Rev.* 53, 341-358.
- 124) Blessing, T., Kursa, M., Holzhauser, R., Kircheis, R., and Wagner, E. (2001) Different Strategies for Formation of PEGylated EGF-conjugated PEI/DNA Complexes for Targeted Gene Delivery. *Bioconjug. Chem.* 12, 529-537.

- 125) Wightman, L., Kircheis, R., Rössler, V., Carotta, S., Ruzicka, R., Kursa, M., Wagner, E. (2001) Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. *J. Gene Medicine* 3, 362-372.
- 126) Felzmann, T., Buchberger, M., Lehner, M., Printz, D., Kircheis, R., Wagner, E., Gadner, H., and Holter, W. (2001) Functional maturation of dendritic cells by exposure to CD40L transgenic tumor cells or primary fibroblasts and keratinocytes. *Cancer Letters* 168, 145-154.
- 127) Ogris, M., Steinlein, P., Carotta, S., Brunner, S., and Wagner E. (2001) DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalisation and gene expression. *AAPS PharmSci*, 3(3) article 21.
- 128) Kircheis, R., Wightman, L., Kursa, M., Smrekar, B., Ostermann, E., and Wagner, E. (2001) Surface-shielded polycation-based systems targeting reporter and therapeutic genes to distant tumors. *Gene Ther. Mol. Biol.* 6, 159-167.
- 129) Wagner, E., Culver, K.W., and Jones, D. (2002) Molecular therapeutics beyond the genome sequencing era. *Curr. Opin. Mol. Ther.* 4 (1), i-ii (editorial).
- 130) Brunner, S., Fürtbauer, E., Sauer, T., Kursa, M., and Wagner, E. (2002) Overcoming the nuclear barrier: cell cycle independent nonviral gene transfer with linear polyethylenimine or electroporation. *Mol. Ther.* 5(1), 80-85
- 131) Kircheis, R., Kursa, M., Wightman, L., Wagner, E. (2002) Transferrin infection for efficient gene transfer to tumor cells. *BenderMedSystems*, 2-7.
- 132) Kircheis, R., Ostermann, E., Wolschek, M.F., Lichtenberger, C., Magin-Lachmann, C., Wightman, L., Kursa, M., and Wagner, E. (2002) Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity. *Cancer Gene Ther.* 9, 673-680.
- 133) Kircheis, R., Ostermann, E., Kursa, M., Wightman, L., and Wagner, E. (2002) Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment. *Gene Ther.* 9, 731-735.
- 134) Vécsey-Semjen, B., Becker, K.-F., Sinski, A., Blennow, E., Vietor, I., Zatloukal, K., Beug, H., Wagner, E., and Huber, L.A. (2002) Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers. *Oncogene* 21, 4646-4662
- 135) Döchler M., Pengg M., Schüller S., Pfeisl F., Bugingo Chr., Brem G., Wagner E., Schellander K., Müller M. (2002) Somatic Gene Transfer into the Lactating Ovine Mammary Gland. *J. Gene Medicine* 4, 282-291.
- 136) Ogris, M., Wagner, E. (2002) Targeting tumors with non-viral gene delivery systems. *Drug Discovery Today* 7, 479-485.
- 137) Wolschek, M.F., Thallinger, C., Kursa, M., Rössler, V., Allen, M., Lichtenberger, C., Kircheis, R., Lucas, T., Willheim, M., Reinisch, W., Gangl, A., Wagner, E., Jansen, B. (2002) Specific systemic non-viral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. *Hepatology* 36, 1106-1114.
- 138) Boeckle, S. Wagner, E., and Ogris, M. (2002) Transmembrane Targeting of DNA with Membrane Active Peptides. Chapter 23 in "Biomedical Aspects of Drug Targeting", V. R. Muzykantov, V. P. Torchilin (Eds), Kluwer Academic Publishers, Boston/Dordrecht/London, p. 441-458.
- 139) Ogris M., Wagner E. (2002) Tumor-targeted Gene Transfer with DNA Polyplexes. *Somatic Cell and Molecular Genetics* 27(1-6), 85-95. Also published as book chapter in "Synthetic DNA Delivery Systems", D. Luo, W. M. Saltzman (Eds), Kluwer Academic/Plenum Publishers, p. 81-91.
- 140) Diebold, S.S., Plank, C., Cotten, M., Wagner, E. and Zenke, M. (2002) Mannose Receptor-Mediated Gene Delivery into Antigen Presenting Dendritic Cells. *Somatic Cell and Molecular Genetics* 27(1-6), 65-74. Also published as book chapter in "Synthetic DNA Delivery Systems", D. Luo, W. M. Saltzman (Eds), Kluwer Academic/Plenum Publishers, p. 61-70.
- 141) Hildebrandt, I.J., Iyer, M., Wagner, E., and Gambhir, S.S. (2003) Optical Imaging of Transferrin Targeted PEI/DNA Complexes in Living Subjects. *Gene Ther.* 10, 758-764.
- 142) Gharwan, H., Wightman, L., Kircheis, R., Wagner, E., and Zatloukal, K. (2003) Nonviral gene transfer into fetal mouse livers. *Gene Ther.* 10, 810-817.

- 143) Smrekar B., Wightman L., Wolschek M.F., Lichtenberger, C., Ruzicka, R., Ogris, M., Rödl, W., Kursa, M., Wagner, E., and Kircheis, R. (2003) Tissue-dependent factors affect gene delivery to tumors in vivo. *Gene Ther.* 10, 1079-1088.
- 144) Wightman, L., Kircheis, R., and Wagner, E. (2003) Polymer-Based Gene Delivery Systems. Chapter 5 in "Pharmaceutical Gene Delivery Systems", *Drugs and the Pharmaceutical Sciences* Vol. 131, A. Rolland, S. M. Sullivan (Eds.), Marcel Dekker Inc., USA, p. 109-135.
- 145) Kircheis, R., and Wagner, E. (2003) Technology evaluation: TNFerade, *Gen Vec. Curr. Opin. Mol. Ther.* 5(4), 437-447.
- 146) Magin-Lachmann, C., Kotzamanis, G., D'Aiuto, L., Wagner, E., and Huxley, C. (2003) Retrofitting BACs with G418 resistance, luciferase, and oriP and EBNA-1 – new vectors for in vitro and in vivo delivery. *BioMedCentral Biotechnology* 3:2.
- 147) Kursa, M., Walker, G. F., Roessler, V., Ogris, M., Roedl, W., Kircheis, R., and Wagner, E. (2003) Novel shielded Transferrin-Polyethylene Glycol-Polyethylenimine / DNA Complexes for Systemic Tumor-Targeted Gene Transfer. *Bioconjug. Chem.* 14, 222-231.
- 148) Ogris, M., Walker, G., Blessing, T., Kircheis, R., Wolschek, M., and Wagner, E. (2003) Tumor-Targeted Gene Therapy: Strategies for the Preparation of Ligand-Polyethylene Glycol-Polyethylenimine / DNA Complexes. *J. Controlled Rel.* 91, 173-181.
- 149) Dätwyler, D.A., Magyar, J.P., Weikert, C., Wightman, L., Wagner, E., and Eppenberger, H.M. (2003) Reactivation of the mitosis-promoting factor in postmitotic cardiomyocytes. *Cell Tissues Organs* 175, 61-71.
- 150) Walker, G.F., and Wagner, E. (2004) Nonviral vector systems for cancer gene therapy. Chapter 24 in "Cancer Gene Therapy", D.T. Curiel and J.T. Douglas (Eds), Humana Press, Totowa, New Jersey, p. 367-378.
- 151) Magin-Lachmann, C., Kotzamanis, G., D'Aiuto, L., Cooke, H., Huxley, C., and Wagner, E. (2004) In vitro and in vivo delivery of intact BAC DNA – comparison of different methods. *J. Gene Med.* 6, 195-209.
- 152) Wagner, E. (2004) Strategies to improve DNA polyplexes for in vivo gene transfer – will "artificial viruses" be the answer? *Pharm. Res.* 21(1), 8-14.
- 153) Kircheis, R., and Wagner, E. (2005) Transferrin Receptor-Targeted Gene Delivery Systems. Chapter 34 in "Polymeric Gene Delivery, Principles and Applications", M.M. Amiji (Ed), CRC Press, Boca Raton, London, New York, Washington D.C., p. 537-556.
- 154) Kloeckner, J., Prasmickaite, L., Hogset, A., Berg, K., and Wagner, E. (2004) Photochemically enhanced gene delivery of EGF receptor-targeted DNA polyplexes. *J. Drug Targeting* 12 (4), 205-213.
- 155) Wagner, E., Kircheis, R., and Walker, G. F. (2004) Targeted nucleic acid delivery into tumors: new avenues for cancer therapy. *Biomedicine & Pharmacotherapy* 58, 152-161.
- 156) Lenter, M. C., Garidel P., Pelisek, J., Wagner, E., and Ogris, M. (2004) Stabilized non-viral formulations for the delivery of MCP-1 gene into cells of the vasculoendothelial system. *Pharm. Res.* 21(4), 683-691.
- 157) Ogris, M., von Gersdorff, K., van der Piepen, S., Brunner, S., and Wagner, E. (2004) Non-viral gene delivery systems – delivery techniques and therapeutic concepts for cancer. Chapter 7 in "Advanced Biomaterials for Medical Applications", D. W. Thomas (Ed), Kluwer Academic Publishers, p. 79-92.
- 158) Pelisek, J., Kühnl, A., Rolland, P.H., Mekkaoui, C., Fuchs, A., Walker, G.F., Ogris, M., Wagner, E., and Nikol, S. (2004) Functional analysis of genomic DNA, cDNA and nucleotide sequence of the mature C-type natriuretic peptide gene in vascular cells. *Arteriosclerosis, Thrombosis, Vascular Biol.* 24, 1646-1651.
- 159) Boeckle, S., von Gersdorff, K., van der Piepen, S., Culmsee, C., Wagner, E., and Ogris, M. (2004) Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. *J. Gene Med.* 6, 1102-1111.
- 160) Wagner, E. (2005) Polymer Nonviral Delivery Vehicles. *Encyclopedia of Diagnostic Genomics and Proteomics*, 1047-1051.
- 161) Von Gersdorff, K., Ogris, M., and Wagner, E. (2005) Cryoconserved Shielded and EGF Receptor Targeted DNA Polyplexes: Cellular Mechanisms. *Eur. J. Pharmaceutics Biopharmaceutics* 60, 279-285.

- 162) Walker, G.F., Fella, C., Pelisek, J., Fahrmeir, J., Boeckle, S., Ogris, M., and Wagner, E. (2005) Toward synthetic viruses: Endosomal pH triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. *Mol Ther* 11(3), 418-425.
- 163) Brabec, M., Schober, D., Wagner, E., Bayer, N., Murphy, R.F., Blaas, D., and Fuchs, R. (2005) Opening of size-selective pores in endosomes during human rhinovirus serotype 2 in vivo uncoating monitored by single-organelle flow analysis. *J Virol.* 79, 1008-16.
- 164) Günther, M., Wagner, E., and Ogris, M. (2005) Specific targets in tumor tissue for the delivery of therapeutic genes. *Curr Med Chem Anti-Canc Agents* 5, 157-171.
- 165) Wagner, E., Culmsee, C., Boeckle, S. (2005) Targeting of Polyplexes: Towards Synthetic Virus Vector Systems. Chapter 13 in "Non-Viral Vectors for Gene Therapy, Second Edition", L. Huang, M.C. Hung, E. Wagner (Eds.), Elsevier Academic Press, *Adv. Genetics* 53, 333-354.
- 166) Culmsee, C., Zhu, C., Landshamer, S., Becattini, B., Wagner, E., Pellechia, M., Blomgren, K., and Plesnila, N. (2005) Apoptosis-Inducing Factor Triggered by Poly(ADP-Ribose) Polymerase and Bid Mediates Neuronal Cell Death after Oxygen-Glucose Deprivation and Focal Cerebral Ischemia. *J. Neuroscience* 25, 10262-10272.
- 167) Zwioerek, K., Kloeckner, J., Wagner, E., and Coester, C. (2005) Gelatin nanoparticles as a new and simple gene delivery system. *J. Pharm. Pharm. Sci.* 7, 22-8.
- 168) Wagner, E., Kloeckner, J., and Ogris, M. (2005) Optimizing polyplexes into synthetic viruses for tumor-targeted gene therapy. Chapter in "Non-viral Gene Therapy: Gene Design and Delivery", K. Taira, K. Kataoka, T. Niidome (Eds.), Springer-Verlag Tokyo, p. 237-245.
- 169) Ameri, K., and Wagner, E. (2005) Receptor-Targeted Polyplexes. Chapter in "Gene Therapy. Therapeutic Mechanisms and Strategies", 2nd Edition, N. Smyth-Templeton (Ed), Marcel Dekker Inc, New York.
- 170) Couvreur, P., Braguer, D., Crommelin, D.J.A., Duchene, D., Engels, J.W., Kerr, D.J., Krogsgaard-Larsen, P., Meijer, D.K., Paoletti, R., and Wagner, E. (2005) Contribution of academic research to discovery and development of medicines: current status and future opportunities. *Eur. J. Pharm. Sci.* 24, 245-252.
- 171) Boeckle, S., Wagner, E., and Ogris, M. (2005) C- versus N-terminally linked melittin-polyethylenimine conjugates: the site of linkage strongly influences activity of DNA polyplexes. *J. Gene Med.* 7, 1335-1347.
- 172) Pelisek, J., Gaedtke, L., DeRouchey, J., Walker, G. F., Nikol, S., and Wagner, E. (2006) Optimized lipopolyplex formulations for gene transfer to human colon carcinoma cells under in vitro conditions. *J. Gene Med.* 8, 186-197.
- 173) Wagner, E., and Kloeckner, J. (2006) Gene delivery using polymer therapeutics. *Adv. Polym. Sci* 192, 135-173.
- 174) Shir, A., Ogris, M., Wagner, E., and Levitzki, A. (2006) EGF Receptor-Targeted Synthetic Double-Stranded RNA Eliminates Glioblastoma, Breast Cancer, and Adenocarcinoma Tumors in Mice. *PLoS Med.* 3(1), e6.
- 175) Bausinger, R., von Gersdorff, K., Braeckmans, K., Ogris, M., Wagner, E., Bräuchle, C., and Zumbusch, A. (2006) The Transport of Nanosized Gene Carriers Unraveled by Live-Cell Imaging. *Angew. Chem.* 118, 1598-1602.
- 176) Zintchenko, A., Ogris, M., and Wagner, E. (2006) Temperature Dependent Gene Expression Induced by PNIPAM-based Copolymers: Potential of Hyperthermia in Gene Transfer. *Bioconjug. Chem.* 17(3), 766-772.
- 177) Boeckle, S., Fahrmeir, J., Roedl, W., Ogris, M., Wagner, E. (2006) Melittin analogs with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes. *J. Control. Rel.* 112, 240-248.
- 178) Prasmickaite, L., Hellum, M., Kaalhus, O., Hogset, A., Wagner, E., and Berg, K. (2006) Photochemical Internalisation (PCI) of Transgenes Controlled by the Heat-Shock Protein 70 Promoter. *Photochemistry Photobiology* 82, 809-816.
- 179) Günther, M., Waxman, D. J., Wagner, E., and Ogris, M. (2006) Effects of Hypoxia and Limited Diffusion in Tumor Cell Microenvironment on Bystander Effect of P450 Prodrug Therapy. *Cancer Gene Ther.* 13(8), 771-779.

- 180) DeRouchey, J., Walker, G.F., Wagner, E., and Rädler, J.O. (2006) Decorated Rods: A “Bottom-Up” Self-Assembly of Monomolecular DNA Complexes. *J. Phys. Chem.* 110, 4548-4554.
- 181) Von Gersdorff, K., Sanders, N.N., Vandenbroucke, R., De Smedt, S.C., Wagner, E., and Ogris, M. (2006) The internalization route resulting in successful gene expression depends on both cell line and polyethylenimine polyplex type. *Mol. Ther.* 14(5), 745-753.
- 182) Meyer, M., and Wagner, E. (2006) Bioresponsive shielding of nonviral gene vectors. *Expert Opinion on Drug Delivery* 3(5), 563-571.
- 183) Kloeckner, J., Bruzzano, S., Ogris, M., and Wagner, E. (2006) Gene Carriers Based on Hexanediol Diacrylate-linked Oligoethylenimine: Effect of Chemical Structure of Polymer on Biological Properties. *Bioconjug. Chem.* 17(5), 1339-1345.
- 184) Kloeckner, J., Boeckle, S., Persson, D., Roedl, W., Ogris, M., Berg, K., Wagner, E. (2006) DNA polyplexes based on degradable oligoethylenimine-derivatives: Combination with EGF receptor targeting and endosomal release functions. *J. Control. Rel.* 116, 115-122.
- 185) Kloeckner, J., Wagner, E., and Ogris, M. (2006) Degradable Gene Carriers Based on Oligomerized Polyamines. *Eur. J. Pharm. Sci.* 29, 414-425.
- 186) Culmsee, C., Gasser, E., Hansen, S., Tonn, J.C., Wagner, E., and Goldbrunner, R. (2006) Effects of Raf-1 siRNA on human cerebral microvascular endothelial cells: A potential therapeutic strategy for inhibition of tumor angiogenesis. *Brain Research* 1125, 147-154.
- 187) Meyer, M., and Wagner, E. (2006) Recent Developments in the Application of Plasmid DNA-Based Vectors and Small Interfering RNA Therapeutics for Cancer. *Human Gene Ther.* 17, 1062–1076.
- 188) Boeckle, S., and Wagner, E. (2006) Optimizing Targeted Gene Delivery: Chemical Modification of Viral Vectors and Synthesis of Artificial Virus Vector Systems. *AAPS J.* 8(4), E731-E742.
- 189) Bonsted, A., Høgset, A., Wagner, E., Berg, K. (2007) Photochemical internalization for light-directed gene delivery. Chapter 73 in “Gene Transfer: Delivery and expression of DNA and RNA. A laboratory manual”, T. Friedmann, J. Rossi (Eds.), CSHL Press, New York, pp. 731-737.
- 190) Wagner, E. and Ogris, M. (2007) Strategies to incorporate CPPs into synthetic viruses for tumor-targeted gene therapy. Chapter 26 in “Cell-Penetrating Peptides, 2nd Edition”, Ü. Langel (Ed.), CRC Press, pp. 455-468.
- 191) Wagner, E. (2007) Selective Targeting to Tumors and Other Tissues with Cell-Penetrating Peptides: In Vivo Applications. In “Cell-Penetrating Peptides, 2nd Edition”, Ü. Langel (Ed.), CRC Press, pp. 409-411.
- 192) Gaedtke, L., Pelisek, J., Lipinski, K. S., Wrighton, C. J., and Wagner, E. (2007) Transcriptionally targeted nonviral gene transfer using a β -catenin/TCF-dependent promoter in a series of different human low passage colon cancer cells. *Mol. Pharmaceutics* 4(1), 129-139.
- 193) Ogris, M. and Wagner, E. (2007) Linear Polyethylenimine: synthesis and transfection procedures for in vitro and in vivo. Chapter 51 in “Gene Transfer: Delivery and expression of DNA and RNA. A laboratory manual”, T. Friedmann, J. Rossi (Eds.), CSHL Press, New York, pp. 521-526.
- 194) Ogris, M., Kotha, A.K., Tietze, N., Wagner, E., Palumbo, F.S., Giammona, G., and Cavallaro, G. (2007) Novel Biocompatible Cationic Copolymers Based on Polyaspartylhydrazide Being Potent as Gene Vector on Tumor Cells. *Pharm. Res.* 24(12), 2213-2222.
- 195) Cardoso, A.L.C., Simões, S., de Almeida, L.P., Pelisek, J., Culmsee, C., Wagner, E., Pedroso de Lima, M.C. (2007) siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. *J. Gene Med.* 9, 170-183.
- 196) Berg, K., Folini, M., Prasmickaite, L., Selbo, P.K., Bonsted, A., Engesæter, B.O., Zaffaroni, N., Weyergang, A., Dietze, A., Mælandsmo, G.M., Wagner, E., Norum, O., Høgset, A. (2007) Photochemical internalization. A new tool for drug delivery. *Curr. Pharm. Biotechnol.* 8, 362-372.
- 197) Ameri, K., Hammond, E.M., Culmsee, C., Raida, M., Katschinski, D.M., Wenger, R.H., Wagner, E., Davis, R.J., Hai, T., Denko, N., and Harris, A.L. (2007) Induction of activating transcription factor 3 by anoxia is independent of p53 and the hypoxic HIF signalling pathway. *Oncogene* 26, 284-289.
- 198) Knorr, V., Allmendinger, L., Walker, G.F., Paintner, F.F., and Wagner, E. (2007) An acetal based PEGylation reagent for pH-sensitive shielding of DNA polyplexes. *Bioconjug. Chem.* 18(4), 1218-1225.
- 199) Russ, V. and Wagner, E. (2007) Cell and tissue targeting of nucleic acids for cancer gene therapy. *Pharm. Res.* 24(6), 1047-1057.

- 200) Gaedtke, L., Thoenes, L., Culmsee, C., Mayer, B., and Wagner, E. (2007) Proteomic analysis reveals differences in protein expression in spheroid versus monolayer cultures of low passage colon carcinoma cells. *J. Proteome Res.* 6, 4111-4118.
- 201) Wagner, E. (2007) Advances in cancer gene therapy: tumor-targeted delivery of therapeutic pDNA, siRNA, and dsRNA nucleic acids. *J. BUON* 12, S77-S82.
- 202) de Bruin, K., Ruthardt, N., von Gersdorff, K., Bausinger, R., Wagner, E., Ogris, M., and Braeuchle, C. (2007) Cellular dynamics of EGF receptor-targeted synthetic viruses. *Mol. Ther.* 15(7), 1297-1305.
- 203) Tarcha, P.J., Pelisek, J., Merdan, T., Waters, J., Cheung, K., von Gersdorff, K., Culmsee, C., and Wagner, E. (2007) Synthesis and characterization of chemically condensed oligoethylenimine containing beta-aminopropionamide linkages for siRNA delivery. *Biomaterials* 28(25), 3731-3740.
- 204) Meyer, M., Zintchenko, A., Ogris, M., and Wagner, E. (2007) A dimethylmaleic acid-melittin-polylysine conjugate with reduced toxicity, pH-triggered endosomolytic activity and enhanced gene transfer potential. *J. Gene Med.* 9(9), 797-805.
- 205) Plesnila, N., von Baumgarten, L., Retiounskaia, M., Engel, D., Ardeshiri, A., Zimmermann, R., Hoffmann, F., Landshamer, S., Wagner, E., and Culmsee, C. (2007) Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF- κ B transcriptional activity. *Cell Death Differ.* 14, 1529-1541.
- 206) Wagner, E. (2007) Programmed drug delivery: nanosystems for tumor targeting. *Expert Opin. Biol. Ther.* 7(5), 587-593.
- 207) Fahrmeir, J., Gunther, M., Tietze, N., Wagner, E., and Ogris, M. (2007) Electrophoretic purification of tumor-targeted polyethylenimine-based polyplexes reduces toxic side effects in vivo. *J. Control. Rel.* 122, 236-245.
- 208) Wagner, E. (2007) Nonviral gene transfer to tumors. A new route to programmed drug delivery? In: "Eurocancer 2007", M. Boiron, M. Marty (Eds), John Libbey Eurotext, Paris, pp 115-116.
- 209) Wagner, E. (2007) Gentherapie. Chapter 3A in "Pathophysiologie, Molekulare, zelluläre, systemische Grundlagen von Krankheiten". S. Schwarz, O. Förster, M. Peterlik, K. Schauenstein, G. Wick (Eds.), Maudrich, Vienna, pp. 3-1 - 3-8.
- 210) Tietze, N., Pelisek, J., Philipp, A., Roedl, W., Merdan, T., Tarcha, P., Ogris, M., and Wagner, E. (2008) Induction of apoptosis in murine neuroblastoma by systemic delivery of transferrin-shielded siRNA polyplexes for downregulation of RAN. *Oligonucleotides* 18, 161-174.
- 211) Cardoso, A.L., Simões, S., de Almeida, L.P., Plesnila, N., Pedroso de Lima, M.C., Wagner, E., and Culmsee, C. (2008) Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS. *J. Control. Release* 132(2), 113-123.
- 212) Philipp, A., Wagner, E. (2008) Receptor-targeted polyplexes for DNA and siRNA delivery. Chapter 15 in "Gene and Cell Therapy. Therapeutic Mechanisms and Strategies", 3rd Edition, N. Smyth Templeton (Ed), CRC Press, pp. 341-361.
- 213) Russ, V., Elfberg, H., Thoma, C., Kloeckner, J., Ogris, M., and Wagner, E. (2008) Novel degradable oligoethylenimine-acrylate ester-based pseudodendrimers for in vitro and in vivo gene transfer. *Gene Ther.* 15, 18-29.
- 214) Landshamer, S., Hoehn, M., Barth, N., Duvezin-Caubet, S., Schwake, G., Tobaben, S., Kazhdan, I., Becattini, B., Zahler, S., Vollmar, A., Pellicchia, M., Reichert, A., Plesnila, N., Wagner, E., and Culmsee, C. (2008) Bid-induced release of AIF from mitochondria causes immediate neuronal cell death. *Cell Death Differ.* 15, 1553-1563.
- 215) Bonsted, A., Wagner, E., Prasmickaite, L., Høgset, A., Berg, K. (2008) Photochemical enhancement of DNA delivery by EGF receptor targeted polyplexes. Chapter 11 in "Methods in Molecular Biology, vol.434: Volume 2", J. M. LeDoux (Ed.), Humana Press, pp. 171-181.
- 216) Wagner, E. (2008) Converging paths of viral and non-viral vector engineering. *Mol. Ther.* 16, 1-2.
- 217) Meyer, M., Philipp, A., Oskuee, R., Schmidt, C., and Wagner, E. (2008) Breathing life into polycations: functionalization with pH-responsive endosomolytic peptides and polyethylene glycol enables siRNA delivery. *J. Am. Chem. Soc.* 130, 3272-3273.
- 218) DeRouchey, J., Schmidt, C., Walker, G. F., Koch, C., Plank, C., Wagner, E., and Rädler, J. O. (2008) Monomolecular Assembly of siRNA and Poly(ethyleneglycol)-Peptide Copolymers. *Biomacromolecules* 9, 724-732.

- 219) Günther, M., Wagner, E., Ogris, M. (2008) Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy? *J. Cell. Mol. Med.* 12, 2704-2716.
- 220) Vandenbroucke R.E., de Geest, B.G., Bonne, S., Vinken, M., van Haecke, T., Heimberg, H., Wagner, E., Rogiers, V., de Smedt, S., Demeester, J., and Sanders, N.N. (2008) Prolonged gene silencing in hepatoma cells and primary hepatocytes after siRNA delivery with biodegradable poly(beta-amino esters). *J. Gene Med.* 10, 783-794.
- 221) Schaffert, D., Wagner, E. (2008) Gene therapy progress and prospects: synthetic polymer-based systems. *Gene Ther.* 15, 1131-1138.
- 222) Wagner, E. (2008) Ten-Year anniversary of *Current Opinion in Molecular Therapeutics*: A decade of experience in molecular therapeutics – Progress, setbacks and surprises. *Curr. Opin. Mol. Ther.* 10(6), 544-547.
- 223) Knorr, V., Russ, V., Allmendinger, L., Ogris, M., and Wagner, E. (2008) Acetal linked oligoethylenimines for use as pH-sensitive gene carriers. *Bioconjug. Chem.* 19, 1625-1634.
- 224) Fella, C., Walker, G.F., Ogris, M., and Wagner, E. (2008) Amine-reactive pyridylhydrazone-based PEG reagents for pH-reversible PEI polyplex shielding. *Eur. J. Pharm. Sc.* 34, 309-320.
- 225) Cavallaro, G., Scirè, S., Licciardi, M., Ogris, M., Wagner, E., Giammona, G. (2008) Polyhydroxyethylaspartamide-spermine copolymers: Efficient vectors for gene delivery. *J. Control. Release* 131, 54-63.
- 226) de Bruin, K.G., Fella, C., Ogris, M., Wagner, E., Ruthardt, N., Bräuchle, C. (2008) Dynamics of photoinduced endosomal release of polyplexes. *J. Control. Release* 130, 175-182.
- 227) Wagner, E. (2008) The Silent (R)evolution of Polymeric Nucleic Acid Therapeutics. *Pharm. Res.* 25, 2920-2923.
- 228) Zintchenko, A., Philipp, A., Dehshahri, A., and Wagner, E. (2008) Simple Modifications of Branched PEI Lead to Highly Efficient siRNA Carriers with Low Toxicity. *Bioconjug. Chem.* 19, 1448-1455.
- 229) Coulter, J.A., McCarthy, H.O., Xiang, J., Roedl, W., Wagner, E., Robson, T., and Hirst, D.G. (2008) Nitric oxide – A novel therapeutic for cancer. *Nitric Oxide* 19, 192-198.
- 230) Knorr, V., Ogris, M., and Wagner, E. (2008) An Acid Sensitive Ketal-Based Polyethylene Glycol-Oligoethylenimine Copolymer Mediates Improved Transfection Efficiency at Reduced Toxicity. *Pharm. Res.* 25, 2937-2945.
- 231) Schwerdt, A., Zintchenko, A., Concia, M., Roesen, N., Fisher, K., Lindner, L.H., Issels, R., Wagner, E., and Ogris, M. (2008) Hyperthermia induced targeting of thermosensitive gene carriers to tumors. *Hum. Gene Ther.* 19, 1283-1292.
- 232) Russ, V., Günther, M., Halama, A., Ogris, M., and Wagner, E. (2008) Oligoethylenimine-grafted polypropylenimine dendrimers as degradable and biocompatible synthetic vectors for gene delivery. *J. Control. Release* 132(2), 131-140.
- 233) Schlossbauer, A., Schaffert, D., Kecht, J., Wagner, E., and Bein, T. (2008) Click Chemistry for High-Density Biofunctionalization of Mesoporous Silica. *J. Am. Chem. Soc.* 130, 12558-12559.
- 234) Philipp, A., Meyer, M., and Wagner, E. (2008) Extracellular Targeting of Synthetic Therapeutic Nucleic Acid Formulations. *Curr. Gene Ther.* 8, 324-334.
- 235) Slemmer, J.E., Zhu, C., Landshamer, S., Trabold, R., Grohm, J., Ardeshiri, A., Wagner, E., Sweeney, M.I., Blomgren, K., Culmsee, C., Weber, J.T., and Plesnila, N. (2008) Causal role of apoptosis-inducing factor (AIF) for neuronal cell death following traumatic brain injury. *Am. J. Pathol.* 173, 1795-1805.
- 236) Yu, H., Wagner, E. (2009) Bioresponsive Polymers for Nonviral Gene Delivery. *Curr. Op. Mol. Ther.* 11, 165-178.
- 237) Philipp, A., Zhao, X., Tarcha, P., Wagner, E., Zintchenko, A. (2009) Hydrophobically Modified Oligoethylenimines as Highly Efficient Transfection Agents for siRNA Delivery. *Bioconjugate Chem.* 20, 2055-2061.
- 238) Meyer, M., Dohmen, C., Philipp, A., Kiener, D., Maiwald, G., Scheu, C., Ogris, M., Wagner, E. (2009) Synthesis and Biological Evaluation of a Bioresponsive and Endosomolytic siRNA-Polymer Conjugate. *Mol. Pharm.* 6, 752-762.

- 239) Klutz, K., Russ, V., Willhauck, M.J., Wunderlich, N., Zach, C., Gildehaus, F.J., Göke, B., Wagner, E., Ogris, M., Spitzweg, C. (2009) Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene. *Clin. Cancer Res.* 15(19), 6079-6086.
- 240) Yu, H., Russ, V., Wagner, E. (2009) Influence of the Molecular Weight of Bioreducible Oligoethylenimine Conjugates on the Polyplex Transfection Properties. *AAPS J.* 11(3), 445-455.
- 241) Zintchenko, A., Susha, A.S., Concia, M., Feldmann, J., Wagner, E., Rogach, A.L., Ogris, M. (2009) Drug Nanocarriers Labeled With Near-infrared-emitting Quantum Dots (Quantoplexes): Imaging Fast Dynamics of Distribution in Living Animals. *Mol. Ther.* 17(11), 1849-1856.
- 242) Russ, V., Fröhlich, T., Li, Y., Halama, A., Ogris, M., Wagner, E. (2010) Improved in vivo gene transfer into tumor tissue by stabilization of pseudodendritic oligoethylenimine-based polyplexes. *J. Gene Med.* 12, 180-193.
- 243) Buyens, K., Meyer, M., Wagner, E., Demeester, J., De Smedt, S.C., Sanders, N.N. (2010) Monitoring the disassembly of siRNA polyplexes in serum is crucial for predicting their biological efficacy. *J. Control. Release* 141(1), 38-41.
- 244) Cardoso, A.L., Costa, P., de Almeida, L.P., Simões, S., Plesnila, N., Culmsee, C., Wagner, E., Pedroso de Lima, M.C. (2010) Tf-lipoplex-mediated c-Jun silencing improves neuronal survival following excitotoxic damage in vivo. *J. Control. Release* 142, 392-403.
- 245) Fröhlich, T., Wagner, E. (2010) Peptide- and polymer-based delivery of therapeutic RNA. *Soft Matter* 6, 226-234.
- 246) Salcher, E.E., Wagner, E. (2010) Chemically programmed polymers for targeted DNA and siRNA transfection. *Topics in Current Chemistry* 296, 227-249. Also in: *Nucleic Acid Transfection* (W. Bielke, C. Erbacher, Eds.), Springer.
- 247) Maier, K., Wagner, E. (2010) Intracellular fate of plasmid DNA polyplexes. Chapter 7 in: *Organelle-Specific Pharmaceutical Nanotechnology* (V. Weissig, G. D'Souza, Eds.), John Wiley & Sons, pp. 123-142.
- 248) Espenlaub, S., Corjon, S., Engler, T., Wagner, E., Ogris, M., Fella, C., Kochanek, S., Kreppel, F. (2010) Capsomer-specific fluorescent labeling of adenovirus vector particles allows for detailed analysis of intracellular particle trafficking and the performance of bioresponsive bonds for vector capsid modifications. *Hum. Gene Ther.* 21, 1155-1167.
- 249) Navarro, G., Maiwald, G., Haase, R., Rogach, A., Wagner, E., Tros de Ilarduya, C., Ogris, M. (2010) Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumors after systemic delivery. *J. Control. Rel.* 146, 99-105.
- 250) Thoenes, L., Hoehn, M., Kashirin, R., Ogris, M., Arnold, G.J., Wagner, E., Guenther, M. (2010) In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy. *J. Proteomics* 73, 1342-1354.
- 251) Rupprecht, S., Hagedorn, C., Seruggia, D., Magnusson, T., Wagner, E., Ogris, M., Lipps, H.J. (2010) Controlled removal of a nonviral episomal vector from transfected cells. *Gene* 466, 36-42.
- 252) Wagner, E. (2010) Die Barriere Zellmembran – Wie sie von natürlichen und künstlichen Viren überwunden wird. In: *Biologie für Einsteiger* (Fritsche, O., Ed.), Springer.
- 253) de Vrij, J., Willemsen, R.A., Lindholm, L., Hoeben, R.C.; GIANT Consortium, Bangma, C.H., Barber, C., Behr, J.P., Briggs, S., Carlisle, R., Cheng, W.S., Dautzenberg, I.J., de Ridder, C., Dzojic, H., Erbacher, P., Essand, M., Fisher, K., Frazier, A., Georgopoulos, L.J., Jennings, I., Kochanek, S., Koppers-Lalic, D., Kraaij, R., Kreppel, F., Magnusson, M., Maitland, N., Neuberg, P., Nugent, R., Ogris, M., Remy, J.S., Scaife, M., Schenk-Braat, E., Schooten, E., Seymour, L., Slade, M., Szyjanowicz, P., Totterman, T., Uil, T.G., Ulbrich, K., van der Weel, L., van Weerden, W., Wagner, E., Zuber, G. (2010) Adenovirus-derived vectors for prostate cancer gene therapy. *Hum. Gene Ther.* 21(7), 795-805.
- 254) Schenk, E., Essand, M., Bangma, C.H.; GIANT FP6 Consortium, Barber, C., Behr, J.P., Briggs, S., Carlisle, R., Cheng, W.S., Danielsson, A., Dautzenberg, I.J., Dzojic, H., Erbacher, P., Fisher, K., Frazier, A., Georgopoulos, L.J., Hoeben, R., Kochanek, S., Koppers-Lalic, D., Kraaij, R., Kreppel, F., Lindholm, L., Magnusson, M., Maitland, N., Neuberg, P., Nilsson, B., Ogris, M., Remy, J.S., Scaife, M., Schooten, E., Seymour, L., Totterman, T., Uil, T.G., Ulbrich, K., Veldhoven-Zweistra, J.L., de Vrij, J., van Weerden, W., Wagner, E., Willemsen, R. (2010) Clinical adenoviral gene therapy for prostate cancer. *Hum. Gene Ther.* 21(7), 807-813.

- 255) Oskuee, R.K., Philipp, A., Dehshahri, A., Wagner, E., Ramezani, M. (2010) The impact of carboxyalkylation of branched polyethylenimine on effectiveness in small interfering RNA delivery. *J Gene Med.* 12, 729-738.
- 256) Berg, K., Weyergang, A., Prasmickaite, L., Bonsted, A., Høgset, A., Strand, M.T., Wagner, E., Selbo, P.K. (2010) Photochemical internalization (PCI): a technology for drug delivery. *Methods Mol Biol.* 635, 133-145.
- 257) Nie, Y., Schaffert, D., Rödl, W., Ogris, M., Wagner, E., Günther, M. (2011). Dual-Targeted Polyplexes: One step towards a synthetic virus for cancer gene therapy. *J. Control. Release* 152,127-134.
- 258) Schlossbauer, A., Dohmen, C., Schaffert, D., Wagner, E., Bein, T. (2011) pH-Responsive Release of Acetal-Linked Mellitin from SBA-15 Mesoporous Silica. *Angew. Chem. Int. Ed. Engl.* 50(30), 6828-6830.
- 259) Edinger, D., Wagner, E. (2011) Bioresponsive polymers for the delivery of therapeutic nucleic acids. *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* 3(1), 33-46.
- 260) Schaffert, D., Kiss, M., Rödl, W., Shir, A., Levitzki, A., Ogris, M., Wagner, E. (2011) Poly(I:C) mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier. *Pharm. Res.* 28(4), 731-741.
- 261) Philipp, A., Meyer, M., Zintchenko, A., Wagner, E. (2011) Functional modification of amide-crosslinked oligoethylenimine for improved siRNA delivery. *React. Funct. Polym.* 71, 288-293.
- 262) Kasper, J.C., Schaffert, D., Ogris, M., Wagner, E., Friess, W. (2011) The establishment of an up-scaled micro-mixer method allows the standardized and reproducible preparation of well-defined plasmid/LPEI polyplexes. *Eur. J. Pharm Biopharm.* 77(1), 182-185.
- 263) Kasper, J.C., Schaffert, D., Ogris, M., Wagner, E., Friess, W. (2011) Development of a Lyophilized Plasmid/LPEI Polyplex Formulation with Long-Term Stability - A Step Closer from Promising Technology to Application. *J. Control Rel.* 151, 246-255.
- 264) Klutz, K., Schaffert, D., Willhauck, M.J., Grünwald, G.K., Haase, R., Wunderlich, N., Zach, C., Gildehaus, F.J., Senekowitsch-Schmidtke, R., Göke, B., Wagner, E., Ogris, M., Spitzweg, C. (2011) Epidermal Growth Factor Receptor-targeted (131I)-therapy of Liver Cancer Following Systemic Delivery of the Sodium Iodide Symporter Gene. *Mol. Ther.* 19, 676-685.
- 265) Schaffert, D., Badgular, N., Wagner, E. (2011) Novel Fmoc-Polyamino Acids for Solid-Phase Synthesis of Defined Polyamidoamines. *Org. Lett.* 13, 1586-1589.
- 266) Dohmen, C., Wagner, E. (2011) Multifunctional CPP polymer system for tumor-targeted pDNA and siRNA delivery. *Methods Mol Biol.* 683, 453-463. Also Chapter 32 in: *Cell-Penetrating Peptides: Methods and Protocols* (Ülo Langel, Ed.), Humana Press.
- 267) Shir, A., Ogris, M., Roedl, W., Wagner, E., Levitzki, A. (2011) EGFR-homing dsRNA activates cancer targeted immune response and eliminates disseminated EGFR over-expressing tumors in mice. *Clin. Cancer Res.* 17, 1033-1043.
- 268) Nie, Y, Guenther, M., Gu, Z., Wagner, E. (2011) Pyridylhydrazone-based PEGylation for pH-reversible lipopolyplex shielding. *Biomaterials* 32, 858-869.
- 269) Bogomilova, A., Günther, M., Hägele, G., Wagner, E., and Troev, K. (2011) Synthesis, NMR-Spectroscopy and Molecular Structure of a Phosphonyl Ene Diamine. *Z. Anorg. Allg. Chem.* 637, 1213–1219.
- 270) Yu, H., Nie, Y., Dohmen, C., Li, Y., Wagner, E. (2011) Epidermal Growth Factor–PEG Functionalized PAMAM-Pentaethylenehexamine Dendron for Targeted Gene Delivery Produced by Click Chemistry. *Biomacromolecules* 12, 2039-2047.
- 271) Knoop, K., Kolokythas, M., Klutz, K., Willhauck, M.J., Wunderlich, N., Draganovici, D., Zach, C., Gildehaus, F.J., Böning, G., Göke, B., Wagner, E., Nelson, P.J., Spitzweg, C. (2011) Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. *Mol. Ther.* 19, 1704-1713.
- 272) Shir, A., Levitzki, A., Wagner, E., Ogris, M. (2011) Nucleic acid-based therapeutics for glioblastoma. *Anticancer Agents Med Chem.* 11, 693-699.
- 273) Ogris, M., Wagner, E. (2011) To be targeted: Is the magic bullet concept a viable option for synthetic nucleic acid therapeutics? *Human Gene Ther.* 22, 799-807.

- 274) Schäfer, A., Pahnke, A., Schaffert, D., van Weerden, W.M., de Ridder, C.M., Rödl, W., Vetter, A., Spitzweg, C., Kraaij, R., Wagner, E., Ogris, M. (2011) Disconnecting the Yin and Yang Relation of Epidermal Growth Factor Receptor (EGFR)-Mediated Delivery: A Fully Synthetic, EGFR-Targeted Gene Transfer System Avoiding Receptor Activation. *Hum. Gene Ther.* 22, 1463-1473.
- 275) Lächelt, U., Wagner, E. (2011) Invading target cells: multifunctional polymer conjugates as therapeutic nucleic acid carriers. *Frontiers Chem. Science Eng.* 5, 275–286.
- 276) Troiber, C., Wagner, E. (2011) Nucleic acid carriers based on precise polymer conjugates. *Bioconjug. Chem.* 22, 1737–1752.
- 277) Dussmann, P., Pagel, J.I., Vogel, S., Magnusson, T., Zimmermann, R., Wagner, E., Schaper, W., Ogris, M., Deindl, E. (2011) Live in vivo imaging of Egr-1 promoter activity during neonatal development, liver regeneration and wound healing. *BMC Developmental Biology* 11, 28.
- 278) Schaffert, D., Troiber, C., Salcher, E.E., Fröhlich, T., Martin, I., Badgular, N., Dohmen, C., Edinger, D., Kläger, R., Maiwald, G., Farkasova, K., Seeber, S., Jahn-Hofmann, K., Hadwiger, P., Wagner, E. (2011) Solid-Phase Synthesized Sequence-Defined T-Shape, i-Shape and U-Shape Polymers for pDNA and siRNA Delivery. *Angew. Chem. Int. Ed. Engl.* 50, 8986-8989.
- 279) Schaffert, D., Troiber, C., Salcher, E.E., Fröhlich, T., Martin, I., Badgular, N., Dohmen, C., Edinger, D., Kläger, R., Maiwald, G., Farkasova, K., Seeber, S., Jahn-Hofmann, K., Hadwiger, P., Wagner, E. (2011) Festphasen-basierte Synthese sequenzdefinierter T-, i- und U-Form-Polymere für den pDNA- und siRNA-Transfer. *Angew. Chem.* 123, 9149 –9152.
- 280) Magnusson, T., Haase, R., Schleef, M., Wagner, E., Ogris, M. (2011) Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations. *J. Gene Med.* 13, 382–391.
- 281) Klutz, K., Willhauck, M.J., Dohmen, C., Wunderlich, N., Knoop, K., Zach, C., Senekowitsch-Schmidtke, R., Gildehaus, F.J., Ziegler, S., Fürst, S., Göke, B., Wagner, E., Ogris, M., Spitzweg, C. (2011) Image-guided tumor-selective radioiodine therapy of liver cancer following systemic nonviral delivery of the sodium iodide symporter gene. *Hum. Gene Ther.* 22, 1563-1574.
- 282) Bogomilova, A., Hägele, G., Troev, K., Wagner, E. and Günther, M. (2012) Hydrogen Bonding in α -Aminophosphonic Acids. Phosphorus, Sulfur, and Silicon and the Related Elements 187, 165-180.
- 283) Nie, Y., Wagner, E. (2012) pH-responsive Polymers for Delivery of Nucleic Acid Therapeutics. In: *Polymeric Biomaterials, Volume II* (Severian Dumitriu Ed.), Taylor&Francis.
- 284) Wagner, E. (2012) Functional Polymer Conjugates for Medicinal Nucleic Acid Delivery. *Adv. Polymer Sci.* 247, 1–30.
- 285) Wagner, E. (2012) Polymers for siRNA Delivery: Inspired by Viruses to be Targeted, Dynamic and Precise. *Accounts Chem. Res.* 45, 1005–1013.
- 286) Scholz, C., Wagner, E. (2012) Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. *J. Control. Rel.* 161, 554-65.
- 287) Dohmen, C., Fröhlich, T., Lächelt, U., Röhl, I., Vornlocher, H.-P., Hadwiger, P., Wagner, E. (2012) Defined Folate-PEG-siRNA Conjugates for Receptor Specific Gene Silencing. *Mol. Ther. Nucleic Acids* 1, e7, 1-6.
- 288) Abourbeh, G., Shir, A., Mishani, E., Ogris, M., Rödl, W., Wagner, E., Levitzki, A. (2012) PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors. *IUBMB Life* 64, 324-30.
- 289) Bogomilova, A., Günther, M., Wagner, E., Hägele, G., Troev, K. (2012) Synthesis and Characterization of New Platinum (II) Phosphinate Complexes. *J. Coord. Chem.* 65, 1093-1106.
- 290) Noga, M., Edinger, D., Rödl, W., Wagner, E., Winter, G., Besheer, A. (2012) Controlled shielding and deshielding of gene delivery polyplexes using hydroxyethyl starch (HES) and alpha-amylase. *J. Control. Rel* 159, 92-103.
- 291) Martin, I., Dohmen, C., Mas-Moruno, C., Troiber, C., Kos, P., Schaffert, D., Lächelt, U., Teixidó, M., Günther, M., Kessler, H., Giralt, E., Wagner, E. (2012) Solid-phase-assisted synthesis of targeting peptide-PEG-oligo(ethane amino)amides for receptor-mediated gene delivery. *Org. Biomol. Chem.* 10, 3258–3268.
- 292) Ogris, M., Wagner, E. (2012) Synthesis of linear polyethylenimine and use in transfection. *Cold Spring Harb. Protoc.* 2012, 246-50.

- 293) Oak, P.S., Kopp, F., Thakur, C., Ellwart, J.W., Rapp, U.R., Ullrich, A., Wagner, E., Knyazev, P., Roidl, A. (2012) Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently eradicates HER2-positive cancer cells and cancer stem cells. *Int. J. Cancer* 131, 2808-19.
- 294) Fröhlich, T., Edinger, D., Kläger, R., Schaffert, D., Troiber, C., Badgular, N., Martin, I., Salcher, E., Hadwiger, P., Vornlocher, H.-P., Wagner, E. (2012) Structure-activity relationships of precise oligo(ethane amino) amides for siRNA delivery. *J. Control. Rel.* 160, 532-541.
- 295) Schaffert, D., Troiber, C., Wagner, E. (2012) New Sequence-defined polyaminoamides with tailored endosomolytic properties for plasmid DNA delivery. *Bioconjug. Chem.* 23, 1157-1165.
- 296) Rath, S., Liebl, J., Fürst, R., Ullrich, A., Burkhart, J.L., Kazmaier, U., Herrmann, J., Müller, R., Günther, M., Schreiner, L., Wagner, E., Vollmar, A.M., Zahler, S. (2012) Anti-angiogenic effects of the tubulysin precursor pretubulysin and of simplified pretubulysin derivatives. *British J. Pharmacology* 167, 1048-1061.
- 297) Maier, K., Wagner, E. (2012) Acid-labile traceless click linker for protein transduction. *J. Am. Chem. Soc.* 134, 10169-73.
- 298) Mickler, F.M., Möckel, L., Ruthardt, N., Ogris, M., Wagner, E., Bräuchle, C. (2012) Tuning nanoparticle uptake: Live-cell imaging reveals two endocytosis mechanisms mediated by natural and artificial EGFR targeting ligand. *Nano Letters* 12, 3417-23.
- 299) Dohmen, C., Edinger, D., Fröhlich, T., Schreiner, L., Lächelt, U., Troiber, C., Rädler, J.O., Hadwiger, P., Vornlocher, H.-P., Wagner, E. (2012) Nano sized carrier system with beneficial biophysical properties for folic acid receptor specific siRNA delivery. *ACS Nano* 6, 5198–5208.
- 300) Salcher, E., Kos, P., Fröhlich, T., Badgular, N., Scheible, M., Wagner, E. (2012) Sequence-defined Four-arm Oligo(ethan amino)amides for pDNA and siRNA Delivery: Impact of Building Blocks on Efficacy. *J. Control. Rel.* 164, 380–386.
- 301) Wiedmann, R.M., von Schwarzenberg, K., Palamidessi, A., Schreiner, L., Kubisch, R., Liebl, J., Schempp, C., Trauner, D., Vereb, G., Zahler, S., Wagner, E., Muller, R., Scita, G., Vollmar, A.M. (2012) The V-ATPase-inhibitor Archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. *Cancer Res.* 72, 5976-5987.
- 302) Fröhlich, T., Edinger, D., Wagner, E. (2012) Stabilization of Polyplexes via Polymer Crosslinking for Efficient siRNA Delivery. *Eur. J. Pharm. Sci.* 47, 914-20.
- 303) Kopp, F., Oak, P., Wagner, E., Roidl, A. (2012) miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression, *PLOS One* 7(11), e50469.
- 304) Maier, K., Martin, I., Wagner, E. (2012) Sequence Defined Disulfide-linked Shuttle for Strongly Enhanced Intracellular Protein Delivery, *Mol. Pharmaceutics* 9, 3560–3568.
- 305) Terziyska, N., Castro Alves, C., Groiss, V., Schneider, K., Farkasova, K., Ogris, M., Wagner, E., Ehrhardt, H., Brentjens, R.J., zur Stadt, U., Horstmann, M., Quintanilla-Martinez, L., Jeremias, I. (2012) In Vivo Imaging Enables High Resolution Preclinical Trials on Patients' Leukemia Cells Growing in Mice. *PLOS One* 7(12), e52798.
- 306) Rödl, W., Schaffert, D., Wagner, E., Ogris, M. (2013) Synthesis of polyethylenimine based nanocarriers for systemic tumor targeting of nucleic acids. *Methods Molecular Biology* 948, 105-20.
- 307) Troiber, C., Edinger, D., Kos, P., Schreiner, L., Kläger, R., Herrmann, A., Wagner, E. (2013) Stabilizing effect of tyrosine trimers on pDNA and siRNA polyplexes. *Biomaterials* 34, 1624-1633.
- 308) Troiber, C., Kasper, J.C., Milani, S., Scheible, M., Schaubhut, F., Kuchler, S., Rädler, J., Simmel, F.C., Friess, W., Wagner, E. (2013) Comparison of four different particle sizing methods for siRNA polyplex characterization. *Eur J. Pharm. Biopharm.* 84, 255–264.
- 309) Su, B., Cengizeroglu, A., Farkasova, K., Anton, M., Ellwart, J.W., Haase, R., Wagner, E., Ogris, M. (2013) Systemic TNF alpha gene therapy synergizes with liposomal doxorubicine in the treatment of metastatic cancer. *Mol. Ther.* 21, 300-308.
- 310) Culmes, M., Eckstein, H.-H., Burgkart, R., Nüssler, A. K., Guenther, M., Wagner, E., Pelisek, J. (2013) Endothelial differentiation of adipose-derived mesenchymal stem cells is improved by epigenetic modifying drug BIX-01294. *Eur. J. Cell Biol.* 92, 70-79.
- 311) Li, Y., Lei, Y., Wagner, E., Xie, C., Lu, W., Zhu, J., Shen, J., Wang, J., Liu, M. (2013) A Potent Retro-Inverso D-peptide for Simultaneous Targeting Angiogenic Blood Vasculature and Tumor Cells. *Bioconjugate Chem.* 24, 133–143.

- 312) Knoop, K., Schwenk, N., Dolp, P., Willhauck, M.J., Zischek, C., Zach, C., Hacker, M., Göke, B., Wagner, E., Nelson, P.J., Spitzweg, C. (2013) Stromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma. *Human Gene Therapy* 24, 306-16.
- 313) Kubisch, R., Meissner, L., Krebs, S., Blum, H., Günther, M., Roidl, A., Wagner, E. (2013) A comprehensive gene expression analysis of resistance formation upon metronomic cyclophosphamide therapy. *Translational Oncology* 6, 1-9.
- 314) Noga, M., Edinger, D., Kläger, R., Wegner, S.V., Spatz, J.P., Wagner, E., Winter, G., Besheer, A. (2013) The effect of molar mass and degree of hydroxyethylation on the controlled shielding and deshielding of hydroxyethyl starch-coated polyplexes. *Biomaterials* 34, 2530-2538.
- 315) Vetter, A., Viridi, K., Espenlaub, S., Rödl, W., Wagner, E., Holm, P., Scheu, C., Kreppel, F., Spitzweg, C., Ogris, M. (2013) Adenoviral vectors coated with PAMAM dendrimer conjugates allow CAR independent virus uptake and targeting to the EGF Receptor. *Mol. Pharmaceutics* 10, 606-618.
- 316) Grünwald, G.K., Vetter, A., Klutz, K., Willhauck, M.J., Schwenk, N., Senekowitsch-Schmidtke, R., Schwaiger, M., Zach, C., Wagner, E., Göke, B., Holm, P.S., Ogris, M., Spitzweg, C. (2013) Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene. *J. Nuclear Medicine* 54(8):1450-7.
- 317) Kos, P., Wagner, E. (2013) Polymers for siRNA Delivery: Combining precision with multifunctionality. *Chimica Oggi -Chemistry Today* 31(2), 6-10.
- 318) Marfels, C., Hoehn, M., Wagner, E., Günther, M. (2013) Characterization of in vivo chemoresistant human hepatocellular carcinoma cells with transendothelial differentiation capacities. *BMC Cancer* 13,176.
- 319) Viola, J.R., Rafael, D.F., Wagner, E., Besch, R., Ogris, M. (2013) Gene therapy for advanced melanoma: selective targeting and therapeutic nucleic acids. *J. Drug Delivery* 2013, 897348.
- 320) Wagner, E. (2013) Biomaterials in RNA therapeutics: Quo vadis? *Biomater. Sci.* 1, 804–809.
- 321) Haase, R., Magnusson, T., Su, B., Kopp, F., Wagner, E., Lipps, H., Baiker, A., Ogris, M. (2013) Generation of a tumor- and tissue-specific episomal non-viral vector system. *BMC Biotechnology* 13, 49.
- 322) Kopp, F., Schnoedt, M., Haase, R., Wagner, E., Roidl, A., Ogris M. (2013) Detargeting by miR-143 decreases unwanted transgene expression in non-tumorigenic cells. *Gene Ther.* 20, 1104-1109.
- 323) Bogomilova, A., Höhn, M., Günther, M., Herrmann, A., Troev, K., Wagner, E., Schreiner, L. (2013) A polyphosphoester conjugate of melphalan as antitumoral agent. *Eur. J. Pharm. Sci.* 50, 410–419.
- 324) Lei, Y., Wang, J., Xie, C., Wagner, E., Lu, W., Li, Y., Wei, X., Dong, J., Liu, M. (2013) Glutathione-sensitive RGD-Poly(ethylene glycol)-SS-Polyethylenimine for intracranial glioblastoma targeted gene delivery. *J. Gene Med.* 15, 291–305.
- 325) Grünwald, G.K., Vetter, A., Klutz, K., Willhauck, M.J., Schwenk, N., Senekowitsch-Schmidtke, R., Schwaiger, M., Zach, C., Wagner, E., Göke, B., Holm, P.S., Ogris, M., Spitzweg, C. (2013) EGFR-Targeted adenovirus dendrimer coating for improved systemic delivery of the theranostic NIS gene. *Mol. Ther. Nucleic Acids* 2, e131.
- 326) Kasper, J., Troiber, C., Kuchler, S., Wagner, E., Friess, W. (2013) Formulation development of lyophilized, long-term stable siRNA/oligoaminoamide polyplexes. *Eur. J. Pharm. Biopharm.* 85, 294-305.
- 327) Kos, P., Scholz, C., Salcher, E.E., Herrmann, A., Wagner, E. (2013) Gene transfer with sequence-defined oligo(ethan amino)amides bioreducibly attached to a polypropylenimine dendrimer core. *Pharm. Nanotechnology* 1, 269-281.
- 328) Salcher, E.E., Wagner, E. (2014) Nano-encapsulation of Oligonucleotides for Therapeutic Use. Chapter in *Nucleic Acid Nanotechnology, Nucleic Acids Molecular Biology* 29, 245-260.
- 329) Edinger, D., Kläger, R., Troiber, C., Dohmen, C., Wagner, E. (2014) Gene Silencing and Antitumoral Effects of Eg5 or Ran siRNA Oligoaminoamide Polyplexes. *Drug Deliv. Transl. Res.* 4 (1), 84-95.
- 330) Klein, P., Wagner, E. (2014) Bioreducible Polycations as Shuttles for Therapeutic Nucleic Acid and Protein Transfection. *Antiox. Red. Signal.* 21(5), 804-817.
- 331) Lächelt, U., Kos, P., Mickler, F.M., Herrmann, A., Salcher, E.E., Rödl, W., Badgular, N., Bräuchle, C., Wagner, E. (2014) Fine-tuning of proton sponges by precise diaminoethanes and histidines in pDNA polyplexes. *Nanomedicine NBM* 10, 35–44.

- 332) Kubisch, R., Fröhlich, T., Arnold, G. J., Schreiner, L., von Schwarzenberg, K., Roidl, A., Vollmar, A.M., Wagner, E. (2014) V ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo. *Int. J. Cancer* 134, 2478-88.
- 333) Kopp, F., Wagner, E., Roidl, A. (2014) The proto-oncogene KRAS is targeted by miR-200c. *Oncotarget* 5, 185-95.
- 334) Braig, S., Wiedmann, R. M., Liebl, J., Singer, M., Kubisch, R., Schreiner, L., Abhari, B. A., Wagner, E., Kazmaier, U., Fulda S., Vollmar, A. M. (2014) Pretubulysin: a new option for the treatment of metastatic cancer. *Cell Death Dis.* 5, e1001.
- 335) Hütz, K., Mejías-Luque, R., Farkasova, K., Ogris, M., Krebs, S., Anton, M., Vieth, M., Schüller, U., Schneider, M.R., Blum, H., Wagner, E., Jung, A., Gerhard, M. (2014) The stem cell factor Sox2 regulates the tumorigenic potential in human gastric cancer cells. *Carcinogenesis* 35(4), 942-50.
- 336) Scholz, C., Kos, P., Wagner, E. (2014) Comb-like oligoaminoethane carriers: change in topology improves pDNA delivery. *Bioconjugate Chem.* 25, 251-61.
- 337) Scholz, C., Kos, P., Leclercq, L., Jin, X., Cottet, H., Wagner, E. (2014) Correlation of length of linear oligo(ethanamino) amides with gene transfer and cytotoxicity. *ChemMedChem* 9, 2104-2110.
- 338) Beckert, L., Philipp, A., Wagner, E. (2014) Receptor Targeted Polyplexes for pDNA and siRNA Delivery. In: *Gene and Cell Therapy: Therapeutic Mechanisms and Strategies*, 4th Edition.
- 339) Müller, K., Wagner, E. (2014) RNAi-based Nano-Oncologicals – Delivery and Clinical Applications, Chapter in “Nano-Oncologicals: New Targeting and Delivery Approaches”, *Advances in Delivery Science and Technology*, Controlled Release Society and Springer. Eds. M.J. Alonso and M. Garcia-Fuentes.
- 340) Murayama, S., Kos, P., Miyata, K., Kataoka, K., Wagner, E., Kato, M. (2014) Gene regulation by intracellular delivery and photodegradation of nanoparticles containing small interfering RNA, *Macromol. Biosci.* 14, 626-31.
- 341) Kopp, F., Hermawan, A., Oak, P.S., Herrmann, A., Wagner, E., Roidl, A. (2014) Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration. *Mol. Cancer* 13:16.
- 342) Wang, J., Lei, Y., Xie, C., Lu, W., Wagner, E., Xie, Z., Gao, J., Zhang, X., Yan, Z., Liu, M. (2014) Retro-inverso CendR peptide-mediated polyethyleneimine for intracranial glioblastoma-targeting gene therapy. *Bioconjug. Chem.* 25, 414-23.
- 343) Zhang, C.Y., Kos, P., Müller, K., Schrimpf, W., Troiber, C., Lächelt, U., Scholz, C., Lamb, D.C., Wagner, E. (2014) Native Chemical Ligation for Conversion of Sequence-defined Oligomers into Targeted pDNA and siRNA Carriers. *J. Control. Release* 180, 42–50.
- 344) Schempp, C.M., v. Schwarzenberg, K., Schreiner, L., Kubisch, R., Müller, R., Wagner, E., Vollmar, A.M. (2014) V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells. *Mol. Cancer Ther* 13, 926–37.
- 345) Noga, M., Edinger, D., Wagner, E., Winter, G., Besheer, A. (2014) Characterization and compatibility of hydroxyethyl starch-polyethylenimine copolymers for DNA delivery. *J. Biomater. Sci. Polymer Ed.* 25(9), 855-71.
- 346) Noga, M., Edinger, D., Wagner, E., Winter, G., Besheer, A. (2014) Stability and activity of hydroxyethyl starch-coated polyplexes in frozen solutions or lyophilizates. *Int. J. Pharm.* 469(1), 50-58.
- 347) Lächelt, U., Wittmann, V., Müller, K., Edinger, D., Kos, P., Höhn, M., Wagner, E. (2014) Synthetic polyglutamylation of dual-functional MTX-ligands for enhanced combined cytotoxicity of poly(I:C) nanoplexes. *Mol. Pharm.* 11(8) 2631–2639.
- 348) Wagner, E. (2014) Nucleic Acid Medicines: The Polymer Option. *Encyclopedia of Polymeric Nanomaterials*, DOI 10.1007/978-3-642-36199-9_267-1.
- 349) Röder, R., Wagner, E. (2014) Sequence-defined shuttles for targeted nucleic acid and protein delivery. *Therapeutic Delivery* 5 (9), 1025-1045.
- 350) Förster, F., Braig, S., Moser, C., Kubisch, R., Busse, J., Wagner, E., Schmöckel, E., Mayr, D., Schmitt, S., Zischka, H., Müller, R., Vollmar, A.M. (2014) Targeting the actin cytoskeleton: selective anti-tumor action via trapping PKC ϵ . *Cell Death & Disease* 5, e1398.
- 351) Lehto, T., Wagner, E. (2014) Sequence-defined polymers for the delivery of oligonucleotides. *Nanomedicine* 9 (18), 2843–2859.

- 352) Wang, Y., Wang, K., Zhang, R., Liu, X., Yan, X., Wang, J., Wagner, E., Huang, R. (2014) Synthesis of core-shell graphitic Carbon@Silica nanospheres with dual-ordered mesopores for cancer-targeted photothermochemotherapy. *ACS Nano* 8(8), 7870-9.
- 353) Kopp, F., Hermawan, A., Oak, P.S., Ulaganathan, V.K., Herrmann, A., Elnikhely, N., Thakur, C., Xiao, Z., Knyazev, P., Ataseven, B., Savai, R., Wagner, E., Roidl, A. (2014) Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells. *Translational Oncology* 7(6), 702-711.
- 354) Menhofer, M.H., Kubisch, R., Schreiner, L., Zorn, M., Foerster, F., Mueller, R., Raedler, J.O., Wagner, E., Vollmar, A.M., Zahler, S. (2014) The actin targeting compound Chondramide inhibits breast cancer metastasis via reduction of cellular contractility. *PLOS One* 9 (11), e112542.
- 355) Wagner, E. (2014) Polymers for Nucleic Acid Transfer — An Overview. *Adv. Genetics* 88, 231-261.
- 356) Menhofer, M.H., Bartel, D., Kubisch, R., Busse, J., Wagner, E., Müller, R., Vollmar, A.M., Zahler, S. (2014) In vitro and in vivo characterization of the actin polymerizing compound Chondramide as angiogenic inhibitor. *Cardiovasc. Res.* 104 (2), 303-14.
- 357) Lee, D.-J., Wagner, E., Lehto, T. (2015) Sequence-defined oligoaminoamides for the delivery of siRNAs. *Meth. Mol. Biol.* 1206, 15-27.
- 358) Kos, P., Lächelt, U., He, D., Nie, Y., Gu, Z., Wagner, E. (2015) Dual-Targeted Polyplexes Based on Sequence-Defined Peptide-PEG-Oligoaminoamides. *J. Pharm. Sci.* 104 (2), 464-75.
- 359) Kos, P., Lächelt, U., Herrmann, A., Mickler, F.M., Döblinger, M., He, D., Krhač Levačić, A., Morys, S., Bräuchle C, Wagner, E. (2015) Histidine-rich stabilized polyplexes for cMet-directed tumor-targeted gene transfer. *Nanoscale* 7, 5350–5362.
- 360) Klein, P.M., Müller, K., Gutmann, C., Kos, P., Krhač Levacic, A., Edinger, D., Höhn, M., Leroux, J.-C., Gauthier, M. A., E. Wagner. (2015) Twin disulfides as opportunity for improving stability and transfection efficiency of oligoaminoethane polyplexes. *J. Control. Release* 205, 109–119.
- 361) Knoop, K., Schwenk, N., Schmohl, K., Müller, A., Zach, C., Cyran, C., Carlsen, J., Böning, G., Bartenstein, P., Göke, B., Wagner, E., Nelson, P.J., Spitzweg, C. (2015) Mesenchymal stem cell (MSC)-mediated, tumor stroma-targeted radioiodine therapy of metastatic colon cancer using the sodium iodide symporter as theranostic gene. *J. Nuclear Medicine* 56, 600-606.
- 362) He, D., Wagner, E. (2015) Defined Polymeric Materials for Gene Delivery. *Macromol. Bioscience* 15(5), 600-12.
- 363) Jorge, A.F., Röder, R., Kos, P., Dias, R.S., Wagner, E., Pais, A.A. (2015) Combining polyethylenimine and Fe(III) for mediating pDNA transfection. *Biochim. Biophys. Acta* 1850, 1325-1335.
- 364) Greißel, A., Culmes, M., Napieralski, R., Wagner, E., Gebhard, H., Schmitt, M., Zimmermann, A., Eckstein, H.-H., Zerneck, A., Pelisek, J. (2015) Alternation of histone and DNA methylation in human atherosclerotic carotid plaques. *Thromb Haemost.* 114, 390-402.
- 365) Wagner, E. (2015) Tumor-targeted Delivery of Anti-microRNA for Cancer Therapy: pHLIP is Key. *Angew. Chem. Int. Ed. Engl.* 54(20), 5824-6.
- 366) Wagner, E. (2015) Tumorspezifischer Transfer von Anti-microRNA zur Krebstherapie - pHLIP ist der Schlüssel. *Angew. Chem.* 127, 5918 – 5920.
- 367) Lächelt, U., Wagner, E. (2015) Nucleic Acid Therapeutics Using Polyplexes – A Journey of 50 Years (and Beyond). *Chem. Rev.* 115, 11043–11078 (2015).
- 368) Niedermayer, S., Weiss, V., Herrmann, A., Schmidt, A., Datz, S., Müller, K., Wagner, E., Bein, T., Bräuchle, C. (2015) Multifunctional polymer-capped mesoporous silica nanoparticles for pH-responsive targeted drug delivery. *Nanoscale* 7(17), 7953-64.
- 369) Urbiola, K., Blanco-Fernández, L., Navarro, G., Rödl, W., Wagner, E., Ogris, M., Tros de Ilarduya, C. (2015) Evaluation of improved PAMAM-G5 conjugates for gene delivery targeted to the transferrin receptor. *Eur. J. Pharm. Biopharm.* 94, 116–122.
- 370) Weber, J., Lächelt, U., Wagner, E. (2015) Multifunctional oligoaminoamides for the receptor-specific delivery of therapeutic RNA. *Meth. Mol. Biol.* 1324, 369-86.
- 371) Broda, E., Mickler, F.M., Lächelt, U., Morys, S., Wagner, E., Bräuchle, C. (2015) Assessing potential peptide targeting ligands by quantification of cellular adhesion of model nanoparticles under blood flow-like conditions. *J. Control. Release* 213, 79-85.

- 372) An, S., He, D., Wagner, E., Jiang, C. (2015) Peptide-like polymers exerting effective glioma-targeted siRNA delivery and release for therapeutic application. *Small* 11, 5142-50.
- 373) Zhang, W., Rödl, W., He, D., Döblinger, M., Lächelt, U., Wagner, E. (2015) Combination of Sequence-defined Oligoaminoamides with Transferrin-polycation Conjugates for Receptor-Targeted Gene Delivery. *J. Gene Medicine* 17, 161–172.
- 374) Zhang, P., He, D., Klein, P., Liu, X., Röder, R., Döblinger, M., Wagner, E. (2015) Enhanced intracellular protein transduction by sequence defined tetra oleoyl-oligoaminoamides targeted for cancer therapy. *Adv. Funct. Materials* 25, 6627–6636.
- 375) Leclercq, L., Reinhard, S., Chamieh, J., Döblinger, M., Wagner, E., Cottet, H. (2015) Fast Characterization of Polyplexes by Taylor Dispersion Analysis. *Macromolecules* 48, 7216–7221.
- 376) Lee, D.J., Kessel, E., Edinger, D., He, D., Klein, P.M., Voith von Voithenberg, L., Lamb, D.C., Lächelt, U., Lehto, T., Wagner, E. (2015) Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand. *Biomaterials* 77, 98-110.
- 377) Hermawan, A., Wagner, E., Roidl, A. (2016) Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity. *Oncology Reports* 35, 1732-1740.
- 378) Morys, S., Wagner, E., Lächelt, U. (2016) pH-Responsive Polyplexes: From Artificial Amino Acids to Sequence-defined Targeted Oligoaminoamides. *Meth. Mol. Biol.* in press.
- 379) Liu, X., Zhang, P., He, D., Rödl, W., Preiß, T., Rädler, J., Wagner, E., Lächelt, U. (2016) pH-reversible cationic RNase A conjugates for enhanced cellular delivery and tumor cell killing. *Biomacromolecules* 17, 173-82.
- 380) Möller, K., Müller, K., Engelke, H., Bräuchle, C., Wagner, E., Bein, T. (2016) Highly Efficient siRNA Delivery from Core-Shell Mesoporous Silica Nanoparticles with Multifunctional Polymer Caps. *Nanoscale* 8, 4007-4019.
- 381) He, D., Müller, K., Krhac Levacic, A., Kos, P., Lächelt, U., Wagner, E. (2016) Combinatorial optimization of sequence-defined oligo(ethan amino)amides for folate receptor-targeted pDNA and siRNA delivery. *Bioconjugate Chem.* 27, 547-59.
- 382) Heissig, P., Klein, P.M., Hadwiger, P., Wagner, E. (2016) DNA as tunable adaptor for siRNA polyplex stabilization and functionalization. *Mol. Ther. Nucleic Acids* 5, e288.
- 383) Zhang, W., Müller, K., Kessel, E., Reinhard, S., He, D., Klein, P.M., Höhn, M., Rödl, W., Kempter, S., Wagner, E. (2016) Targeted siRNA Delivery Using a Lipo-Oligoaminoamide Nano-Core with an Influenza Peptide and Transferrin Shell. *Adv. Healthcare Materials* 5, 1493-504.
- 384) Jiang, Q., Yue, D., Nie, Y., Xu, X., He, Y., Zhang, S., Wagner, E., Gu, Z. (2016) Specially-Made Lipid-based Assemblies for Improving Transmembrane Gene Delivery: Comparison of Basic Amino Acid Residues-Rich Periphery. *Mol. Pharmaceutics* 13, 1809-1821.
- 385) Schreiber, C., Segerer, F.J., Wagner, E., Roidl A., Rädler, J.O. (2016) Ring-Shaped Microlanes and Chemical Barriers as a Platform for Probing Single-Cell Migration. *Scientific Reports* 6, 26858.
- 386) Urnauer, S., Morys, S., Krhac Levacic, A., Müller, A.M., Schug, C., Schmohl, K.A., Schwenk, N., Zach, C., Carlsen, J., Bartenstein, P., Wagner, E., Spitzweg, C. (2016) Sequence defined cMET/HGFR-targeted polymers as gene delivery vehicles for the theranostic sodium iodide symporter (NIS). *Molecular Therapy* 24, 1395-1404.
- 387) Müller, K., Eva Kessel, Philipp M. Klein, Miriam Höhn, Ernst Wagner (2016) Post-PEGylation of siRNA lipo-oligoamino amide polyplexes using tetra-glutamylated folic acid as ligand for receptor-targeted delivery. *Molecular Pharmaceutics* 13, 2332-2345.
- 388) Beckert, L., Kostka, L., Kessel, E., Krhac Levacic, A., Kostkova, H., Etrych, T., Lächelt, U., Wagner, E. (2016) Acid-labile pHPMA modification of four-arm oligoaminoamide pDNA polyplexes balances shielding and gene transfer activity in vitro and in vivo. *Eur. J. Pharm. Biopharm.* 105, 85–96.
- 389) Zimpel, A., Preiß T., Röder, R., Engelke, H., Ingrisich, M., Peller, M., Rädler, J.O., Wagner, E., Bein, T., Lächelt, U., Wuttke, S. (2016) Imparting Functionality to MOF Nanoparticles by External Surface Selective Covalent Attachment of Polymers. *Chem. Mater.* 28, 3318-3326.
- 390) Lee, D.-J., He, D., Kessel, E., Padari, K., Kempter, S., Lächelt, U., Rädler, J.O., Pooga, M., Wagner, E. (2016) Tumoral gene silencing by receptor-targeted combinatorial siRNA polyplexes. *J. Control. Release* 244, 280-291.

- 391) Sommer, A.-K., Hermawan, A., Mickler, F.M., Ljepoja, B., Knyazev, P., Bräuchle, C., Ullrich, A., Wagner, E., Roidl, A. (2016) Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases. *Oncotarget* 7, 50461-50476.
- 392) Müller, A. M., Schmohl, K.A., Knoop, K., Schug, C., Urnauer, S., Hagenhoff, A., Clevert, D.-A., Ingrisch, M., Niess, H., Carlsen, J., Zach, C., Wagner, E., Bartenstein, P., Nelson, P. J., Spitzweg, C. (2016) Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery, *Oncotarget* 7, 54795-54810.
- 393) Westerhausen, C., Schnitzler, L.G., Wendel, D., Krzysztóń, R., Lächelt, U., Wagner, E., Rädler, J.O., Wixforth, A. (2016) Controllable Acoustic Mixing of Fluids in Microchannels for the Fabrication of Therapeutic Nanoparticles, *Micromachines* 7, 150; doi:10.3390/mi7090150.
- 394) Müller, K., Klein, P.M., Heissig, P., Roidl, A., Wagner, E. (2016) EGF receptor targeted lipopolyplexes for antitumoral siRNA and miRNA delivery, *Nanotechnology* 27, 464001.
- 395) Klein, P. M. Reinhard, S., Lee, D.-J., Müller, K., Ponader, D., Hartmann, L., Wagner, E. (2016) Precise redox-sensitive cleavage sites for improved bioactivity of siRNA lipo-polyplexes. *Nanoscale* 8, 18098–18104.
- 396) Frederickson, R.M., Moghimi, S.M., Wagner, E., Yla-Herttuala, S. (2016) Call for papers: Nanoparticle development and applications in cellular and molecular therapies. *Mol. Ther.* 24, 1334-35.
- 397) Reinhard, S., Wagner, E. (2017) How to Tackle the Challenge of siRNA Delivery with Sequence-Defined Oligoamino Amides. *Macromol Biosci.* 17(1), 1600152 (13 pages).
- 398) Röder, R., Helma, J., Preiß, T., Rädler, J.O., Leonhardt, H., Wagner, E. (2017) Intracellular Delivery of Nanobodies for Imaging of Target Proteins in Live Cells. *Pharm. Res.* 34, 161–174.
- 399) Deglmann, C.J., Blazkow-Schmalzbauer, K., Moorkamp, S., Susha, A.S., Herrler, T., Giunta, R.E., Wagner, E., Rogach, A.L., Baumeister, R.G., Ogris, M. (2017) Cadmium Telluride Quantum Dots as a Fluorescence Marker for Adipose Tissue Grafts. *Ann. Plastic Surg.* 78, 217-222.
- 400) Liu, X, Zhang, P, Rödl, W, Maier, K, Lächelt, U, Wagner, E. (2017) Towards artificial immunotoxins: traceless reversible conjugation of RNase A with receptor targeting and endosomal escape domains. *Mol. Pharmaceutics* 14, 1439–1449.
- 401) Röder, R., Preiß, T., Hirschle, P., Steinborn, B., Zimpel, A., Höhn, M., Rädler, J.O., Bein, T., Wagner, E., Wuttke, S., Lächelt, U. (2017) Multifunctional nanoparticles by coordinative self-assembly of His-tagged units with metal-organic frameworks. *J Am Chem Soc.* 139, 2359-2368.
- 402) Zhang, P., Wagner, E. (2017) History of Polymeric Gene Delivery Systems. *Top. Curr. Chem.* 375: 26.
- 403) Hall, A., Lächelt, U., Bartek, J., Wagner, E., Moghimi, S.M. (2017) Polyplex Evolution: Understanding Biology, Optimizing Performance. *Molecular Therapy* 25, 1476-1490.
- 404) Heissig, P., Schrimpf, W., Hadwiger, P., Wagner, E., Lamb, D.C. (2017) Monitoring integrity and localization of modified single-stranded RNA oligonucleotides using ultrasensitive fluorescence methods. *PLOS One* 12: e0173401.
- 405) Truebenbach, I., Gorges, J., Kuhn, J., Kern, S., Baratti, E., Kazmaier, U., Wagner, E., Lächelt, U. (2017) Sequence-defined oligoamide drug conjugates of pretubulysin and methotrexate for folate receptor targeted cancer therapy. *Macromol. Bioscience* 2017, 17 (10) 1600520.
- 406) Schmohl, K.A., Gupta, A., Grünwald, G.K., Trajkovic-Arsic, M., Klutz, K., Braren, R., Schwaiger, M., Nelson, P.J., Ogris, M., Wagner, E., Siveke, J.T., Spitzweg, C. (2017) Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene. *Oncotarget* 8, 33393-33404.
- 407) Niño-Pariente, A., Armiñán, A., Reinhard, S., Scholz, C., Wagner, E., Vicent, M.J. (2017) Design of Poly-L-Glutamate-based Complexes for pDNA delivery. *Macromol. Bioscience* 2017, 17 (10) 1700029. Erratum 1700245.
- 408) Wang, S., Reinhard, S., Li, C., Qian, M., Jiang, H., Du, Y., Lächelt, U., Lu, W., Wagner, E., Huang, R. (2017). Antitumoral Cascade-Targeting Ligand for IL-6 Receptor-Mediated Gene Delivery to Glioma. *Molecular Therapy* 25, 1556-1566.

- 409) Morys, S., Krhac Levacic, A., Urnauer, S., Kempter, S., Kern, S., Rädler, J.O., Spitzweg, C., Lächelt, U., Wagner, E. (2017) Influence of Defined Hydrophilic Blocks within Oligoaminoamide Copolymers: Compaction versus Shielding of pDNA Nanoparticles. *Polymers* 9(4), 142.
- 410) Urnauer, S., Klutz, K., Grünwald, G.K., Morys, S., Schwenk, N., Zach, C., Gildehaus, F.J., Rödl, W., Ogris, M., Wagner, E., Spitzweg, C. (2017) Systemic tumor-targeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes. *J. Gene Medicine* 19(5). doi: 10.1002/jgm.2957.
- 411) Krzysztóń, R., Salem, B., Lee, D.J., Schwake, G., Wagner, E., Rädler, J. O. (2017) Microfluidic Self-Assembly of Folate-Targeted Monomolecular siRNA-Lipid Nanoparticles. *Nanoscale* 9, 7442-7453.
- 412) Heller, P., Hobernik, D., Lächelt, U., Schinnerer, M., Weber, B., Schmidt, M., Wagner, E., Bros, M., Barz, M. (2017) Combining reactive triblock copolymers with functional cross-linkers: A versatile pathway to disulfide stabilized-polyplex libraries and their application as pDNA vaccines. *J. Control. Release* 258, 146-160.
- 413) Wang S, Li C, Qian M, Jiang H, Shi W, Chen J, Lächelt U, Wagner E, Lu W, Wang Y, Huang R. (2017) Augmented glioma-targeted theranostics using multifunctional polymer-coated carbon nanodots, *Biomaterials* 141, 29-39.
- 414) Moghimi, S.M., Wagner, E. (2017) Nanoparticle Technology: Having Impact, but Needing Further Optimization. *Molecular Therapy* 25, 1461-1463.
- 415) Zhang, P., Steinborn, B., Lächelt, U., Zahler, S., Wagner, E. (2017) Lipo-Oligomer Nanoformulations for Targeted Intracellular Protein Delivery. *Biomacromolecules* 18, 2509-2520.
- 416) Reinhard, S., Zhang, W., Wagner, E. (2017) Optimized solid-phase assisted synthesis of oleic acid-containing siRNA nanocarriers. *ChemMedChem* 12, 1464-1470.
- 417) Morys, S., Urnauer, S., Spitzweg, C., Wagner, E. (2017) EGFR targeting and shielding of pDNA lipopolyplexes via bivalent attachment of a sequence-defined PEG agent. *Macromol Bioscience* 2017, 1700203.
- 418) Lee, D.J., Kessel, E., Lehto, T., Liu, X., Yoshinaga, N., Padari, K., Chen, Y.-C., Kempter, S., Uchida, S., Rädler, J.O., Pooga, M., Sheu, M.-T., Kataoka, K., Wagner, E. (2017) Systemic delivery of folate-PEG siRNA lipopolyplexes with enhanced intracellular stability for gene silencing in leukemia. *Bioconjugate Chem.* 28, 2393-2409.
- 419) Urnauer S., Müller A. M., Schug, C., Schmohl, K.A., Tutter, M., Schwenk, N., Rödl, W., Morys, S., Ingrisch, M., Bertram, J., Bartenstein, P., Clevert, D.A., Wagner, E., Spitzweg, C. (2017) EGFR-targeted nonviral NIS gene transfer for bioimaging and therapy of disseminated colon cancer metastases. *Oncotarget*. 2017, 8, 92195-92208.
- 420) Krhac Levacic, A., Morys, S., Kempter, S., Lächelt, U., Wagner, E. (2017) Minicircle versus plasmid DNA delivery by receptor-targeted polyplexes. *Human Gene Therapy* 28, 862-874.
- 421) Krhac Levacic, A., Morys, S., Wagner, E. (2017) Solid-phase Supported Design of Carriers for Therapeutic Nucleic Acid Delivery. *Bioscience Reports* 37 (5) BSR20160617 (20 pages).
- 422) Schmohl, K.A., Dolp, P., Schug, C., Knoop, K., Klutz, K., Schwenk, N., Bartenstein, P., Nelson, P.J., Ogris, M., Wagner, E., Spitzweg, C. (2017) Reintroducing the sodium iodide symporter (NIS) to anaplastic thyroid carcinoma. *Thyroid* 27 (12), 1534-1543.
- 423) Hirschberger, K., Jarzebinska, A., Kessel, E., Kretzschmann, V., Aneja, M.K., Dohmen, C., Herrmann-Janson, A., Wagner, E., Plank, C., Rudolph, C. (2017) Exploring cytotoxic mRNAs as a novel class of anti-cancer biotherapeutics. *Mol. Ther. Methods Clin. Devel.* 8, 141-151.
- 424) Urbiola, K., Blanco-Fernández, L., Ogris, M., Rödl, W., Wagner, E., Tros de Ilarduya, C. (2018). Novel PAMAM-PEG-peptide conjugates for siRNA delivery targeted to the transferrin and epidermal growth factor receptors. *J. Pers. Med.* 2018, 8, 4 (12 pages).
- 425) Qian, M., Du, Y., Wang, S., Li, C., Jiang, H., Shi, W., Chen, J., Wang, Y., Wagner, E., Huang, R. (2018) Highly Crystalline Multicolor Carbon Nanodots for Dual-Modal Imaging-Guided Photothermal Therapy of Glioma. *ACS Applied Materials & Interfaces* 10 (4), 4031-4040.
- 426) Deglmann, C.J., Błażków-Schmalzbauer, K., Moorkamp, S., Wallmichrath, J., Giunta, R.E., Rogach, A.L., Wagner, E., Baumeister, R.G., Ogris, M. (2018) In vivo tracking of adipose tissue grafts with cadmium-telluride quantum dots. *Arch Plast Surg.* 45, 111-117.

- 427) Klein, P.M., Kern, S., Lee, D.J., Schmaus, J., Höhn, M., Gorges, J., Kazmaier, U., Wagner, E. (2018) Folate receptor-directed orthogonal click-functionalization of siRNA lipopolyplexes for tumor cell killing in vivo. *Biomaterials* 178, 630-642.
- 428) Ljepoja B, García-Roman J, Sommer AK, Fröhlich T, Arnold GJ, Wagner E, Roidl A. (2018) A proteomic analysis of an in vitro knock-out of miR-200c. *Sci Rep.* 8(1), 6927.
- 429) Schug C, Sievert W, Urnauer S, Müller AM, Schmohl KA, Wechselberger A, Schwenk N, Lauber K, Schwaiger M, Multhoff G, Wagner E, Nelson PJ, Spitzweg C. (2018) External Beam Radiation Therapy Enhances Mesenchymal Stem Cell-Mediated Sodium-Iodide Symporter Gene Delivery. *Hum Gene Ther.* 29 (11), 1287-1300.
- 430) Sommer, A.K., Hermawan, A., Ljepoja, B., Fröhlich, T., Arnold, G.J., Wagner, E., Roidl, A. (2018) A proteomic analysis of chemoresistance development via sequential treatment with doxorubicin reveals novel players in MCF-7 breast cancer cells. *Int. J. Mol. Medicine* 42, 1987-1997.
- 431) Klein, P.M., Klinker, K., Zhang, P., Kern, S., Kessel, E., Wagner, E., Barz, M. (2018) Efficient Shielding of Polyplexes using Heterotelechelic Polysarcosines. *Polymers* 2018, 10, 689.
- 432) Wagner, E. (2018) Nanomedicines for targeted therapy, Chapter 2, pp 16-36 in *Nanoscience and Nanotechnology, Advances and Developments in Nano-Sized Materials*, Marcel Van de Voorde (Ed.), de Gruyter, Berlin, 2018.
- 433) Steinborn, B., Truebenbach, I., Morys, S., Lächelt, U., Wagner, E., Zhang, W. (2018) EGF receptor targeted methotrexate and siRNA co-delivery. *J. Gene Medicine* 2018, e3041.
- 434) Hager, S., Wagner, E. (2018) Bioresponsive polyplexes – chemically programmed for nucleic acid delivery. *Exp. Opin Drug Delivery.* 15(11), 1067-1083.
- 435) Reinhard, S., Wang, Y., Dengler, S., Wagner, E. (2018) Precise enzymatic cleavage sites for improved bioactivity of siRNA lipo-polyplexes. *Bioconjug. Chem.* 29(11), 3649-3657.
- 436) Ljepoja, B., García-Roman, J., Sommer, A.K., Wagner, E., Roidl, A. (2018) miRNA-27a sensitizes breast cancer cells to treatment with selective estrogen receptor modulators. *Breast* 43, 31-38.
- 437) Schug, C., Urnauer, S., Jäckel, C., Schmohl, K.A., Tutter, M., Steiger, K., Schwenk, N., Schwaiger, M., Wagner, E., Nelson, P.J., Spitzweg, C. (2019) TGFB1-driven mesenchymal stem cell-mediated NIS gene transfer. *Endocr Relat Cancer* 26, 89–101.
- 438) Kern, S., Truebenbach, I., Höhn, M., Gorges, J., Kazmaier, U., Zahler, S., Vollmar, A. M., Wagner, E. (2019) Combined Antitumoral Effects of Pretubulysin and Methotrexate. *Pharmacol. Res. Perspect.* 2019; 7(1):e00460.
- 439) Urnauer, S., Schmohl, K. A., Tutter, M., Schug, C., Schwenk, N., Morys, S., Ziegler, S., Bartenstein, P., Clevert, D. A., Wagner, E., Spitzweg, C. (2019) Dual-targeted NIS polyplexes – a theranostic strategy towards tumors with heterogenous receptor expression. *Gene Therapy* 26(3-4):93-108.
- 440) Reinhard, S., Wagner, E. (2019) Sequence-defined cationic lipo-oligomers containing unsaturated fatty acids for transfection. *Methods Mol Biol* 1943, 1-25.
- 441) Rödl, W., Taschauer, A., Schaffert, D., Wagner, E., Ogris, M. (2019) Synthesis of polyethylenimine based nanocarriers for systemic tumor targeting of nucleic acids. *Methods Mol Biol* 1943, 83-99.
- 442) Mastrella, G., Hou, M., Li, M., Stoecklein, V.M., Zdouc, N., Volmar, M.N.M., Miletic, H., Reinhard, S., Herold-Mende, C.C., Kleber, S., Eisenhut, K., Gargiulo, G., Synowitz, M., Vescovi, A.L., Harter, P.N., Penninger, J.M., Wagner, E., Mittelbronn, M., Bjerkvig, R., Hambardzumyan, D., Schüller, U., Tonn, J.C., Radke, J., Glass, R., Kälin, R.E. (2019) Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma. *Cancer Res.* 79, 2298-2313.
- 443) Lee, D.-J., Wagner, E. (2019) Combinatorial siRNA polyplexes for receptor targeting. *Methods Molecular Biology* 1974, 83-98.
- 444) Klein, P.M., Wagner, E. (2019) Click-shielded and targeted lipopolyplexes. *Methods Mol Biol* 2036, 141-164.
- 445) Zimpel, A., Al Danaf, N., Steinborn, B., Kuhn, J., Höhn, M., Bauer, T., Hirschle, P., Schrimpf, W., Engelke, H., Wagner, E., Barz, M., Lamb, D.C., Lächelt, U., Wuttke, S. (2019) Coordinative binding of polymers to metal-organic framework nanoparticles for control of interactions at the biointerface. *ACS Nano* 13(4), 3884-3895.

- 446) Pfitzer, L., Moser, C., Gegenfurtner, F., Arner, A., Foerster, F., Atzberger, C., Zisis, T., Kubisch-Dohmen, R., Busse, J., Smith, R., Timinszky, G., Kalinina, O., Müller, R., Wagner, E., Vollmar, A.M., Zahler, S. (2019) Targeting actin inhibits repair of doxorubicin induced DNA damage: a novel therapeutic approach for combination therapy. *Cell Death Dis.* 10(4), 302.
- 447) Schnitzler, L.G., Junger, S., Loy, D.M., Wagner, E., Wixforth, A., Hörner, A., Lächelt, U., Westerhausen, C. (2019) Size tunable nanoparticle formation employing droplet fusion by acoustic streaming applied to polyplexes. *J Physics D: Applied Physics*, 52, 244002.
- 448) Luo, J., Höhn, M., Reinhard, S., Loy, D.M., Klein, P.M., Wagner, E. (2019) IL4-receptor-targeted dual antitumoral apoptotic peptide - siRNA conjugate lipoplexes. *Adv. Funct. Materials* 29 (25), 1900697.
- 449) Truebenbach, I., Kern, S., Loy, D.M., Hoehn, M., Gorges, J., Kazmaier, U., Wagner E. (2019) Combination chemotherapy of L1210 tumors in mice with pretubulysin and methotrexate nanoparticles. *Mol. Pharmaceutics*, 16, 2405–2417.
- 450) Schug, C., Kitzberger, C., Sievert, W., Spellerberg, R., Tutter, M., Schmohl, K.A., Eberlein, B., Biedermann, T., Steiger, K., Zach, C., Schwaiger, M., Multhoff, G., Wagner, E., Nelson, P.J., and Spitzweg, C. (2019) Radiation-induced amplification of TGFB1-induced mesenchymal stem cell-mediated NIS gene 131I therapy. *Clin. Cancer Res* 25, 5997-6008.
- 451) Truebenbach, I., Zhang, W., Wang, Y., Kern, S., Höhn, M., Reinhard, S., Gorges, J., Kazmaier, U., Wagner, E. (2019) Co-delivery of pretubulysin and siEG5 to EGFR overexpressing carcinoma cells. *Int J Pharm* 569, 118570.
- 452) Loy, D.M., Klein, P.M., Krzysztoń, R., Lächelt, U., Rädler, J.O., Wagner, E. (2019) A microfluidic approach for sequential assembly of siRNA polyplexes with a defined structure – activity relationship. *PeerJ Materials Science* 1, 1-37. DOI: 10.7717/peerj-matsci.1
- 453) Peng, L., Wagner, E. (2019) Polymeric Carriers for Nucleic Acid Delivery: Current Designs and Future Directions. *Biomacromolecules* 20 (10), 3613-3626.
- 454) Kuhn, J., Klein, P. M., Al Danaf, N., Nordin, J. Z., Reinhard, S., Loy, D. M., Höhn, M., El Andaloussi, S., Lamb, D. C., Wagner, E., Aoki, Y., Lehto, T., Lächelt, U. (2019) Supramolecular Assembly of Aminoethylene-Lipopeptide PMO Conjugates into RNA Splice-Switching Nanomicelles. *Adv. Funct. Mater.* 29, 1906432.
- 455) Steinborn, B., Hirschle, P., Höhn, M., Bauer, T., Barz, M., Wuttke, S., Wagner, E., Lächelt, U. (2019). Core-Shell Functionalized Zirconium-Pemetrexed Coordination Nanoparticles as Carriers with a High Drug Content. *Adv Therapeutics* 2019, 1900120.
- 456) Sommer, A.K., Falcenberg, M., Ljepoja, B., Fröhlich, T., Arnold, G.J., Wagner, E., Roidl, A. (2019) Downregulation of GRK5 hampers the migration of breast cancer cells. *Scientific Reports* 9, 15548.
- 457) Ljepoja B, Schreiber C, Gegenfurtner FA, García-Roman J, Köhler B, Zahler S, Rädler JO, Wagner E, Roidl A. (2019) Inducible microRNA-200c decreases motility of breast cancer cells and reduces filamin A. *PLoS One* 14, e0224314.
- 458) Wang, Y. Luo, J., Truebenbach, I., Reinhard, S., Klein, P., Hoehn, M., Kern, S., Morys, S., Loy, D., Wagner, E., Zhang, W. (2020) Double click-functionalized siRNA polyplexes for gene silencing in EGF receptor-positive tumor cells. *ACS Biomaterials Science & Engineering* 6, 2, 1074-1089
- 459) Kuhn J, Lin Y, Krhac Levacic A, Al Danaf N, Peng L, Höhn M, Lamb DC, Wagner E, Lächelt U. (2020) Delivery of Cas9/sgRNA Ribonucleoprotein Complexes via Hydroxystearyl Oligoamino Amides. *Bioconjug Chem.* 31(3), 729-742.
- 460) Luo, J., Wagner, E., Wang, Y. (2020) Artificial peptides for antitumoral siRNA delivery. *J Materials Chem. B* 2020, *J Mater Chem B.* 8, 2020-2031.
- 461) Reinhard, S., Wagner, E. (2021) Carriers for nucleic acid delivery to the brain. Chapter 9 in “Nanoparticles for Brain Drug Delivery” Edited by Carla Vitorino, Andreia Jorge and Alberto A. C. C. Pais, Jenny Stanford Publishing Pte. Ltd.
- 462) Tutter M, Schug C, Schmohl KA, Urnauer S, Schwenk N, Petrini M, Lokorse WJM, Zach C, Ziegler S, Bartenstein P, Weber WA, Wagner E, Lindner LH, Nelson PJ, Spitzweg C. (2020) Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter (NIS) gene expression using a heat-inducible gene promoter in engineered mesenchymal stem cells. *Theranostics* 10, 4490-4506.

- 463) Hirschle, P, Hirschle, C, Böll, K, Döblinger, M, Hoehn, M, Tuffnell, J, Ashling, C, Keen, D, Bennett, T, Rädler, J, Wagner, E, Peller, M, Lächelt, U, Wuttke, S. (2020) Tuning the morphological appearance of iron(III) fumarate: impact on material characteristics and biocompatibility. *Chem. Mater.* 32, 6, 2253-2263.
- 464) Benli-Hoppe, T., Wagner, E. (2020) Polymer-based Tumor Targeting Nanosystems, Book Chapter in Huang: *New Nanomaterials and Techniques for Tumor-targeted Systems*, Springer.
- 465) Zhang X, Feng L, Dong Z, Xin X, Yang Z, Deng D, Wagner E, Liu Z, Liu X. (2020) Protein-drug conjugate programmed by pH-reversible linker for tumor hypoxia relief and enhanced cancer combination therapy. *Int J Pharm.* 582, 119321.
- 466) Haddick L, Zhang W, Reinhard S, Möller K, Engelke H, Wagner E, Bein T. (2020) Particle-size-dependent delivery of antitumoral miRNA using targeted mesoporous silica nanoparticles. *Pharmaceutics* 12(6), 505.
- 467) Wang, Y., Wagner, E. (2020) Non-Viral Targeted Nucleic Acid Delivery: Apply Sequences for Optimization. *Pharmaceutics* 12 (9), e888.
- 468) Hager, S., Fittler, F.J., Wagner, E., Bros, M. (2020) Nucleic acid-based approaches for tumor therapy. *Cells* 29(9), e2061.
- 469) Zhang P, Zhang Y, Ding X, Shen W, Li M, Wagner E, Xiao C, Chen X. (2020) A Multistage Cooperative Nanoplatfom Enables Intracellular Co-Delivery of Proteins and Chemotherapeutics for Cancer Therapy. *Adv Mater.* 2020, 32(46), e2000013.
- 470) Ritt, N.; Berger, S.; Wagner, E.; Zentel, R. (2020) Versatile, Multifunctional Block Copolymers for the Self-Assembly of Well-Defined, Nontoxic pDNA Polyplexes. *ACS Appl. Polym. Mater.* 2, 5469–5481.
- 471) Freitag, F., Wagner, E. (2021) Optimizing synthetic nucleic acid and protein nanocarriers: the chemical evolution approach. *Adv. Drug Deliv. Rev.* 168, 30-54.
- 472) Tutter M, Schug C, Schmohl KA, Urnauer S, Kitzberger C, Schwenk N, Petrini M, Zach C, Ziegler S, Bartenstein P, Weber WA, Multhoff G, Wagner E, Lindner LH, Nelson PJ, Spitzweg C. (2021) Regional hyperthermia enhances mesenchymal stem cell recruitment to tumor stroma: Implications for mesenchymal stem cell-based tumor therapy. *Mol Ther* 29(2), 788-803.
- 473) von Schirnding, C., Giopanou, I., Hermawan, A., Wehl, L., Ntaliarda, G., Illes, B., Datz, S., Geisslinger, F., Bartel, K., Sommer, A.K., Lianou, M., Weiß, V., Feckl, J., Vollmar, A.V., Bräuchle, C., Stathopoulos, G. T., Wagner, E., Roidl, A., Bein, T., Engelke, H. (2021) Synergistic Combination of Calcium and Citrate in Mesoporous Nanoparticles Targets Pleural Tumors. *Chem* 7 (2), 480-494.
- 474) Luo J, Schmaus J, Cui M, Hörterer E, Wilk U, Höhn M, Däther M, Berger S, Benli-Hoppe T, Peng L, Wagner E. (2021) Hyaluronate siRNA nanoparticles with positive charge display rapid attachment to tumor endothelium and penetration into tumors. *J Control Release* 329, 919-933.
- 475) Loy, D.M., Krzysztoń, R., Lächelt, U, Rädler, J.O., Wagner, E. (2021) Controlling Nanoparticle Formulation: A Low-Budget Prototype for the Automation of a Microfluidic Platform. *Processes* 9, 129.
- 476) Berger, S., Krhač Levačić, A., Hörterer, E., Wilk, U., Benli-Hoppe, T., Wang, Y., Öztürk, Ö., Luo, J., Wagner, E. (2021) Optimizing pDNA lipo-polyplexes: A balancing act between stability and cargo release. *Biomacromolecules* 22, 1282-1296.
- 477) Kamenac A, Schilberth F, Wagner E, Wixforth A, Lächelt U, Westerhausen C (2021) Transient permeabilization of living cells combining shear flow and acoustic trapping for facilitated uptake of molecules. *Processes*, 9 (6), 913.
- 478) Spitzweg C, Nelson PJ, Wagner E, Bartenstein P, Weber WA, Schwaiger M, Morris JC. (2021) The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment. *Endocr Relat Cancer* 28 (10):T193-T213.
- 479) Krhač Levačić A, Berger S, Müller J, Wegner A, Lächelt U, Dohmen C, Rudolph C, Wagner E. (2021) mRNA Lipopolyplexes Benefiting from Precise Redox-sensitive Cleavage Sites. *J Control Release*, 339, 27-40.
- 480) Büning H, Fehse B, Ivics Z, Kochanek S, Koehl U, Kupatt C, Mussolino C, Nettelbeck DM, Schambach A, Uckert W, Wagner E, Cathomen T. (2021) Gene Therapy "Made in Germany": A Historical Perspective, Analysis of the Status Quo, and Recommendations for Action by the German Society for Gene Therapy. *Hum Gene Ther.* 32, 987-996.
- 481) Spellerberg R, Benli-Hoppe T, Kitzberger C, Berger S, Schmohl KA, Schwenk N, Yen HY, Zach C, Schilling F, Weber WA, Kälin RE, Glass R, Nelson PJ, Wagner E, Spitzweg C. (2021) Selective sodium iodide symporter (NIS) gene therapy of glioblastoma mediated by EGFR-targeted lipopolyplexes. *Mol Ther Oncolytics* 23, 432-446.

- 482) Benli-Hoppe T, Göl Öztürk Ş, Öztürk Ö, Berger S, Wagner E, Yazdi M. (2022) Transferrin Receptor Targeted Polyplexes Completely Comprised of Sequence-Defined Components. *Macromol Rapid Comm* 43, e2100602.
- 483) Dezfouli, A.B.; Yazdi, M.; Pockley, A.G.; Khosravi, M.; Kobold, S.; Wagner, E.; Multhoff, G. (2021) NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development. *Cells* 10, 3390.
- 484) Capelôa L, Yazdi M, Zhang H, Chen X, Nie Y, Wagner E, Lächelt U, Barz M. (2022) Cross-linkable Polyion Complex Micelles from Polypept(o)ide-based ABC-triblock Copolymers for siRNA Delivery. *Macromol Rapid Comm* 43, e2100698.
- 485) Berger S, Berger M, Bantz C, Maskos M, Wagner E. (2022) Performance of nanoparticles for biomedical applications: the in vitro / in vivo discrepancy. *Biophysics Reviews* 3, 011303.
- 486) Lin Y, Wagner E, Lächelt U. (2022) Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP. *Biomaterials Science* 10, 1166-1192.
- 487) Vetter, V.C., Wagner, E. (2022) Targeting nucleic acid-based therapeutics to tumors: challenges and strategies for polyplexes. *J Control. Rel.* 346, 110-135.
- 488) Kitzberger C, Spellerberg R, Morath V, Schwenk N, Schmohl KA, Schug C, Urnauer S, Tutter M, Eiber M, Schilling F, Weber WA, Ziegler S, Bartenstein P, Wagner E, Nelson PJ, Spitzweg C. (2022) *EJNMMI Research* 12, 25.
- 489) Bashiri Dezfouli A, Yazdi M, Benmebarek MR, Schwab M, Michaelides S, Micciché A, Geerts D, Stangl S, Klapproth S, Wagner E, Kobold S, Multhoff G. (2022) CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells. *Front Immunol.* 13, 883694.
- 490) Lyu M, Yazdi M, Lin Y, Höhn M, Lächelt U, Wagner E. (2022) Receptor-Targeted Dual pH-Triggered Intracellular Protein Transfer. *ACS Biomater Sci Eng.* 2022, Jul 8. doi: 10.1021/acsbomaterials.2c00476.
- 491) Mirzazadeh Dizaji N, Lin Y, Bein T, Wagner E, Wuttke S, Lächelt U, Engelke H (2022) Biomimetic mineralization of iron-fumarate nanoparticles for protective encapsulation and intracellular delivery of proteins. *Chem. Mater.* 34, 8684–8693.
- 492) M Lee, PJ Rice-Boucher, L Thrasher Collins, E Wagner, L Aulisa, J Hughes, DT Curiel (2022) A Novel Piggyback Strategy for mRNA Delivery Exploiting Adenovirus Entry Biology. *Viruses* 14, 2169.
- 493) Spellerberg R, Benli-Hoppe T, Kitzberger C, Hageneier M, Schwenk N, Öztürk Ö, Steiger K, Multhoff G, Eiber M, Schilling F, Weber WA, Kälin RE, Glass R, Nelson PJ, Wagner E, Spitzweg C. (2022) Dual EGFR- and TfR-targeted gene transfer for sodium iodide symporter gene therapy of glioblastoma. *Mol Ther Oncolytics* 27: 272-287.
- 494) Köhler B, Dubovik S, Hörterer E, Wilk U, Stöckl JB, Tekarslan-Sahin H, Ljepoja B, Paulitschke P, Fröhlich T, Wagner E, Roidl A (2022) Combating drug resistance by exploiting miRNA-200c-controlled phase II detoxification. *Cancers* 14, 5554.
- 495) Lin Y, Wilk U, Pöhmerer J, Hörterer E, Höhn M, Luo X, Mai H, Wagner E, Lächelt U. (2023) Folate receptor-mediated delivery of Cas9 RNP for enhanced immune checkpoint disruption in cancer cells. *Small* 19, e2205318.
- 496) Kitzberger C, Spellerberg R, Han Y, Schmohl KA, Stauss C, Zach C, Kälin RE, Multhoff G, Eiber M, Schilling F, Glass R, Weber WA, Wagner E, Nelson PJ, Spitzweg C (2023) Mesenchymal Stem Cell-mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice. *Clinical Cancer Research* 29, 930-942.
- 497) Steffens RC, Wagner E (2023) Directing the way - Receptor and chemical targeting strategies for nucleic acid delivery. *Pharm. Res.* 40, 47–76.
- 498) Thalmayr S, Grau M, Peng L, Pöhmerer J, Wilk U, Folda P, Yazdi M, Weidinger E, Burghardt T, Höhn M, Wagner E, Berger S. (2023) Molecular Chameleon Carriers for Nucleic Acid Delivery: The Sweet Spot Between Lipoplexes and Polyplexes. *Adv. Mater.* 2023 35, e2211105.
- 499) Zhang F, Lin Y, Höhn M, Wagner E. (2023) Chemical Electron Transfer-Based Lipopolyplexes for Enhanced siRNA Delivery. *Cell Reports Physical Science* 4, 101444.
- 500) Lin Y, Luo X, Burghardt T, Dorrer S, Höhn M, Wagner E, Lächelt U. (2023) Chemical Evolution of Amphiphilic Xenopeptides for Potentiated Cas9 Ribonucleoprotein Delivery. *J Am Chem Soc.* 145, 15171-15179.
- 501) Shen F, Lin Y, Höhn M, Luo X, Döblinger M, Wagner E, Lächelt U. (2023) Iron-gallic acid peptide nanoparticles as versatile platform for cellular delivery with synergistic ROS enhancement effect. *Pharmaceutics* 15, 1789.

- 502) Hall A, Bartek J, Wagner E, Lächelt U, Moghimi SM. (2023) High-resolution bioenergetics correlates the length of continuous protonatable diaminoethane motif of four-armed oligo(ethanamino)amide transfectants to cytotoxicity. *J. Control. Rel.* 361, 115-129.
- 503) Kitzberger C, Shehzad K, Morath V, Spellerberg R, Ranke J, Steiger K, Kälin RE, Multhoff G, Eiber M, Schilling F, Glass R, Weber WA, Wagner E, Nelson PJ, Spitzweg C. (2023) Interleukin-6-Controlled, Mesenchymal Stem Cell-based Sodium/Iodide Symporter Gene Therapy Improves Survival of Glioblastoma-bearing Mice. *Mol. Ther. Oncolytics* 30, 238-253.
- 504) Öztürk Ö, Lessl AL, Höhn M, Wuttke S, Nielsen PE, Wagner E, Lächelt U. (2023) Peptide nucleic acid – zirconium coordination nanoparticles. *Scientific Reports* 13, 14222.
- 505) Zhang F, Benli-Hoppe T, Guo W, Seidl J, Wang Y, Huang R, Wagner E. (2023) Receptor-Targeted Carbon Nanodot Delivery through Polymer Caging and Click Chemistry-Supported LRP1 Ligand Attachment. *Polymers* 15, 4039. doi: 10.3390/polym15204039
- 506) Zhou, F., Huang, L., Li, S., Yang, W., Chen, F., Cai, Z., Liu, X., Xu, W., Lehto, V. P., Lächelt, U., Huang, R., Shi, Y., Lammers, T., Tao, W., Xu, Z., Wagner, E., Xu, Z. P., Yu, H. (2023) From structural design to delivery: mRNA therapeutics for cancer immunotherapy. *Exploration* 20210146. <https://doi.org/10.1002/EXP.20210146>
- 507) Lessl AL, Pöhmerer J, Lin Y, Wilk U, Höhn M, Hörterer E, Wagner E, Lächelt U. (2023) mCherry on Top: A Positive Read-Out Cellular Platform for Screening DMD Exon Skipping Xenopeptide-PMO Conjugates. *Bioconjugate Chem.* 34, 2263–2274. doi: 10.1021/acs.bioconjchem.3c00408.
- 508) Zeyn Y, Hobernik D, Wilk U, Pöhmerer J, Hieber C, Medina-Montano C, Röhrig N, Strähle CF, Thoma-Kress AK, Wagner E, Bros M, Berger S. (2023) Transcriptional Targeting of Dendritic Cells Using an Optimized Human Fascin1 Gene Promoter. *Int J Mol Sci.* 24, 16938. doi: 10.3390/ijms242316938
- 509) Haase F, Pöhmerer J, Yazdi M, Grau M, Zeyn Y, Wilk U, Burghardt T, Höhn M, Hieber C, Bros M, Wagner E, Berger S. (2024) Lipoamino bundle LNPs for efficient mRNA transfection of dendritic cells and macrophages show high spleen selectivity. *Eur. J. Pharm. Biopharm.* 194, 95–109. doi: 10.1016/j.ejpb.2023.11.025.
- 510) Albuquerque LJC, de Oliveira FA, Christoffolete MA, Nascimento-Sales M, Berger S, Wagner E, Lächelt U, Giacomelli FC. (2024) Nucleic acid delivery to retinal cells using lipopeptides as a potential tool towards ocular gene therapies. *J Colloid Interface Sci.* 655, 346-356. doi: 10.1016/j.jcis.2023.11.
- 511) Lyu M, Yazdi M, Lin Y, Höhn M, Lächelt U, Wagner E. (2024) Receptor-Targeted Dual pH-Triggered Intracellular Protein Transfer. *ACS Biomater Sci Eng.* 10, 99–114. doi: 10.1021/acsbiomaterials.2c00476.
- 512) Simone Berger, Ulrich Lächelt, Ernst Wagner (2024) Dynamic Carriers for Therapeutic RNA Delivery. *Proc. Natl. Acad. Sci. U.S.A.*, in press.
- 513) Yazdi M, Hasanzadeh Kafshgari M, Khademi Moghadam F, Zarezade V, Oellinger R, Khosravi M, Haas S, Hoch CC, Pockley AG, Wagner E, Wollenberg B, Multhoff G, Bashiri Dezfouli A. (2024) Crosstalk between NK Cell Receptors and Tumor Membrane Hsp70-Derived Peptide: A Combined Computational and Experimental Study. *Advanced Science*, e2305998. doi: 10.1002/advs.202305998

Lectures:

1. 13. 5. 1991, Gene Therapy Workshop, Broadway, Worcestershire, England, "Receptor-mediated gene delivery using transferrin-polycation conjugates".
2. 15. 10. 1991, Antisense Technology, 5. Mikrosymposium, Leverkusen, Deutschland, "Receptor-mediated Uptake of Nucleic Acids".
3. 8. 4. 1992, Keystone Symposium on Gene Transfer, Replacement and Augmentation, Copper Mountain, Colorado, USA, "Transferrin-polylysine mediated gene transfer and its augmentation by adenoviruses or peptides".
4. 10. 4. 1992, University of Colorado, Health Science Center, Denver, USA.
5. 2. 11. 1992, UCLA, Los Angeles, CA, USA, "Receptor-mediated gene transfer and its augmentation by the endosome-disruption activity of viruses or peptides".
6. 13. 11. 1992, 2. GFM-Tagessymposium, Deutsches Krebsforschungsinstitut, Heidelberg, Deutschland.
7. 15. 4. 1993, Keystone Symposium on Genetically Targeted Research & Therapeutics: Antisense & Gene Therapy, Keystone, Colorado, USA, "Receptor-Mediated Gene Transfer".
8. 21. 5. 1993, European Society for Animal Cell Technology, 12th Meeting, Würzburg, Deutschland, "Receptor-Mediated Gene Delivery into Mammalian Cells".
9. 15. 6. 1993, Ars Electronica, Symposium "Artificial Life", Linz, Österreich, "Gentherapie: Neue Wege in der Krebsbehandlung".
10. 2. 9. 1993, 12th Meeting of the International Society of Haematology, European and African Division, Wien, Österreich, "Receptor-mediated Gene Delivery and Potential Therapeutic Applications".
11. 16.11. 1993, Seattle, University of Washington, "Receptor-mediated gene delivery"
12. 20. 11. 1993, Second International Conference, Gene Therapy of Cancer, San Diego, "Adenovirus-augmented, receptor-mediated gene delivery for immunotherapy of melanoma".
13. 22.11. 1993 Birmingham, Alabama, UAB, "Adenovirus-augmented, receptor-mediated gene delivery"
14. 28. 1. 1994, Kolloquium Universitätsklinik Tübingen, "Rezeptorvermittelter Gentransfer in der somatischen Gentherapie".
15. 26. 4. 1994, XXI International Congress of the World Federation of Hemophilia, Mexico City, "Receptor-mediated gene delivery, application to hemophilia A"
16. 28. 6. 1994, Nice, 21st International CRS Symposium, "Synthetic virus-like gene delivery systems".
17. 11. 7. 1994, Hamburg, Medizinisches Kolloquium, "Somatische Gentherapie".
18. 8. 9. 1994, European Conference on Gene Therapy of Cancer, London, "Receptor-mediated Gene Transfer: Synthetic Virus-like Systems".
19. 14. 9. 1994, 49. Tagung der deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten, Ulm, Gentherapie in der Gastroenterologie, "Rezeptorvermittelter Gentransfer".
20. 18. 9. 1994, Goslar, Gene Therapy: Biosafety Aspects, "Receptor-mediated Gene Transfer: Synthetic Virus-like Systems".
21. 9. 10. 1994, Jahrestagung der Deutschen und der Österreichischen Gesellschaft für Hämatologie und Onkologie, Wien, Gene and Antigene Treatment, "Receptor-mediated Gene Transfer and applications for gene therapy of cancer".
22. 13. 10. 1994, Harvard Club of Boston, Artificial Self-Assembling Systems for Gene Transfer, "Virus-like gene transfer complexes using membrane active peptides"
23. 3. 11. 1994, 422. DECHEMA-Kolloquium, Frankfurt, Somatische Gentherapie, "Rezeptorvermittelter Gentransfer".

24. 30. 11. 1994, Annecy, Septiemes entretiens Jaques Cartier 1994, Fondation Marcel Merieux, Therapie Genique, "Receptor-mediated Gene Transfer: Synthetic Virus-like Systems".
25. 6. 2. 1995, Berlin, Universität Rudolf-Virchow, "Rezeptor-vermittelter Gentransfer".
26. 20. 2. 1995, Marburg, Philipps-Universität, Mini-Symposium Gentherapie (Tarik Möröy). "Receptor-mediated gene transfer; therapeutic applications"
27. 23. 2. 1995, Nice, 7th European Congress on Biotechnology; "Receptor-mediated gene transfer"
28. 30. 3. 1995, Keystone symposium on Gene therapy and Molecular Medicine, Steamboat Springs, USA. "Receptor mediated gene delivery and endosomal release".
29. 26. 4. 1995, Wiesbaden, 101. Tagung der Deutschen Gesellschaft für Innere Medizin; "Somatische Gentherapie: Methodische Grundlagen".
30. 30. 5. 1995, Ljubljana, School of Medicine, Slovenia. Lecture "Gene therapy and applications in oncology"
31. 1. 6. 1995, University of Utrecht, Faculty of Pharmacy, Netherland. Lecture "Receptor-mediated gene transfer: virus-like particles".
32. 2. 6. 1995, University of Groningen, Netherland. Lecture "Receptor-mediated gene transfer: virus-like particles".
33. 27. 6. 1995, Cape Sounion Beach, Greece, NATO ASI Meeting "Targeting of Drugs: Strategies for Oligonucleotide and Gene Delivery in Therapy".
34. 26. 7. 1995, GSF München, Abteilung Molekulare Virologie, Lecture "Nonviral Gene Delivery Systems"
35. 7. 9. 1995, Institut für Biomedizinische Altersforschung, Innsbruck. Vortrag "Rezeptor-vermittelter Gentransfer für den Einsatz in der Tumorthherapie".
36. 28. 9. 1995, Wakefield, MA, USA, Symposium " Artificial Self-assembling Systems for Gene Transfer".
37. 30. 9. 1995, Rockville, MD, USA. Conference on: Stem Cell Gene Therapy. "Receptor-mediated Gene Transfer and endosomal release".
38. 26. 1. 1996, Erlangen. Internationales Symposium "Malignes Melanom". Vortrag "Möglichkeiten der Gentherapie".
39. 31. 5. 1996, "Somatische Gentherapie: eine realistische Zwischenbilanz", E.Broda Vorlesung, Wien.
40. 9. 9. 1996, "Kann Krebs immunologisch beeinflusst werden?", Pharmacon, Sylt/Westerland, Germany.
41. 19. 9. 1996, F.C. Donders Lecture "Gene transfer and applications", Utrecht, The Netherlands.
42. 20. 9. 1996, "Gene modified cancer vaccines", Gastroenterologie '96, 51. Tagung der DGVS, Aachen, Germany.
43. 26. 2. 1997 "Coupling of transferrin to polyethylenimine for gene delivery to tumor cells", Symposium on Recent advances in drug delivery systems, Salt Lake City, Utah
44. 14.-16. 3. 1997, Cold Spring Harbour, Gene transfer symposium
45. 3.-5. 5. 1997, Berlin, MDC Gene Therapy Symposium
46. 15.-16. 6. 1997, Stockholm, CRS meeting
47. 20. 6. 1997, Alpbach, "Gentherapie- Phantasie und Wirklichkeit"
48. 3. 7. 1997, Urbino, Summer School
49. 4,-5. 7. 1997, Strassbourg, Symposium C. Nicolau
50. 19.- 25. 8. 1997, Crete, International Gene therapy conference

51. 13. 9. 1997, Vienna, ESO, New cytokines and genetic vaccines
52. 16. 9. 1997, Vienna, German Society of Experimental and Clinical Pharmacology and Toxicology.
53. 1.-3. 10. 1997, Paris, Gene Therapy
54. 12. 12. 1997, Freiburg i.B., 9th Symposium IECR, Vector Development and Targeting Strategies for Cancer Gene Therapy, Tumor Biology Center
55. 19.1.-25.1. 1998, Keystone, Synthetic Non-viral Gene Delivery Systems (Lecture and Co-organizer)
56. 23.4. 1998, London, EMEA Gene Therapy Workshop, "Gene Therapy in Practise"
57. 4.-5.5. 1998, Berlin-Buch, 6th MDC Symposium on Gene Therapy, "Receptor-targeting of nonviral vectors"
58. 6.5. 1998, Oxford, John Radcliffe Clinics, "Targeted gene transfer: an option for cancer therapy?"
59. 8.5. 1998, Amsterdam, 1. Pasman Symposium, "Receptor-targeting of nonviral vectors"
60. 11.6. 1998, Wien, 10-Jahresfeier CCRI und 11. Kind-Phillip-Tagung, "Cancer Gene Therapy"
61. 6.7.1998, Cividale (Udine), 14th Lecture course on biophysics and molecular biology, "Receptor ligands and shielding molecules for targeted gene delivery".
62. 18.-19.9.1998, Coimbra, Portugal, EC gene delivery meeting.
63. 11.-14. 3. 1999, Cold Spring Habor, Vector Targeting Strategies for Therapeutic Gene Delivery, "Polycation-based DNA complexes for tumor-targeted in vivo gene transfer.
64. 29.-31.3. 1999, Berlin (Döllnsee-Schorfheide) "Cancer Gene Therapy: DNA complexes for tumor-targeted in vivo gene transfer", Graduiertenkolleg "Application of Molecular Methods for Development of New Therapies".
65. 5.6. 1999, Shizuoka (Japan) Special lecture at 8th Drug Delivery System Conference.
66. 22.6. 1999, Nice, FEBS '99, Lecture and Chairman Session Gene targeting/gene therapy
67. 24.6.-5.7. 1999, Marathon (Greece), NATO ASI "Targeting of Drugs: Strategies for Gene Constructs and Delivery".
68. 11.9. 1999, Linz, 31. Jahrestagung Intensivmedizin, Symposium "Molecular and cellular pathology in intensive care medicine", lecture "Gene Therapy"
69. 14.10. 1999, Vienna, AKH seminar, Abt. Innere Medizin I (Prof. Lechner) "Receptor-mediated gene delivery into tumors"
70. 17.-21.10. 1999, Lake Tahoe, 4th Gene delivery & cellular protein expression conference, "Transferrin-mediated gene delivery: ex vivo and in vivo"
71. 7.-9.11. 1999, Washington, Nature Biotechnology symposium: Gene Therapy: Delivering the medicines of the 21st century. "Polymer-based systems for tumor-targeted gene delivery"
72. 26.-28.11. 1999, Munich, 7th meeting of the ESGT, "Transferrin-PEI/DNA complexes for tumor-targeted gene transfer"
73. 21.2. 2000, Munich, "Receptor-mediated gene transfer and application in cancer gene therapy"
74. 12.-14.4. 2000, Noordwijk aan Zee, NL, 6th European Symposium on Controlled Drug Delivery, "Polycation-based gene transfer for cancer gene therapy"
75. 23.-25.5. 2000, Goldegg, "Tumor-directed gene transfer with nonviral vectors"
76. 7.-10.10. 2000, Stockholm, 8th meeting of the ESGT, "Tumour targeting with surface-shielded transferrin-PEI/DNA complexes"
77. 21.-22.10. 2000, Marburg, Int. Symposium on Molecular Radiology, "Tumor-targeting with nonviral vectors"
78. 27.-28.10. 2000, Paris, AFLM/AFM Symposium Intracellular Delivery of DNA by Non-viral Vectors, "Cell targeting using synthetic vectors"

79. 3.11. 2000, Vienna, FSP Symposium Genetic Modification of Cells and Animals for Investigation and Treatment of Disease, "Synthetic self-assembling gene transfer systems"
80. 17.-21.11. 2000, Fukuoka, 13th Annual meeting of the JAACT, Animal Cell Technology for Creation of new Era, "Tumor-targeted gene transfer with nonviral vectors"
81. 1.3. 2001, Vienna, 21st European Workshop for Rheumatological Research, "DNA therapeutics: A feasible option for treatment of inflammatory diseases?"
82. 6.3. 2001, Vienna, Gene Therapy Symposium VUW "Physical methods of DNA delivery for genetic vaccination"
83. 9.-13.9. 2001, Semmering, 5th Gene Delivery and Cellular Protein Expression Conference, "DNA Therapeutics: An Emerging Class of Molecular Medicines"
84. 23.-25.9. 2001, Vienna, 4th Central European Symposium on Pharmaceutical Technology, "Cancer Gene Therapy with Tumor-Targeted DNA Complexes"
85. 30.9.-3.10. 2001, Rome, Genome Medicine: Gene Therapy for the Millenium, "DNA Therapeutics: Cancer Gene Therapy"
86. 28.2.-3.3. 2002, Amsterdam, NDDO European Cancer Gene Therapy meeting, "DNA Therapeutics: Targeting Strategies"
87. 31.5. 2002, Vienna, CRS meeting, "DNA therapeutics for cancer gene therapy"
88. 6.6.-9.6. 2002, Boston, Annual meeting of American Society of Gene Therapy (ASGT) "Tumor-targeted DNA Polyplexes"
89. 5.9. 2002, Oslo, Radium Hospital, "DNA therapeutics for cancer treatment"
90. 23.9. 2002, Rockville, NIH, NCI/CRS 2nd international symposium on tumor targeted delivery, "Tumor-targeted DNA polyplexes for cancer gene therapy"
91. 28.1.2003, Giessen, "DNA based Therapeutics"
92. 14.2.2003, Maui, Hawaii, NCI-JSPS Conference, "Tumor-specific delivery"
93. 23.7. 2003, Glasgow, annual CRS meeting, "Nonviral vectors for targeted and intracytoplasmic delivery"
94. 29.9. 2003, Paris-Versailles, EUFEPS Conference on New Challenges in Drug Delivery, "Will artificial systems outpace viruses for gene delivery?"
95. 01.12.03, Wien, Österreich, European Doctorate in Chemistry and Technology of Drugs, Workshop on Antisense Research, "Targeted delivery of nucleic acid therapeutics"
96. 19.-20.2. 2004, Coimbra, Portugal, Doctoral Programme in Experimental Biology and Biomedicine Course, "Gene Therapy: applications and clinical studies, delivery methods"
97. 20.2. 2004, Coimbra, Portugal, Center for Neuroscience and Cell Biology, University of Coimbra, "Artificial viruses for tumor targeting: a new avenue for cancer therapy?"
98. 2.3. 2004, Saarbruecken, Saarland University, 5th International Conference and Workshop, Impact of Nanobiotechnology on New Drugs and Medicines (theme day), "Artificial Viruses for tumor-targeted therapies"
99. 24.3. 2004; Ulm University "Artificial viruses for targeted therapies"
100. 30.3. 2004; Utrecht University "Artificial viruses for targeted therapies"
101. 12.5. 2004; Marburg University, "Artificial viruses for targeted therapies"
102. 1.7. 2004; LMU München, Antrittsvorlesung "Ein Konzept für zielgerichtete Therapien: Synthetische Viren"
103. 12.7. 2004, Chicago, Fa. Abbott, „Targeted Delivery of siRNA and Other Nucleic Acids “
104. 13.9. 2004, Istanbul, International Pharmaceutical Technology Symposium (IPTS 2004), "Artificial Viruses – The Role of Membrane-Active Peptides in Intracellular Delivery"

105. 30.9. 2004, Philadelphia, National Hemophilia Foundation Workshop; “Targeted DNA Polyplexes with Bioresponsive Elements”
106. 8.10. 2004, Berlin, Jahrestagung der Gesellschaft für Mikrozirkulation und Vasculäre Biologie (GfMVB); “Non-viral gene transfer to the vascular system”
107. 16.11. 2004, Weihenstephan, TU München, „Polyplexes for targeted therapies“
108. 18.11. 2004, Ulm, Klinikum, “Synthetische Viren für zielgerichtete Therapien”
109. 2. 3. 2005, Martinsried, BioM Symposium, „Tumor-Targeted Nucleic Acids for Therapy“
110. 20.5. 2005, Tokyo, 5th Anniversary International Symposium for Gene Design and Delivery, “Synthetic Virus-like Polyplexes for Tumor-Targeted Gene Therapy”
111. 2.6. 2005, St. Louis, Annual meeting of American Society of Gene Therapy (ASGT), “Bioresponsive Deshielding of Targeted DNA Polyplexes”
112. 29.11. 2005 Berlin-Golm/Potsdam, Fraunhofer Institut für Polymerforschung “Novel biodegradable polymers for gene delivery“
113. 21.3. 2006, Munich, Research Seminar of the Graduiertenkolleg 1202, “Artificial viruses for tumor-targeted therapy”.
114. 5.4. 2006, Nordwijk aan Zee, Netherlands, 9th European Symposium on Controlled Drug Delivery, “Bioresponsive shielding of polyplexes for targeted gene delivery into tumors”.
115. 21.4. 2006, Chicago, Abbott, “Novel biodegradable polymers for targeted siRNA delivery“.
116. 2.6. 2006, Baltimore, Annual meeting of American Society of Gene Therapy (ASGT), „Synthetic vectors for tumor targeting”.
117. 11.7. 2006, Sapporo, 1st FIP-APSTJ Joint Workshop on Gene Delivery, “Targeting and intracellular trafficking of polyplexes for tumor therapy”
118. 21.8. 2006, Big Sky, Montana, Gordon Conference, “Synthetic Vectors for Tumor Targeting”
119. 16.-20.9. 2006, Barcelona, ESF, Nanomedicine, “Gene Therapy using Non-Viral Vectors– A Practical Reality?”
120. 26.9. 2006, Halle-Wittenberg, PolyPharma 2006, “Application of polyplexes for targeted gene transfer”
121. 5.-6.10. 2006, Marburg, DPhG, “Nucleic acids for targeted therapies”
122. 15.2. 2007, GSF Munich, “Gene therapy using non-viral vectors - a practical reality?”
123. 26.-28.2. 2007, Drug Delivery Systems, Salt Lake City, Utah, USA. “Bioresponsive polymeric carriers for tumor-targeted gene therapy”
124. 13.3. 2007, Roche Applied Science, Penzberg, ”Programmed drug delivery: Synthetic pDNA, dsRNA and siRNA viruses for targeted therapy“
125. 21.3. 2007, Novartis, Basle, “Programmed drug delivery: Nanosystems for targeted pDNA, dsRNA or siRNA therapy”
126. 24.4. 2007, Chicago, “Programmed drug delivery: Nanoscaled polymer complexes for targeted pDNA or siRNA therapy “
127. 22.6. 2007, Mannheim-Ludwigshafen, Abbott Soliqs Nanosymposium, “Programmed drug delivery: tumor targeting strategies”.
128. 27.6. 2007, Paris, Eurocancer 2006, “Nonviral gene delivery to tumors”.
129. 7.9. 2007, Volos (Greece), Symposium of Balkan Union of Oncology, “Advances in cancer gene therapy: tumor-targeted delivery of therapeutic nucleic acids”.
130. 11.1. 2008, Basel, Novartis, “Nanoscaled dynamic nucleic acid / polymer complexes for therapeutic DNA and siRNA delivery”.

131. 23.1. 2008, Aarhus, Interdisciplinary Nanoscience Center (iNANO) annual meeting, "Nucleic Acid based Therapeutics as Programmed Nanomedicines".
132. 27.2. 2008, York, "Tumor-targeted nucleic acids as programmed nanomedicines"
133. 11.3. 2008, Mainz, DGPT, 49th Annual meeting, Session on Therapeutic RNAs, "Nanoparticle-mediated delivery of siRNA and dsRNA "
134. 27.3. 2008, Ghent, " Synthetic viruses: nanoscaled dynamic polymer complexes for therapeutic DNA and RNA delivery "
135. 28.4. 2008, Palo Alto, Intradigm, " Synthetic viruses: nanoscaled dynamic polymer complexes for therapeutic DNA and RNA delivery "
136. 26.-28.5. 2008, Valencia, 7th International Symposium on Polymer Therapeutics: From Laboratory to Clinical Practice, "Polymer-based vectors designed to promote cytosolic delivery"
137. 2.6. 2008, Chicago, Abbott Laboratories, "The polymer perspective on systemic delivery of siRNA therapeutics: lessons learned during the last 3 years"
138. 11.6. 2008, Helsinki, Helisinki Drug Research 2008, Nanotechnology in pharmacy, "Mechanisms of non-viral gene delivery"
139. 23.6. 2008, Cardiff, Second Cellular Delivery of Therapeutic Macromolecules Symposium, "Interaction of Polyplexes With Cellular Barriers."
140. 23.7. 2008, Kulmbach, Roche , "Nanoscaled dynamic polymeric particles for therapeutic DNA and RNA delivery"
141. 4. 9. 2008, Boston, Alnylam, "Nanoscaled dynamic polymer particles for therapeutic RNA and siRNA delivery."
142. 4.-7. 9. 2008, Potomac, Maryland, American Academy for Nanomedicine, Nanoscaled dynamic polymeric particles for therapeutic RNA and siRNA delivery.
143. 20.-24.9. Barcelona, ESF, Nanomedicine, Therapeutic research strategies using polymer based vectors designed to promote cytosolic delivery.
144. 29.9.-2.10. Venice, CeNS meeting "Nanoscaled dynamic polymer particles for therapeutic RNA delivery"
145. 29.10. 2008 Düsseldorf Coley-Pfizer, "Nanoscaled dynamic polymeric particles for therapeutic DNA and RNA delivery"
146. 17.-18. 11. 2008, Annual Symposium of Japanese Society for Biomaterials in Tokyo, "Synthetic viruses: nanoscaled dynamic polymer complexes for therapeutic DNA and RNA delivery"
147. 23.11. 2008, Changchun, CIAC , Chinese Academy of Sciences, "Targeted dynamic polymer complexes for therapeutic pDNA and RNA delivery"
148. 26.-30.11. 2008, Sanya, Hainan, 6th Asia 3 Symposium, "Targeted dynamic polymer complexes for therapeutic DNA and RNA delivery."
149. 4.-6.3. 2009 Charité, Berlin 6th International Conference on Biomedical Applications of Nanotechnology, "Nanoscaled dynamic polymer particles for therapeutic DNA and RNA delivery"
150. 26. - 28. 4. 2009 (27.4.) Basel, European Nanomedicine meeting „Bioinspired Polymer Nanostructures for Medical Therapy“
151. 29.5.2009, London, IPSEN workshop, "Towards RNAi in vivo: Tumor Targeted Polyplexes"
152. 10-11.6. 2009 London , RNAi, siRNA & miRNA Conference, "Tumor Targeted RNA Polyplexes as Programmed Nanomedicines“
153. 6.7. 2009 Prague PMM, "Dynamic polymers for therapeutic DNA and RNA delivery"
154. 7.7. 2009 34th FEBS symposium 15, W01: Nanotherapeutics, Prague, "Programmed polymer complexes for targeted pDNA and siRNA therapy"

155. 10.7. 2009 Osaka 9th Annual Symposium for Gene Design and Delivery, and JSGT conference, "Dynamic Polymers for Therapeutic DNA and RNA Delivery"
156. 2.-3.9. 2009 Cologne, SPP1230 Summerschool "What you should know about nonviral vector systems"
157. 16.- 19. 9. 2009 San Servolo. SFB486 Nanoman Final Symposium
158. 28. -30. 9. 2009 Bled, Slovenia, EuroNanoMedicine "Dynamic functional nanodevices for tumor targeted nucleic acid therapy"
159. 8.-10.10. 2009, Munich, NIM Workshop
160. 3.-6.11. 2009, Fukuoka, Joint Symposium of Oligonucleotide Therapeutics Society and Antisense Symposium of ASJ Japan "Polymer-mediated oligonucleotide delivery and endosomal release pathways"
161. 23.11. 2009, Hannover, Annual Congress European Society of Gene and Cell Therapy (ESGCT). "Synthetic viruses - dynamic polymer nanosystems for therapeutic pDNA and RNA delivery"
162. 27.11. 2009, Barcelona, IRB, Barcelona Biomed Seminar. "Dynamic Polymers for RNA and DNA based Cancer Therapy".
163. 8.12. 2009 Institut Curie, Paris "Dynamic Polymers for DNA and RNA based Cancer Therapy"
164. 7.-9.12. 2009, GTRV Paris, 9.12., "Dynamic polymer nanoparticles for targeted DNA and RNA therapy"
165. 15.12. 2009, Bologna, Pediatric Oncology, University of Bologna, "Polymer-enhanced Therapeutic Nucleic Acid Delivery: Targeting, Shielding and Intracellular Release"
166. 3.3. 2010, Munich, Center for Advanced Studies (CAS), Workshop " From Nano to Makro - How will nanomedicine shape the future of pulmonary therapies? "
167. 14.- 17.3. 2010, Münster, Frontiers in Medicinal Chemistry, "Chemically programmed nanosystems for therapeutic DNA and RNA delivery"
168. 17. 5. 2010, Westpoint, Philadelphia, Merck Research Laboratories, "Programmed Nanomedicines: dynamic polymers for DNA and RNA delivery"
169. 30.5.-2.6. 2010, Bad Honnef, Haereus Polymer Symposium, "Programmed degradation of polymer nanosystems for intracellular pDNA and RNA delivery"
170. 26.-29.6. 2010, Cardiff, CDTM 2010, "Interaction of polyplexes with cellular barriers".
171. 1.7. 2010 University of Aachen, " Dynamic Polymer Nanoparticles for DNA and RNA based Cancer Therapy "
172. 10.-14. 7. 2010, Portland, Oregon, Controlled Release Society "Targeted Polymer Nanoparticles for RNA based cancer therapy"
173. 6.-9.9. 2010, Chengdu, Sino-German Symposium "Bioinspired systems for drug, protein and gene delivery" (German Organizer and speaker)
174. 14.-18.9. 2010 Suzhou, Symposium on Innovative Polymers for Controlled Delivery, (SIPCD), "Chemically programmed polymers for DNA and RNA based targeted cancer therapy"
175. 20.9. 2010 Shanghai, Fudan University "Targeted Polymer Nanoparticles for DNA and RNA based cancer therapy"
176. 6.9. 2010 Munich, 4th Annual Symposium on Nanobiotechnology (October 5 - 7, 2010), New Directions In Nanotheranostics: Imaging, Biosensors, Materials and DNA Technologies, "Dynamic polymer nanoparticles for DNA and RNA based cancer therapy"
177. 14.10. 2010 Berlin, SFB meeting, "Single and dual targeting of nucleic acid/ polymer nanoparticles"
178. 18.11. 2010 Barcelona, EuroTIDES, "Dynamic polymers for tumor-targeted delivery of siRNA and cytotoxic RNA"

179. 3.2. 2011 Frankfurt, Sanofi Aventis, "Targeted Polymer Nanoparticles for anticancer nucleic acid therapeutics"
180. 28.-29.4. 2011, Seoul, 5th International Symposium for Intelligent Drug Delivery System, at KIST, Korea "Dynamic pDNA and siRNA carriers based on biomimetic polymers"
181. 19.-21.5. 2011 Tallinn, Estonia, Conference 'Peptide Vectors and Delivery of Therapeutics', "Bioresponsive programmed carriers for nucleic acid delivery"
182. 16.6. 2011 Tartu University, Estland "Dynamic pDNA and siRNA carriers based on functionalized polymers"
183. 30.7.- 3.8. 2011 Controlled Release Society annual meeting Washington DC, Minisymposium bioresponsive systems, "Dynamic siRNA and DNA delivery systems based on bioresponsive polymers."
184. 11.-14.9. 2011 Jerusalem School on 'Molecular Medicine - cancer biology and therapy' "Nanoparticle-based programmed nucleic acid delivery: an option for nanomedicine?"
185. 13.10. 2011 Shanghai, Fudan University, The Chinese Pharmaceutical Conference 2011, "Precise Polymers for Targeted Therapeutic Nucleic Acid Delivery"
186. 28.10. 2011 Berlin Teltow, Sino-German Symposium on Multifunctional Biomaterials and Polymer-based Controlled Drug Release Systems, "Precise, Sequence-defined Polymers for Therapeutic Nucleic Acid Delivery"
187. 4.11. 2011 University of Frankfurt, "Polymeric carriers for pDNA and siRNA delivery"
188. 29.11. 2011 Leiden, Prosensa, "Precise polymeric carriers for therapeutic nucleic acid delivery"
189. 6.2. 2012 Stockholm "Polymers for nucleic acid delivery: Inspired by viruses to be targeted, dynamic and precise"
190. 2.3. 2012 Vienna, Pharma Center, "Polymers for Nucleic Acid Delivery: Inspired by Viruses to be Targeted, Dynamic and Precise"
191. 5.3. 2012 Saarbrücken, Biobarriers 2012, "Nonviral Gene Delivery Systems - Invading Target Cells by Multifunctional Carriers"
192. 7.3. 2012 Reutlingen-Tübingen, NMI, "Bioresponsive and sequence-defined polymers for pDNA and siRNA delivery"
193. 24.3. 2012 Dresden, Annual Meeting of the German Society for Cell Biology, "Polymers for DNA and RNA delivery: Inspired by viruses to be targeted, dynamic and precise"
194. 4.-6.4. 2012 Egmond aan Zee, The Netherlands, European Symposium on Controlled Drug Delivery, 4-6 April 2012, Precise sequence-defined multifunctional polymeric carriers for DNA and RNA therapy
195. 18.4. 2012 London, Imperial College, "Polymers as Shuttles for Therapeutic Nucleic Acids: Inspired by Viruses to be Targeted, Dynamic and Precise"
196. 25.4. 2012, Munich, Klinikum Rechts der Isaar, Patienten- und Bürgerforum GAMBA, Stellungnahme zum Laiengutachten.
197. 9.5. 2012 Zürich, ETH, "Polymers for pDNA and siRNA delivery: Inspired by viruses to be targeted, dynamic and precise"
198. 16.-19.5. ASGT Annual meeting 2012, Educational session, "Polymeric Delivery Systems – Compacting, shielding, targeting and intracellular release"
199. 1.-5.7. 2012 Prague, Polymers in Medicine Symposium "Sequence-defined oligo(ethanamino)amides as dynamic carriers for targeted drug delivery"
200. 9.-12.7. 2012 Lausanne, ISP, "Sequence-defined oligo(ethanamino)amides for targeted siRNA and pDNA polyplex delivery"
201. 6.9. 2012 Shanghai, Fudan University "Sequence-defined oligoaminoamides as dynamic carriers for targeted nucleic acid and protein delivery"

202. 11.9. 2012 Shanghai, Shanghai Institute of Materia Medica (SIMM), Chinese Academia of Sciences, "Polymers as shuttles for therapeutic nucleic acids and proteins: Inspired by viruses to be targeted, dynamic and precise"
203. 7.-11.10. 2012 Hernstein-Vienna, *Oligonucleotide Delivery: Biology, Engineering and Development*, "Sequence-defined polymers as dynamic carriers for targeted nucleic acid delivery"
204. 7.-9. 11.2012 Kyoto University, 6th Annual Symposium on Nanobiotechnology, Kyoto Cell-Material Integration 2012, "Sequence-defined oligomers as bioresponsive shuttles for intracellular nucleic acid and protein transduction"
205. 27.-28. 11. 2012, Berlin, EuroTIDES 2012, "Precise polymers for siRNA delivery"
206. 20.12. 2012, University of Orleans, "Sequence-defined dynamic oligomer shuttles for targeted nucleic acid and protein delivery"
207. 15.2. 2013 Vienna, Genetic Transformation Technologies, "Polymers for pDNA and siRNA Delivery: Inspired by Viruses to be Targeted, Dynamic, and Precise".
208. 3.3. 2013 Kirchberg/Kitzbühl, Austria, NIM Winter School, "Nanomedicine: programmed nanocarriers for innovative drugs"
209. 20.-22.3. 2013 Tsukuba, Japan, "Sequence-defined oligo(ethanamino)amides as dynamic carriers for targeted siRNA and protein delivery"
210. 3.6. 2013 Montpellier, France, "Sequence-defined carriers for targeted siRNA and protein delivery"
211. 22.7. 2013 Honolulu, USA, CRS Annual meeting, "Sequence-Defined Multifunctional Carriers for Targeted siRNA Delivery"
212. 29.8. 2013, Fudan University, Shanghai, "Sequence-Defined Oligoaminoamides for Targeted Nucleic Acid Delivery – An Update"
213. 2.9. 2013, SIMM, Shanghai, "Sequence-Defined Oligoaminoamides for Targeted Nucleic Acid Delivery – An Update"
214. 3.9. 2013, Fudan University, Shanghai, "Endosomal Escape in Drug and Gene Delivery: The proton sponge effect: a myth or truth?"
215. 11.9. 2013, Indianapolis, ACS meeting, "Sequence-defined oligomers as shuttles for targeted nucleic acid and protein delivery"
216. 28.9.-2.10. 2013, Changchun, 4th International Advanced Biomaterials Symposium 2013 (IABS 2013), "Sequence-defined Carriers for Targeted Nucleic Acid and Protein Delivery"
217. 6.10. 2013, Naples, Italy, OTS annual meeting, Keynote lecture "Sequence-defined Carriers for Targeted Nucleic Acid Delivery"
218. 3.12. 2013 Copenhagen, "Precision oligomers for targeted for nucleic acid and protein delivery"
219. 4.12. 2013 Martinsried, Ethris, "Precision oligomers for targeted nucleic acid and protein delivery"
220. 22.3. 2014 Ulm, Annual meeting of DGGT, "Receptor targeted transfection by sequence-defined synthetic carriers"
221. 16.4. 2014 Martinsried, U3 Pharma, "Sequence-Defined Carriers for Innovative Drugs"
222. 25.4. 2014 Seoul, Korea Institute of Science and Technology, 8th International Symposium on Intelligent Drug Delivery System, "Sequence-defined oligoaminoamides for targeted delivery of nucleic acids, proteins or other drugs"
223. 10.7. 2014 Hamburg, GDCh lecture "Sequence-defined Oligomers: Chemical Evolution of Tumor-targeted Nucleic Acid and Gene Carriers" ("Sequenz-definierte Oligomere für die Chemische Evolution Tumor-gerichteter Nukleinsäureträger")
224. 22.7. 2014 Mainz „Sequence-defined oligomers: chemical evolution of macromolecular drug and gene carriers“ ("Sequenz-definierte Oligomere zur chemischen Evolution tumorgerichteter Nukleinsäureformulierungen")

225. 15.9. 2014 Chengdu, Sichuan University, "Sequence-defined carriers for targeted intracellular drug and nucleic acid delivery"
226. 19.9. 2014 Suzhou, China, 16. - 19.9. 2014, 3rd Symposium on Innovative Polymers for Controlled Delivery (SIPCD 2014), "Beyond 25 years in polymeric gene delivery: challenges, breakthroughs and perspectives"
227. 24.9. 2014 Venice CeNS meeting Walk and Talk at Nanoscale, "50 years of polymeric gene delivery: challenges, breakthroughs and perspectives".
228. 26.9. 2014 Frankfurt DPhG, plenary lecture and symposium, "Sequence-defined carriers for targeted intracellular drug and nucleic acid delivery"
229. 20.10. 2014 Utrecht university, "50 years of polymeric gene delivery: challenges, breakthroughs and perspectives"
230. 23. 4.2015 Darmstadt, Technical University, "Sequence-defined artificial oligo-amino acids for targeted intracellular drug, protein and nucleic acid delivery"
231. 27.-29.7. 2015 Edinburgh, CRS Annual meeting, moderation of session "in vivo Nucleic Acid Delivery"
232. 22.9. 2015 Basel, Peptide Therapeutic Forum, "Sequence-defined oligomers containing natural and artificial oligo-amino acids for intracellular drug, protein and nucleic acid delivery"
233. 23.9. 2015 Basel, BioPro2015, 5th Novartis conference on biotechnology, "Sequence-defined carriers for targeted intracellular nucleic acid and protein delivery"
234. 29.10. 2015 Martinsried, IZB, LMU-Tokyo Symposium, "Sequence-defined carriers for intracellular nucleic acid and protein delivery"
235. 11.3. 2016 Lunteren, NL, Dutch Society for Cell and Gene Therapy (NVGCT) 2016 Spring Symposium, "Beyond 50 years of polyplexes: new directions in polymer-based nucleic acid delivery"
236. 13.-15.4. 2016 Egmond aan Zee, ESCDD, "Chemical evolution of sequence-defined oligomers for intracellular nucleic acid and protein delivery"
237. 15.-16.9. 2016 Mainz, Symposium SFB1066, Nanodimensional Polymeric Therapeutics for Tumor Immunotherapy, "Design of Nucleic Acid Nanoparticles for Cancer Therapy"
238. 2.11. 2016. Munich, LMU Center "Nanomedizin: Strategien zur zielgerichteten Therapie".
239. 21.11. 2016 Hangzhou, LMU-ChAN annual symposium "Tumor-targeted drug and gene delivery"
240. 23.11. 2016 Shanghai, Fudan University, "Chemical evolution of sequence-based oligomers for nucleic acid and protein delivery"
241. 28.-30.11. 2016 Tokyo, "Chemical evolution of sequence-defined carriers for nucleic acid and protein delivery"
242. 1.12. 2016 Kawasaki, iCONM , COINs seminar "Nucleic acid nanoparticles for cancer therapy"
243. 3.3. 2017 Salzburg, Symposium Nanotechnology, European Academy of Science and Arts, "Nanomedicine – strategies towards targeted therapy"
244. 4.3. 2017 Vienna, Symposium "Von stereoelektronischen Effekten zur Biomedizin" on occasion of Prof. C. Noe's 70th birthday, "Nanotechnology in Biomedicine"
245. 14.3. 2017 Tutzing, SFB1032 conference, "siRNA and microRNA nanoagents for manipulating tumor cells"
246. 17.3. 2017 Shanghai, "Chemical evolution of intracellular delivery agents: new options for macromolecules, NBEs and screening?"
247. 27.4. 2017 Oberambach, FOR1406 Workshop: Nature's Toolbox, "Facilitated delivery in natural product drug research"
248. 29.6. 2017 Valencia, PDDS meeting, "Bioinspired Sequence-defined Drug, Protein and Gene Carriers by Chemical Evolution"

Ernst Wagner

249. 8.9. 2017 Hongkong, "Chemical evolution of macromolecular sequences - for intracellular DNA, siRNA, protein and drug delivery"
250. 26.10. 2017 Lisbon, EurASc, "Chemical evolution of carriers for use in nanomedicine"
251. 27-29.10. 2017 China Pharmaceutical Conference 2017 "Bioinspired Design of Drug, Protein and Nucleic Acid Carriers by Chemical Evolution"
252. 30.10. 2017 Fudan U, "Bioinspired Design of Drug, Protein and Nucleic Acid Carriers by Chemical Evolution"
253. 27.11. 2017 Mainz, "Bioinspired evolution: the type of nucleic acid cargo directs the optimal carrier sequence"
254. 12.12. 2017 San Diego, Dec 11-15, 2017, Antibody Engineering & Therapeutics 2017, "Intracellular Protein Delivery – Towards Artificial Immunotoxins"
255. 25.-27.4. 2018 Graz, BioNanoMed 2018, "Bioinspired design of sequence-defined drug, protein and gene carriers via chemical evolution"
256. 22.-24.6. 2018 New York, CRS, 23.6. Nucleic acid carrier optimization by bioinspired chemical evolution
257. 24.-26.8. 2018 Changchun, 5th International Biomaterials Symposium, "Chemical Evolution of Sequence-Defined Carriers for Therapeutic Delivery"
258. 4.9. 2018 Tutzing, NIM conference "Future of Nanoscience", "Highlights of 12 years NIM Area V biomedical nanotechnologies."
259. 16.-17.10. 2018 Shanghai, ChinaNanoMedicine 2018, "Chemical evolution of bioinspired protein and nucleic acid carriers"
260. 18.10. 2018 Chengdu, NERCB, "Chemical evolution of bioinspired protein and nucleic acid carriers"
261. 19.10. 2018 Chengdu, Sichuan U, School of Pharmacy, "Chemical evolution of bioinspired protein and nucleic acid carriers"
262. 21.11. 2018 Beijing, PKU, "Bioinspired chemical evolution of nucleic acid nanomedicines"
263. 22.11. 2018 Beijing, LMU-ChAN "Drug Innovations: Successful Collaborations of Chemistry & Pharmacy within the LMU-China Academic Network"
264. 3.-5.12. 2018, Montpellier, SF Nano (Société Française de Nanomédecine) "Bioinspired chemical evolution of nucleic acid nanomedicines"
265. 20.-23.5. San Diego, TIDES 2019, "Optimization of novel polymeric delivery vehicles by chemical evolution"
266. 5.6. 2019, Munich, DPhG, „Therapeutische Nucleinsäuren und Gentherapie: Status und Ausblick“
267. 1.-4.9. 2019, Heidelberg, DPhG, "Molecular Therapeutics from DNA to Cas9/sgRNA: Chemical Evolution of Nanocarriers".
268. 19.9. 2019, Basel, Targimmune, "Ethylenimine-based lipopeptides for intracellular delivery: optimization for various nucleic acid cargos"
269. 16.-18.10. 2019 Munich, ICONAN conference, "Optimizing Nucleic Acid Nanomedicines by Chemical Evolution of Carrier Sequences"
270. 12. 11. 2019 Amsterdam TIDES Europe, "Optimizing Polymeric Delivery Vehicles by Chemical Evolution"
271. 20.2. 2020 Munich, CRS Local Chapter, "Chemical evolution of nucleic acid carriers"
272. 15. 20.3. 2020, Siracusa, Delivery of Nucleic acid therapeutics, "Chemical evolution of artificial peptide carriers for nucleic acid delivery"
273. 7.-8. 9. 2020 Jena CRC1278 PolyTarget, (online) "Chemical evolution of peptide-like carriers for nucleic acid delivery"

274. 16.-18. 10. 2020 WBC 2020, Qingdao, China (online) "Chemical evolution of nucleic acid transfection carriers"
275. 18. 12. 2020 Shanghai (online), "Tumor-targeted siRNA polyplexes: Alternative mechanisms"
276. 17.-18. 2. 2021 Mashhad, Iran (online) 8th International E-Congress on Nanoscience & Nanotechnology (ICNN) "Knocking down and knocking out genes: chemical evolution of nucleic acid delivery carriers"
277. 28.6.2021 Paris, EUGLOH, "RNA gene medicines: evolution of synthetic carriers"
278. 29.8. 2021 Beijing, ChinaNANO 2021 "Modulating gene expression by siRNA, sgRNA or mRNA: chemical evolution of gene medicines" online recorded/hybrid, postponed
279. 28.9. 2021 ADRITELF and CRS Italy PhD Summer School on 'Manufacturing, preclinical development and clinical application of biologicals', "RNA gene medicines: evolution of synthetic nanocarriers"
280. 29.9. 2021 Tsinghua University, Beijing "RNA gene medicines: chemical evolution of synthetic nanocarriers"
281. 30.9. 2021 University of Nebraska Medical Center (David Oupicky) "Knocking down and knocking out genes: chemical evolution of nucleic acid delivery carriers"
282. 16.10.2021 SinoGerman Center Symposium, Fudan U "Gene Medicines: Chemical Evolution of Synthetic Delivery Carriers"
283. 20.-22.10. 2021 NanoMedicine 2021, Milan, online "RNA gene medicines: evolution of synthetic carriers"
284. 12.-14.11. 2021 WBC 2021, "RNA Medicines: Evolution of Synthetic Delivery Carriers"
285. 30.11. 2021 Novartis, Basel, "Chemical Evolution for Refining Nanocarriers for siRNA, mRNA, or Cas9/sgRNA Medicines"
286. 3.1.2022, Jinan U, Ceremony receiving Honorary Professorship, "Chemical Evolution of RNA and Protein Delivery for Advanced Therapy"
287. 2. 3. 2022, Tehran Polytechnic, AUT, Winter School on 'Injectable and Implantable polymeric drug delivery systems' lecture on "RNA Medicines: Chemical Evolution of Polymeric Nanocarriers"
288. 23.6. 2022, NanoSeries Conference, Madrid, online, "RNA Medicines: Chemical Evolution of Nanocarriers"
289. 24.6. 2022, LMU CAS, "Chemical Evolution of Sequence-defined Carriers for RNA Delivery"
290. 18.7. 2022 Fulda (online), Summer School SFB 1066/SFB 1278 "DNA and RNA Medicines: Chemical Evolution of Carriers"
291. 08.-09.09.2022, Berlin, ENDOSCAPE symposium, gene delivery "Chemical evolution refining intracellular siRNA, Cas9/sgRNA or mRNA delivery" (onsite)
292. 27.09. 2022 Melbourne, International Human Gene Therapy Conference, "DNA and RNA Medicines: Chemical Evolution of Synthetic Delivery Carriers" (online)
293. 12.10. 2022 Munich, SFB1032, "RNA delivery: chemical evolution of delivery carriers"
294. 29.10. 2022 Munich and online, World Symposium on Smart Materials Sciences and Engineering 2022 (SMSE), keynote, "RNA nanomedicines: smart materials for delivery"
295. 10.11. 2022 NanoTech 2022, 2nd Global Virtual Summit on Nanoscience & Nanotechnology, "DNA and RNA medicines: Evolution of nanocarriers"
296. 19.11. 2022 International Graduate Symposium on Biopharmaceuticals (IGSB), 18.-20.11. 2022 On-line, Suzhou, China "Sequence-Defined Chemical Evolution of RNA Carriers"
297. 7.-8. 12. 2022 KAST meeting, Seoul, KIST (onsite), keynote lecture "RNA Medicines: Chemical Evolution of Synthetic Carriers"
298. 22.12. 2022 Chinese Pharmaceutical Conference, Shanghai (online), Keynote lecture "Sequence-defined chemical evolution of RNA carriers"
299. 9.3. 2023 Boston (online), Targeted-Intracellular-Delivery-Summit, "RNA Medicines: Chemical Evolution of Synthetic Carriers"
300. 18.3. 2023, AMSE (Advanced Materials – Sciences and Engineering), Vienna, (onsite) "DNA and RNA medicines: evolution of nanocarriers"
301. 18.4. 2023, Munich Martinsried, Coriolis Academy, "Chameleon Nanocarriers for Delivery of RNA Nanomedicines"
302. 29.5. 2023, Materials World 2023, online, "Chameleon Nanocarriers for Delivery of RNA Nanomedicines"
303. 30.5. 2023, EMRS, Strasbourg, "Evolution of Chameleon Nanocarriers: RNA transfer at ultralow picogram dose"

Ernst Wagner

304. 10.6. 2023, NanoTech 2023 "Innovatory Advancements: Micro to Nanotechnology and Real-World Applications", online, "Evolution of Chameleon Nanocarriers for mRNA delivery at ultralow dose"
305. 17.7. 2023, Zhejiang online lecture, "Evolution of Nanocarriers for RNA Delivery".
306. 15.9. 2023, Valencia, Spain, online keynote, 2023PDDS 2023, "10th Edition of Global Conference on Pharmaceutics and Drug Delivery Systems. "Chameleon nanocarriers for dynamic delivery of RNA medicines"
307. 19.9. 2023, Würzburg, PhAT 2023, "RNA Arzneimittel: Evolution synthetischer Trägermoleküle"
308. 25.9. 2023 NanoMat2023, Barcelona, online keynote " RNA Medicines: Chemical Evolution of Nanocarriers".
309. 26.10. 2023 Future Materials 2023, Valencia 10:10 – 10:45, online keynote "Chameleon Nanocarriers for Delivery of RNA Nanomedicines".
310. 26.10. 2023 NanoMed 2023 Albufeira, Portugal, 14:00-14:30 online keynote "Chameleon Nanocarriers for Delivery of Therapeutic RNA
311. 7.11. 2023 7th World Congress on Materials Science and Engineering, November 6 & 7, 2023, <https://materialsscience.mindauthors.com/> online keynote "Chameleon Nanocarriers for Dynamic Delivery of Therapeutic RNA"
312. 21.11. 2023 Zhejiang University, online, "Chemical Evolution of Cas9/sgRNA and mRNA Carriers"
313. 4.12. 2023, Hebei University, National Center for Nanoscience and Technology of China, online, "Therapeutic RNA: Chemical Evolution of Synthetic Carriers"
314. 11.12. 2023 Vienna, Vienna University, "Therapeutic RNA: Chemical Evolution of synthetic Carriers"
315. 12.12. 2023, London, Gene and Cell Therapy-Virtual Conference (GCT-Virtual), "Chemical Evolution of Amphiphilic Xenopeptides for RNA Delivery"